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1. NORMAL AND MALIGNANT HEMATOPOIESIS 
Normal hematopoiesis and hematopoietic stem cells 
In the mammalian blood system, there are more than ten different types of mature 
blood cells, including red blood cells (RBCs), megakaryocytes, myeloid cells (monocyte/
macrophage and neutrophil), and lymphocytes.1,2 Most mature blood cells have a short life 
span, so hematopoietic stem cells (HSCs) are required to continuously replenish the blood 
system in adult life (Figure 1). During mammalian development, HSCs emerge from multiple 
hematopoietic sites sequentially, including the yolk sac, the aorta-gonad mesonephros 
(AGM) region, placenta, fetal liver, and eventually the bone marrow. Interestingly, the HSCs 
from different sites have distinct characteristics, reflecting the diversity in the supporting 
niche and in the intrinsic properties of HSCs at each developmental stage. For example, it 
is well known that HSCs in the fetal liver stage are actively in cycle and in the adult bone 
marrow, they reside as rare cells that are mostly quiescent. During development, multiple 
waves of hematopoiesis have been defined including the primitive and definitive wave. The 
primitive wave of hematopoiesis is transient and takes place in the yolk sac, which is quickly 
replaced by the definitive wave, adult-type hematopoiesis in the AGM region followed by 
other hematopoietic sites.1
The two defining features of HSCs are self-renewal and multi-potency (Figure 1), a state 
usually referred to as pluripotency. It is critical for the HSCs to keep these two processes in a 
delicate balance: a sufficient pool of quiescent HSCs must be maintained throughout the life 
time of an organism; meanwhile HSCs must continuously differentiate to replenish the short 
lived progenitor and mature blood cells. Any imbalance in these two processes would cause 
severe diseases. For instance, if differentiation of HSCs is not complemented with a usual loss 
of self-renewal capacity, or incomplete differentiation into mature blood cells occurs, pre-
leukemic progression might be the end result.3,4 Tremendous efforts have been dedicated 
to isolate and define the differentiation potential of subsets of developing hematopoietic 
cells, so to have a better understanding of how HSCs keep these two processes in check. 
In particular, immunophenotypic cell surface markers have been frequently applied, in 
combination with sensitive in vitro (e.g. colony-forming assays) and in vivo (transplantation) 
functional assays.2 These studies have shown that HSC differentiation follows a hierarchical 
structure in which the multipotent capacity of these cells is progressively limited (Figure 1). 
Firstly, sitting atop of the hematopoietic tree, HSCs can be subdivided into long-
term and short-term HSCs (LT-HSCs and ST-HSCs), which can give rise to the multipotent 
progenitors (MPPs). MPPs no longer contain self-renewal ability, but still have the full-
lineage differentiation potential.5,6 Going down the hierarchy, MPPs differentiate into the 
oligopotent progenitors: the common lymphoid progenitors (CLPs)7,8 and the common 
myeloid progenitors (CMPs).9 Together, the oligopotent CLPs and CMPs give rise to all the 
lineage-committed mature blood cells in the hematopoietic system. For example, CLPs 
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produce different lymphoid cells that comprise the immune system, including nature 
killer (NK) cells, B and T lymphocytes; whereas CMPs differentiate into megakaryocytes/
erythrocyte progenitors (MEPs) or granulocytes/macrophage progenitors (GMPs). MEPs can 
further give rise to RBCs or megakaryocytes, whereas GMPs differentiate into monocytes/
macrophages and granulocytes. 
Mast cellMegakaryocyteRBC Eosinophil Neutrophil Monocyte/
Macrophage
B 
lymphocyte
T 
lymphocyte
Platelets               
LT-HSC
ST-HSC
CMP
GMP
CLP
MEP
Self renewal
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NK 
Cells
Figure 1. Scheme of the hematopoietic tree1 (adapted from Orkin et al, 2008) A LT-HSC can undergo either self-
renewal or differentiation. The production of mature blood cells of different lineages depends on the differentiation 
of the LT-HSCs and ST-HSCs. As the lineage development takes place, the multipotency of these stem/progenitor 
cells becomes progressively limited. Eventually fully committed mature blood cells are produced, continuously 
replenishing the blood system in adult life.   
The conventional view of the architecture of hematopoiesis is challenged
Recent discoveries using different HSC labelling techniques such as endogenous fluorescent 
tagging10 and inducible genetic labelling11 in combination with transplantation data, 
gene expression analysis and epigenetic profiling, have challenged the traditional view 
of the architecture of hematopoiesis as discussed above. These data suggest that under 
homeostatic and/or stress conditions, hematopoiesis is comprised of heterogeneous clones 
of HSCs with pre-defined functional features challenging the dogma that a single HSC 
continuously differentiates to replenish the blood system. Rather than a single pluripotent 
HSC balancing between self-renewal and differentiation, the new findings suggest that the 
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heterogeneous clones of HSCs have different cell kinetics, balancing multipotent clones 
that are transient with clones that provide long-term cell output. A latest study10 suggests 
HSCs have a clone-specific stereotyped behavior that is epigenetically instructed, where 
the “epigenetic memory” is persistent and guides their function under different exogenous 
conditions, supporting a notion of cell autonomy. This notion seems to contradict the 
general thoughts of stem/progenitors being plastic cells capable of responding variably to 
the specific environment, arguing at least partially against the niche hypothesis (discussed 
in section 2 of this chapter) that the self-renewal or differentiation features of HSCs are 
dependent on HSC niche cues. These new findings challenge the traditional concepts of 
stem cell plasticity, hematopoietic hierarchy and stem cell niche to be refined. Bearing 
these evolving data in mind, the rest of this introduction relates to the conventional view of 
hematopoiesis and the work in this thesis builds on the current knowledge about the stem 
cell niche. 
Malignant transformation of HSCs
Following the conventional view of hematopoiesis, to ensure the homeostasis of the 
hematopoietic system, the normal HSCs must sustain self-renewal and multi-lineage 
differentiation in balance. Dysregulation in any of the two mechanisms may lead to the 
multi-step malignant transformation of HSCs to cancer/leukemia stem cells (CSCs/LSCs), 
hence the development of leukemia. Disruptions in many signaling pathways regulating self-
renewal of the normal HSCs have been shown to result in tumorigenesis/leukemogenesis, 
among which are the well-studied Wnt, Sonic hedgehog (Shh), Notch, JAK/STAT and RAS/
MAPK pathways.12 Genetic changes that lead to leukemia development must occur either 
in the LT-HSCs or in progenies that first acquire the self-renewal capacity. For example, LT-
HSCs can undergo a series of independent genetic and/or epigenetic changes that enable 
them to evade apoptosis and protective immune surveillance, transforming the HSCs to 
become leukemic-like. Alternatively, self-renewal genes or genes that block differentiation 
can be activated at the progenitor level (e.g. GMPs), giving rise to LSCs with the ability of 
deregulated self-renewal.3 On the other hand, transcriptional factors (TFs) regulating the 
lineage-restricted differentiation must be tightly regulated, any disturbance in these TFs 
would lead to leukemia development as well.1 More than twenty transcriptional factors have 
been described in hematopoietic malignances.1 Among others, somatic mutations in GATA-
1, PU.1 and C/EBPɑ, Pax5 and E2A have been respectively identified in Down Syndrome-
associated megakaryocytic leukemia, myeloid leukemias and B-lymphoid leukemia.13-16
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2. THE BONE MARROW MICROENVIRONMENT AND THE HSC NICHE 
Composition of the bone marrow niche and its function
The diverse functions of HSCs (incl. self-renewal, differentiation, and proliferation) must be 
tightly regulated and maintained in a finely tuned balance, which depends on factors derived 
from cell intrinsic and extrinsic sources. Extrinsic factors can be secreted from an assorted 
cellular types, among which components of the bone marrow microenvironment (BMME) 
have  been regularly implicated as one of the many sources. Architecture of the BMME 
is rather complex and a dynamic range of components have been identified. This thesis 
focuses on one of them: the “HSC niche”, an essential element of the BMME. The concept 
of the HSC niche has not been fully appreciated until half a century ago, we finally began to 
understand the crucial role of the HSC niche in hematopoietic homeostasis. Following the 
first experimental definition of a stem cell,17,18 Michael Dexter, Brian Lord, Raymond Schofield 
and their colleagues in Manchester developed in vitro assays of mesenchymal “stromal” 
cultures that could maintain primitive hematopoietic cells;19 in addition, they provided in 
vivo evidence showing that the stem and progenitor cells localize in specific regions within 
the bone marrow, suggesting the role of the bone in regulating hematopoiesis.20 Shortly 
thereafter, the “niche hypothesis” was formulated, introducing the stem cell niche as a 
specific regulatory unit in maintaining the stem cell function and protecting them from 
external insults.21 
Structural appreciation of the BMME is continuously evolving and distinct niches have 
been anatomically and physiologically defined within the BM. Among the different niches 
identified, this thesis focuses on the HSC niche, an important constituents of the BMME. 
Though the cellular complexity and functional heterogeneity of the HSC niche remain 
incompletely understood, this chapter (Chapter 1) reviews some aspects of the current 
understanding of the BM HSC and progenitor (HSPC) niche. Building on these discoveries, 
we performed a series of experiments described in this thesis, hoping to bring new insights 
into the contribution of the BM HSC niche to normal and malignant hematopoiesis.
A niche is defined by its anatomy and function,22 a local microenvironment that directly 
maintains and regulates a stem or progenitor cell.23 Throughout development, the HSCs 
reside in dynamic niches of different tissues defining the specific HSC developmental 
state. The first HSC niche is probably in the AGM region and yolk sac, allowing the HSCs 
to proliferate and expand; then the HSCs localize to the placenta and fetal liver, before 
migrating to the bone marrow where they are mostly quiescent to protect their integrity 
and functions.24 It is of considerable interest to better understand the cellular composition 
and function of the HSC niche, especially the BM HSC niche, which is key to the maintenance 
of postnatal hematopoietic homeostasis. In the recent years, the discovery of cell surface 
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markers that could robustly identify HSCs in vivo25 has critically contributed to the effort 
in defining the HSC niche. The fact that a simple combination of a few surface markers 
can accurately identify HSCs with high purity, allowed us to localize HSCs in tissue sections, 
providing important clues about the relevant localizations of the bone marrow HSC niche. In 
addition, a combination of experiments using in vitro (co-)culture assays and genetic mouse 
models have generated crucial insights into the functional relevance of a specific HSC niche 
component (Figure 2). 
Osteoblasts and the endosteal niche 
Osteoblasts lining along the endosteal surface (Figure 2) were the first niche component 
described to regulate hematopoiesis. In the 1990s, Taichman et al established in vitro co-
culture systems showing that osteoblasts could maintain primitive hematopoietic cells via 
the production of granulocyte colony-stimulating factor (G-CSF).26,27 Later in vivo experiments 
using the Col2.3ΔTK conditional mouse model have revealed that specific ablation of 
osteoblast lineage cells resulted in bone loss and reduced HSCs numbers, accompanied 
by decreased level of hematopoietic progenitors.28,29 Other in vivo studies uncovered 
the potential mechanism,   showing the loss of HSPCs upon osteoblastic perturbation is 
mediated via Notch signaling and N-cadherin (Cdh2)-mediated adhesion.30,31
Since then, researchers have questioned the exact/direct role of these mature bone-lining 
cells in HSC regulation. For instance, absence of osteoblasts in biglycan-deficient mice showed 
no effects on HSC number or function32; whereas, increasing the number of osteoblasts by 
treating the mice with the chemical element strontium did not alter HSC activity33 either. In 
addition, in vivo imaging studies of mice under homeostatic condition indicated few HSCs 
were in direct contact with osteoblasts and also few HSCs could be detected within 5 µm 
range of the endosteum.25,34 Surprisingly, conditional deletion of Cdh2 in hematopoietic 
and stromal cells or osteolineage cells had no effects on the number and function of HSCs, 
questioning the involvement of N-cadherin in osteoblasts-HSCs interaction.32,35,36
In fact, more recent work has suggested an indirect effect of mature osteoblasts in HSC 
maintenance. For example, through activation of parathyroid hormone receptor (PTHR), 
osteoblasts secrete cytokines, chemokines, growth factors (e.g. IL-6, RANKL and Jagged1) and 
extracellular matrix proteins (MMPs) that can influence other bone marrow cells including 
the vasculature, which could indirectly contribute to HSC regulation.30,37 Though these data 
seem to suggest that the mature osteoblasts do not directly contribute to HSC maintenance, 
bone-forming progenitors around the endosteum are crucial for hematopoiesis. Conditional 
postnatal deletion of Sp7 (osterix) (marks osteoprogenitors) severely impaired hematopoiesis 
in the metaphysis region38 and bone-forming osteoprogenitors can promote the formation 
of HSCs niche (e.g. by recruiting vasculature) in the bone marrow.39,40 Moreover, during BM 
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tissue injury, such as in a transplantation setting, HSCs have been found to preferentially 
home to the endosteal region in irradiated mice; but in mice under normal condition, HSCs 
seem to distribute randomly across the marrow.41 Altogether, these findings indicate that 
the endosteal niche is essential for hematopoiesis and the mature osteoblasts probably 
have an indirect role in modulating HSCs by influencing other bone marrow cells and the 
vasculature via secreted factors (Figure 2). 
The perivascular niche 
As earlier mentioned, the complexity and heterogeneity of the cellular components of the 
HSPC niche have been gradually appreciated, thanks to technical advancements. The first 
milestone was the introduction of SLAM family receptors, allowing identification of LT-HSCs 
(CD48-CD150+Lin-c-Kit+Sca-1+)25 to an accuracy where one in two isolated cells is able to 
reconstitute the whole BM of a transplant mouse. In parallel, optical clearing techniques 
enabling deep imaging through tissue sections, have granted much better assessments of 
the spatial relationship between HSCs and the relevant niche components. Combination 
of cell surface markers and the recent in situ imaging studies have revealed interesting 
findings. In homeostatic conditions, around 85% of HSCs are in close contact with sinusoidal 
blood vessels; meanwhile, both dividing and non-dividing HSCs (defined by Ki-67 staining) 
are shown to be distant from the endosteal surface.34 These data suggest that HSCs are likely 
nurtured in a perivascular niche composed of perivascular stromal cells and endothelial cells, 
which secrete factors that are essential to HSCs maintenance and regulation (Figure 2). The 
exact relationship among these perivascular niche cells expressing different markers remain 
to be defined. Researchers just begin to deconstruct the complexity in relating each niche 
component to HSC function by experiments using a reductionist approach: systematically 
depleting essential niche factors from different cellular sources and examining the effect of 
such depletion on HSC biology.
Key HSC supporting factors & the perivascular mesenchyme
The identity and function of niche components and key factors relevant for HSPC regulation 
have been much better defined in mice than in human. CXC chemokine ligand 12 (CXCL12), 
also known as stromal cell-derived factor (SDF)-1 has long been described to be a key HSC 
niche factor. Together with its primary binding receptor CXCR4, CXCL12-CXCR4 signaling 
plays a crucial role in the retention42-45, quiescence46,47 and repopulating47 of HSCs in the 
bone marrow. It is worth noting that recent findings have indicated the cellular sources of 
CXCL12 are critical to HSC or progenitor activity; depending on the source, CXCL12 could 
differentially affect the stem cells or progenitors. For instance, loss of Cxcl12 or Cxcr4 
expression from several perivascular mesenchymal stem/progenitor cells (MSCs/MPCs), 
including CXCL12-abundant reticular (CAR) cells48, Nestin-GFP cells49, Lepr+ cells50, and Prx-
1+ cells51, resulted in reduced number of HSCs accompanied by an elevated mobilization. 
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Findings from these mouse models are congruent with several imaging studies showing 
that most HSCs juxtapose sinusoidal blood vessels, which are closely associated with the 
perivascular mesenchymal cells expressing high levels of CXCL12 (Figure 2).25,32,34 On the other 
hand, instead of the HSCs, depletion of Cxcl12 from osterix+ (Sp7-Cre) osteoprogenitors and 
osteoblasts (Col2.3-cre) affected the progenitors, where the hematopoietic progenitor cells 
(HPCs) are mobilized. Furthermore, diminution of osteoblast-expressing CXCL12  specifically 
depleted the lymphoid progenitors.50,51 Interestingly, conditional deletion of Cxcl12 from 
Nestin-Cre-expressing stromal cells or Vav1-Cre hematopoietic cells had little or no effects 
on HSCs,  nor on the more restricted HPCs.50 These studies provided a more refined insight 
into the heterogeneity of CXCL12-producing cells in the perivascular niche and their distinct 
relations with the activities of HSCs and HPCs (Figure 2), suggesting  the existence of distinct 
cellular niches in the bone marrow for stem and progenitor cells.
In addition to CXCL12, stem cell factor (SCF; also known as KITL) is another essential HSC-
maintenance factor. SCF is primarily expressed perivascularly, as revealed by studies in 
a ScfGFP knock-in model.52 Similar to CXCL12, the cellular source of SCF is relevant to the 
different effects on stem or progenitor cells and this relevance has been interrogated using 
mouse models of conditional Scf deletion from distinct stromal population(s). Deletion of 
Scf from Lepr-expressing perivascular stromal cells depleted HSCs; whereas loss of Scf from 
hematopoietic cells (Vav1-cre), osteoblasts (Col2.3-cre) and Nestin-Cre or Nestin-CreER-
expressing cells did not affect HSC frequency.52 Besides CXCL12 and SCF, other factors such 
as angiopoietin-1 (Ang-1) and thrombopoietin (TPO) have also been indicated important to 
HSC maintenance. Ang-1 signaling promotes the quiescent state of HSCs in the bone marrow 
niche and protects the stem cells from myelosuppression.53 Together with its receptor MPL 
(expressed on HSCs), Ang1-MPL signaling is required for maintaining the quiescence of 
LT-HSCs by regulating cell-cycle related genes.54 However, the important cellular source(s) 
of Ang-1 and TPO for HSC maintenance remain to be defined and conditional deletion 
experiments will be required to address this. 
Perivascular endothelial cells
Staining of bone marrow tissue section using SLAM-HSCs and endothelial markers 
demonstrated that endothelial cells also contribute to the perivascular niche.25 VEGFR2 
and E-selectin are specific markers for BM endothelial cells. Conditional deletion of VEGFR2 
signalling blocked the recovery of sinusoidal endothelial cells (SECs) and prevented the 
engraftment and reconstitution of HSPCs in irradiated mice;55 whereas deletion of E-selectin 
improved HSCs survival and accelerated hematopoietic recovery after chemotherapy or 
irradiation in mice, suggesting E-selectin promotes HSC proliferation.56 In addition, loss of 
Cxcl12 or Scf from Tie2-Cre endothelial cells specifically reduced the frequency of LT-HSCs 
and donor cells from the mutant mice showed significantly lower reconstitution capacity 
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during transplantation.50,52 Taken together, these data demonstrated that endothelial cells 
are a crucial component of the perivascular niche and BM endothelial cells derived niche 
factors are physiologically important to HSPCs biology.
Other components in the perivascular niche 
It is important to note that endothelial cells and mesenchymal stromal cells are not the 
only cellular components of the perivascular niche (Figure 2). The sympathetic nervous 
system (SNS),57,58 macrophages,59,60 non-myelinating Schwann cells61 among others have 
all been implicated in regulating HSCs retention, mobilization and circulation via CXCL12 
expression, interaction with other (e.g. Nestin+) mesenchymal cells, circadian oscillation 
or TGF-ß activation. Interestingly, mature hematopoietic cells such as macrophages or 
megakaryocytes can also regulate HSC activity by interacting with other niche elements or 
on their own. For example, in normal condition, megakaryocytes can act as a gatekeeper 
for HSC quiescence through secretion of CXCL4 and TGFß-1; while after chemotherapeutic 
challenge, megakaryocytes can promote HSC expansion via FGF1 secretion.62,63 In a nutshell, 
experiments derived from these mouse models have highlighted the complexity of the HSPC 
niche. Our understanding of the identity, function and the lineage relationship among the 
many different niche cell types remains incomplete. Besides, still little is known about the 
human equivalence of the identified niche populations in mice.  
In the few studies that investigated the cellular component of the HSC niche in human, 
nerve growth factor receptor (CD271) and melanoma cell adhesion molecule (CD146) 
have been the most widely studied markers. Human bone marrow CD271+ cells has been 
shown to support hematopoiesis and are enriched for CFU-Fs with tri-lineage differentiation 
potential in vitro. In situ histology staining showed that marker CD271 stains for bone-lining 
cells in the trabecular region as well as perivascular cells in the marrow, both in proximity 
to human CD34+ HSPCs.64,65 CD146 defines subsets of bone marrow CD271 population to 
be either endosteal (CD146-) or perivascular (CD146+), labelling adventitial reticular cells 
that are enriched for CFU-F and express SCF and CXCL12.40,64 Other markers such as PDGFRɑ 
(CD140ɑ) and integrin ɑV (CD51) have also been demonstrated to label clonogenic cells in 
the human bone marrow that support hematopoiesis and form mesenspheres in vitro.66 To 
date, very little is known about how the different niche populations described in mice are 
reflected in humans. Hence, the spatial and functional relationship between the different 
mesenchymal cells and HSPCs in humans remains to be defined.    
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Figure 2. the HSPC niche composition (adapted from Morrison et al, 2014).23 The HSCs and HPCs occupy distinct 
bone marrow niche, which is typically divided into the endosteal niche and the perivascular niche. Majority 
of HSCs are found to localize adjacent to sinusoids or other blood vessels, where endothelial cells (typically 
marked by VEGFR2 and E-selectin) and mesenchymal stromal cells (expressing CAR, nestin, lepr, and prx1) 
regulate HSC activity via the secretion of HSC-supporting factors, such as CXCL12 and SCF. Other factors might 
also be involved. Osteoprogenitors (osterix expressing) are important bone forming cells that play a key role in 
HSC regulation as well. The bone-lining osteoblasts and osteoclasts seem to be more directly involved in the 
maintenance and differentiation of the early lymphoid progenitors, while they are more likely to play an indirect 
role in HSC regulation. Other cellular types also contribute to the complex architecture of the HSPC niche, including 
sympathetic nerves, non-myelinating Schwann cells, macrophages and megakaryocytes.
The cellular composition of the HSPC niche is complex and heterogeneous. This thesis 
covered the role of several key HSPC niche components in mouse models and human 
patients. Specifically,  in Chapter 3, we extensively investigated osterix+ mesenchymal 
progenitor cells (MPCs) using mouse models. In Chapter 2, 3 and 4, we studied CD271+ 
mesenchymal cells in human patients.
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3. HUMAN PRE-LEUKEMIC CONDITIONS  
3.1 Bone marrow failure syndromes: ribosomopathies 
Bone marrow failure (BMF) syndromes can be either inherited or acquired. The inherited 
form is characterized by ineffective hematopoiesis, frequent physical anomalies and 
predisposition to cancer with distinct clinical presentations specific to each disease. Inherited 
BMF syndromes include Fanconi Anemia (FA), Dyskeratosis Congenita (DC), Shwachman-
Diamond Syndrome (SDS), Diamond-Blackfan Anemia (DBA), congenital amegakaryocytic 
thrombocytopenia (CAMT) and severe congenital neutropenia (SCN).67 In the past decades, 
tremendous efforts have been dedicated to a better understanding of the genetics 
associated with inherited BMF syndromes. Alongside, we have also gained considerable 
insights in normal hematopoiesis and how this is disrupted in BMF patients. Importantly, 
these studies have advanced our knowledge in fundamental biological pathways, such 
as ribosome biogenesis. A group of inherited BMF syndromes including DBA, SDS and DC 
is associated with defective ribosome biogenesis. These syndromes, together with 5q- 
syndrome, a subtype of adult myelodysplastic syndrome (MDS) where the ribosomal gene 
RPS14 is mutated, are collectively known as ribosomopathies.
Ribosome biogenesis is a highly-regulated and complex process that plays a key role in the 
regulation of protein translation.68 Eukaryotic ribosomes consist of the small 40S and the 
large 60S subunits, which join together to form the translationally active 80S ribosome. 
Ribosome assembly is a complex process using large amount of cellular biosynthetic energy. 
This process requires many important components including 4 structural ribosomal RNAs 
(rRNAs), around 80 core ribosomal proteins, more than 150 associated proteins and around 
70 small nucleolar RNAs (snoRNAs).69 The 40S subunit contains 18S rRNA and the 60S 
subunit contains 28S, 5.8S, and 5S rRNAs. The 5.8S, 18S and 28S rRNAs are transcribed by 
RNA polymerase I whereas 5S rRNA is transcribed by RNA polymerase III. In the nucleolus, 
ribosomal proteins, nonribosomal assembly/processing factors and snoRNAs bind to the 
precursor rRNA transcripts to facilitate a series of cleavage and modification events, including 
methylation and pseudouridylation to produce pre-60S and pre-40S preribosomal/precursor 
particles. These preribosomal/precursor particles are then transported to the cytoplasm for 
the final steps of producing actively translating mature ribosomes.70 Mutations in distinct 
ribosomal proteins have been linked to defects at the specific steps in pre-rRNA processing, 
resulting in incomplete/dysfunctional ribosome biogenesis and ultimately defects in protein 
translation machinery, which give rise to specific ribosomal abnormalities that present 
diverse clinical phenotypes (Figure 3). 
Chapter 1
21
Shwachman Diamand Syndrome
SBDS protein
Function: Joins ribosomal subunits
Required for the formatin of mature
80S ribosome
Dyskeratosis Congenita (DC)
Dyskerin protein: Converts
Uridine → Pseudouridine (Ψ)
Funtion: Binding of RNA ligands,
translation of IRES-containing
mRNA, translation fidelity
Diamond Blackfan Anemia
Ribosomal proteins
RPs mutated in 60S:
RPL5, RPL11, RPL15, RPL26,
RPL35A
RPs mutated in 40S:
RPS7, RPS10, RPS17,
RPS19,RPS24, RPS26
Function: Involved in ribosome biogenesis,
protein synthesis, and translation of specific mRNAs
mRNA
60S
40S
SBDS
RPL
RPS
Figure 3. Key ribosome components and mutations associated with ribosomopathies (adapted from Ruggero 
et al, 2014).68 The dyskerin protein, an rRNA pseudouridine synthase is encoded by DKC1 gene, that is frequently 
mutated in X-DC. SDS is caused by mutations in Sbds gene that is important for joining the two ribosomal subunits. 
In DBA, RP genes encoding ribosomal proteins that are associated with small and large ribosomal subunits are 
often mutated. 
Diamond-Blackfan Anemia 
In 1999, recurrent mutations in a ribosomal protein gene RPS19 were reported in patients 
with DBA.71 Thereafter, heterozygous mutations resulting in haploinsufficiency in 11 
additional ribosomal genes have been identified (Table 1). DBA is probably the congenital 
BMF syndrome with the highest degree of genetic heterogeneity. On average, 60%-70% of 
DBA cases are due to mutations in ribosomal genes, which leave the rest of the patients 
genetically unidentified.68 In some cases of DBA, X-linked mutations in the transcription 
factor GATA1, which is critical for erythropoiesis have been reported.72 Typically, DBA patients 
have normochromic anemia that is macrocytic with reticulocytopenia. Bone marrow of 
these patients is usually normocellular with defective or absence of erythroid precursors. 
Approximately 40%-62% of DBA patients have physical anomalies including craniofacial (e.g. 
lip or palate cleft) or thumb abnormalities, cardiac defects and short stature.73 Other noted 
characteristics that have been integrated into the diagnosis of DBA include elevated level of 
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adenosine deaminase in RBCs and the presence of fetal membrane antigen “i” (Table 1).74,75 
Currently, the only curative treatment is bone marrow transplantation. Typical supportive 
care for DBA patients aims to improve erythropoiesis by applying steroids and chronic RBCs 
transfusions.76 
Generally in DBA, as a result of heterozygous mutations leading to haploinsufficiency 
or reduced expression in different ribosomal proteins, the level of 40S or 60S ribosomal 
subunits is significantly lower, so as the amount of mature 80S ribosomes.77-80 Though an 
overall decrease in the number of mature ribosomes, DBA patients carrying mutations in the 
11 different ribosomal genes present distinct clinical features; yet the effect of decreased 
ribosomal protein activity in vivo and in a tissue-specific manner remain to be revealed.
5q_ Syndrome
5q_ syndrome was first described in 1974. It is an acquired MDS characterized by a 5q_ 
cytogenetic clonal abnormality. Interestingly, 5q_ patients shares many clinical features with 
DBA patients.81 According to the World Health Organization (WHO) criteria, 5q_ syndrome is 
clinically characterized by severe macrocytic anemia, thrombocytosis with hypolobulated 
micromegakaryocytes, and a lower rate of progression to acute myeloid leukemia (AML) 
compared to other MDS subtypes (Table 1).82 Ribosomal gene RPS14 resides in the common 
deleted region of 5q. The link between this ribosomal gene and the disease dates back to the 
experiment where a small interfering RNA screen was performed. Each gene within the 5q_ 
syndrome common deleted region was knocked down, only knock-down of RPS14 showed 
defects specifically in erythropoiesis, while the other lineages were relatively preserved. 
Notably, introduction of the RPS14 gene back into the samples from 5q_ patients rescued 
erythroid differentiation.83 RPS14 haploinsufficiency results in significantly lower level of the 
40S small ribosomal subunit, most likely due to defective pre-18S rRNA processing.83 Thus, 
the molecular pathophysiology of 5q_ MDS appears to overlap with that of DBA.84 In addition 
to RPS14, other genes and microRNAs present within the 5q locus have been shown to 
contribute to other aspects of the disease phenotype.85 
Shwachman-Diamond Syndrome  
SDS was first reported in 1964 in a group of 5 children.86 It is a rare (around 1 in 50,000 
births) autosomal recessive disease69, characterized by ineffective hematopoiesis(mostly 
neutropenia), exocrine pancreatic dysfunction, and an increased risk for the development 
of clonal cytogenetic abnormalities, MDS and AML (Table 1). Patients typically present 
steatorrhea and serious infection due to neutropenia, but often show signs of anemia, 
thrombocytopenia, short stature and skeletal defects as well.68 Bone marrow transplantation 
is the only definitive therapy and SDS patients are mostly treated with supportive cares 
including pancreatic enzymes, antibiotics, RBCs or platelets transfusions, and G-CSF.87 
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Approximately 90% of SDS patients are caused by biallelic mutations in the SBDS 
gene located on chromosome 7q11, among which 75% of these mutations are due to a 
gene conversion with an adjacent highly homologous pseudogene, SBDSP, which contains 
mutations that disrupt protein production.88 The SBDS gene is revolutionarily conserved with 
orthologs in archaea, plants and vertebrates, and it is ubiquitously expressed across a broad 
range of tissues. Though the exact structure and function of SBDS remain to be revealed, 
accumulating evidence indicates the important role it plays in ribosome biogenesis and RNA 
processing.89 A number of experiments conducted earlier in yeast, followed by findings in 
mouse models, suggest that SBDS promotes the release of eukaryotic initiating factor (EIF6) 
from the pre-60S ribosome by catalyzing the GTPase activity of elongation factor-like 1 
(EFL1).90,91 The GTP coupled EFL1 undergoes a structural conformation change that induces 
the release of ELF6, which then allows the full maturation of the large 60S subunit and its 
binding to the 40S.90,91 This ribosome joining step is crucial to the subsequent formation of 
the mature 80S functional ribosome. Deletion of Sbds in animal models resulted in polysome 
profiles with halfmers, a pattern that is observed when the 40S subunit failed to join the 60S 
subunit.91 In addition, reduced ribosomal subunit joining has been observed in SDS patients, 
further indicating that the ELF6 releasing function of SBDS is impaired due to mutations in 
the SBDS gene.92,93 Interestingly, besides the suggested role of SBDS in ribosome biogenesis, 
recent evidence has uncovered its non-ribosomal activities, ranging from stabilizing the 
mitotic spindle,94,95 to the metabolism of cytoskeleton in neutrophils,96 to improving cellular 
survival in the context of cellular stress.97 These non-ribosomal activities may also play an 
important role in the clinical phenotypes of SDS patients. 
Disease Gene Defect Clinical Features Cancer Risk Diagnosis
Diamond 
Blackfan 
Anemia (DBA)
RPS: 7, 10, 17, 19, 24, 26
RPL: 5, 11, 15, 26, 35A
Macrocytic anemia;
short stature;
cranifocial defects;
thumb abnormalities
?osteosarcoma;
?MDS
RPS19/RPS24 
sequencing;
elevated ADA;
elevated Hgb F 
levels
5q-syndrome RPS14 Macrocytic anemia;
hypolobulated
micromegakaryocytes
10% progression
to ALM
bone marrow
aspiration/biopsy
with karyotype
Swachman-
Diamond
syndrome (SDS)
SBDS neutroponie/infections;
pancreatic
insufficiency; short 
stature
MDS and AML SBDS gene testing
Table 1. Summary of the clinical features, cancer risks and diagnostics for ribosomopathies: DBA, 
5q- syndrome and SDS.69 
ADA: adenosine deaminase; Hgb F: fetal hemoglobin 
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Of the abovementioned ribosomopathies, Chapter 3 in this thesis studied the rare 
congenital BMF disease SDS. In this chapter, we modelled SDS by specifically deleting 
the gene Sbds in the osterix-expressing MPCs and investigated the contribution of the 
niche to disease pathogenesis. 
3.2 (Low-risk) Myelodysplastic Syndromes (LRMDS) 
Myelodysplastic syndromes (MDS) probably represent the most common group of acquired 
bone marrow failures syndrome in adults, specifically in the elderly.98 So far, MDS have 
been considered to be clonal disorders of the hematopoietic compartment characterized 
by ineffective hematopoiesis, dysplastic cell morphology, cytopenia in the peripheral 
blood, and a high propensity for clonal evolution to AML. Typically, MDS may be classified 
as indolent (low-risk) or aggressive (high-risk) MDS, depending on the survival and risk 
for leukemic progression. The clinical presentation of MDS patients is heterogeneously 
grouped to many different subtypes, likely due to the great variety of genetic lesions 
contributing to disease pathogenesis. It is the principal hematological pre-malignancy, 
with >30,000 patients diagnosed per year in the United states.99 At the moment, MDS is 
diagnosed through a combination of assessments on both morphologic abnormalities and 
histological architecture using bone marrow aspirate and biopsy. When these assessments 
are coupled with conventional karyotyping (abnormal in ~50% of de novo MDS patients) 
and mutation analysis, we can in most cases confirm disease clonality.98 In the past decades, 
the classical prognostication scoring systems of MDS have undergone continuous revisions, 
trying to address the limitations of each version. The International Prognostic Scoring 
System (IPSS) was first introduced in 1997,100 and revised in 2012 (IPSS-R).101 Though IPSS-R 
is the most widely used tool for predicting the disease risk, complementary risk models 
including the WHO classification-based prognostic scoring system (WPSS), the MD Anderson 
Comprehensive Scoring system, and the MDS Anderson Lower Risk MDS Model have been 
developed.102-104
Model of disease pathogenesis 
In order for a MDS clone to result in clinical manifestations, the balance of self-renewal and 
differentiation must be deregulated as discussed in section 1.2 of this introduction, usually 
via a multi-step transformation. The steps associated with MDS disease pathogenesis (Figure 
4)105 include 1) enhanced self-renewal in the MDS disease-initiating HSPCs;106 2) increased 
proliferative capacity accompanied by the acquisition of anti-apoptotic mechanisms in 
the disease-sustaining clone; 3) impaired differentiation; 4) (epi)genetic instability; 5) 
circumvention of the immune system; and (6) suppressed normal hematopoiesis. The 
clinical manifestation of the disease, including the types/degrees of cytopenia present and 
whether the disease is indolent or aggressive, could be perhaps due to the degree at which 
each step is affected.    
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Normal 
Hematopoiesis 
Stem Cell Progenitor Cells
Mature Cells
Enhanced 
Self-renewal Mature Cells
Enhanced 
Self-renewal &
Impaired differentiation
Cytopenias
Acquired self-renewal &
Impaired differentiation Cytopenias
Increased proliferation &
differentiation block X Leukemia
Figure 4. Different pathways to transformation in MDS (adapted from Bejar R et al, 2011).105 The key feature of 
MDS is clonal expansion and ineffective hematopoiesis, which often result in cytopenias. The observed clinical 
phenotypes are likely due to the combination of different genetic and epigenetic abnormalities, driving cellular 
events that give clonal advantage of certain lesions. Individual lesions, such as enhanced self-renewal or altered 
apoptosis may cause one single transformation step, where in itself is clinically silent. However, when several 
abnormalities (e,g, acquired self-renewal and impaired differentiation) co-occur, such cooperation between two or 
more lesions is likely required for the full disease manifestation.     
Molecular genetics of MDS
Recent advancements in high-resolution genome-wide techniques, e.g. single nucleotide 
polymorphism (SNP) genotyping arrays, comparative genome hybridization, and targeted 
sequencing have allowed us to discover additional (recurrently) mutated genes, and (occult) 
chromosomal abnormalities, which have improved our understanding of the genetic basis 
associated with MDS development.98
Chromosomal abnormalities 
Knowing the chromosomal abnormalities of a patient is useful both diagnostically and 
prognostically. For example, deletion of Chromosome 5q (5q-) is the most common 
cytogenetic abnormality in MDS patient, with an incidence of roughly 15%. These patients 
typically have a relatively favorable prognosis with particularly good response to lenalidomide 
treatment.101,107 Careful analysis of the genes associated with commonly deleted regions 
(CDRs) in 5q- patients have implicated the importance of several genes in the pathogenesis 
of this MDS subtype.  Haploinsufficiency of the ribosomal gene RPS14 was identified to be 
General introduction
1
26
critical for the severe dyserythropoiesis, of which the mechanism was detailed in section 
3.1. Haploinsufficiencies of the two microRNAs, miR-145 and miR-146 are found to cause 
elevated platelet counts and may provide a selective advantage to the 5q- clone.108 Another 
two groups of MDS patients with 20q- (2-5%) and –Y (2-4%) abnormalities are also considered 
to be in the favorable prognosis group as are patients with a normal karyotype.105 The loss of 
Y chromosome seems to be unrelated to the disease pathogenesis of –Y patients.109 Unlike 
5q- subtype, analysis of the CDR of 20q identified 19 genes localized in this region; yet none 
of these genes have been conclusively associated with MDS pathogenesis.110,111
Unlike the good-risk cytogenetic abnormalities mentioned above, patients with 7q 
deletion, also known as monosomy 7 (~10%) are associated with relatively poor prognosis.105 
So far, at least three CDRs on 7q have been identified; unfortunately, the underlying 
molecular lesions that drive the disease phenotypes are not well understood.112-114 As the 
only recurrent chromosomal amplification, trisomy 8 is indicated in around 8% of MDS 
patients and belongs to the group of intermediate-risk cytogenetic abnormality with less 
than half the median expected survival of patients with a normal karyotype (22.0 vs 53.4 
months).115 Nevertheless, trisomy 8 patients respond to immunosuppressive therapy quite 
well.105 
Common genetic and epigenetic abnormalities 
Numerous sequencing studies have identified a number of frequently mutated genes in MDS 
and many of them directly contribute to disease pathogenesis and leukemia development. 
To date, TET2 is one of the most frequently mutated genes in MDS patients with an 
incidence of nearly 20%; TET2 mutations have also been identified in several other myeloid 
neoplasms, including MPN (10%), CML (30%-50%) and AML (25%).116,117 TET2 is a member 
of the TET family, which encodes methylcytosine oxidases, involved in regulating DNA 
methylation.118,119 In addition, mutations in ASXL1 and EZH2 have been identified to affect 
histone modifications with an incidence of 10% and 6% respectively in MDS patients.120-122 In 
line with these reports, mutations in the DNA methyltransferase gene DNMT3A have been 
identified in ~12% of MDS patients.98,123 Collectively, these findings indicate the important 
role of epigenetic dysregulation and altered gene expression in driving the pathogenesis of 
MDS. 
Interestingly, in 2009, the first whole-genome sequencing of an AML sample discovered 
recurrent mutations in the isocitrate dehydrogenase genes IDH1 and IDH2, which were 
first described in glioblastoma and thought to be tissue-specific oncogenes.124 Later work 
has focused on targeted sequencing of these two genes in AML and MDS. These work 
demonstrated that IDH mutations altered the function of these metabolic enzymes catalyzing 
the conversion of ɑ-ketoglutarate (ɑKG) to 2-hydroxyglutarate (2HG), which resulted in the 
accumulation of the 2HG oncometabolite.125,126 Mutations in IDH1 and IDH2 have been 
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identified in rare cases of MDS (~5%) and are often associated with more advanced disease 
and progression to AML.127,128   
Subsequently, whole genome sequencing has identified a novel class of mutated genes in 
MDS patients, encoding mRNA splicing factors. The first gene identified in this group was 
SF3B1. It is particularly frequently mutated (>70%) in a subgroup of MDS patients with 
refractory anemia with ring sideroblasts (RARS).129 Soon after, mutations in other splicing 
factors such as SRSF2, U2AF1 and ZRSR2 were identified.130,131 Together as a group, splicing 
factor mutations became the most frequently mutated class of genes in MDS, which were 
identified in >50% of MDS patients (Figure 5). Nonetheless, the association between these 
splicing factor mutations and MDS disease pathogenesis is yet to be understood. 
In the earlier genetic studies conducted between 1987 and 2005, the first genetic mutations 
identified in MDS patients were TP53, NRAS/KRAS and RUNX1 among many others.132-135 
TP53 is a classical tumor suppressor gene, which is often mutated in tumor cells, associated 
with genomic instability. Mutation of TP53 is found in 5%-15% of MDS patients, associated 
with poor prognosis and treatment resistance.136,137 In some cases of MDS, patients are 
characterized by activating mutations of the downstream RAS genes such as NRAS (10%-
15%) and KRAS (1%-2%), often associated with poor prognosis and progression to AML.135 
RUNX1 belongs to the member of the transcriptional core-binding factor gene family and 
is the second most commonly mutated gene in MDS with a frequency of 7%-15%; the 
incidence is higher in therapy-related diseases.138 In both MDS and AML, the presence of 
RUNX1 mutations indicate poor prognosis.139
Taken altogether, developments in whole genome sequencing techniques have provided us 
with a much better understanding of the mutational landscape of MDS and valuable insights 
into the clonal architecture of different neoplasms. However, these discoveries have not 
yet had major impact on treatment. Until today, the available drugs are not curative and 
allogeneic hematopoietic stem cell transplantation (HSCT) remains to be the only curative 
therapy. 
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Both splicing factors (SF) & 
Epigenetic regulators (ER) 
Overlap (25%) 
Splicing factors (~50%)
- SF3B1 (18%)
- U2AF1 (12%)
- SRSF2 (12%)
- ZRSR2 (5%)
- Others (5%) 
Rarely co-occure 
Epigenetic Regulators (~45%)
- TET2 (20%)
- ASXL1 (15%)
- DNMT3A (12%)
- EZH2 (5%)
- IDH1/2 (5%)
- Others (5%) 
Often co-occur except for 
TET2 & IDH
TP53 and no SF or ER (~5%)
often complex karyotypes with 
frequent del(5q), abnormal
chromosome 7, and monosomies 
Other mutations less frequent 
mutations in other genes only (~15%)
-TFs (Runx1, GATA2, etc)  
- Kinase Signalling (NRAS, KRAS, etc) 
- Cohesins
- DNA repair 
Karyotype abnormality only (~5%)
No common abnormality (~5%)
Figure 5. Distribution of chromosomal abnormalities and (recurrent) genetic mutations in MDS (adapted from 
Bejar R et al, 2014).98 The most frequent mutations seen in MDS patients are mutations in splicing factors (SF) 
(~50%) or epigenetic regulators (ER) (~45%); around 25% of patients have mutations in both groups. Mutations 
in TP53 gene often co-occur with other complex chromosomal abnormalities. Mutations in other genes can co-
occur with or in the absence of SF or ER lesions in ~15% of patients; where only 10% of patients do not carry the 
commonly recurrent mutations. 
MDS - the principal human pre-leukemic disorder is extensively studied in this thesis. 
Chapter 2 and Chapter 4, for the first time in the field, characterized the molecular 
landscape of highly purified mesenchymal population in LRMDS. In Chapter 3, to 
investigate the broader relevance of the findings in SDS mouse model to human 
patients, we looked into the purified mesenchymal cells from 45 MDS patients. Chapter 
5 explored the stromal compartment in a mouse model of MDS.
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4. ROLE OF THE HSPC NICHE IN HEMATOPOIETIC DISORDERS  
As mentioned earlier, the HSPC niche plays a critical role in regulating stem cell quiescence 
and number, particularly, in ensuring HSPC homeostasis. It is therefore reasonable to 
hypothesize that perturbation of the HSPC niche may contribute to the disease pathogenesis 
of hematological (pre)malignancies. Increasing evidence has challenged the traditional view 
that pre-leukemic and leukemic disorders are hematopoietic cell-autonomous diseases, 
but rather that the microenvironmental context can initiate and/or modify hematopoietic 
neoplasia.140 The hypothesis was first (indirectly) supported by the description of donor 
derived leukemia (DDL), a rare event following allogeneic hematopoietic cell transplantation 
(HCT), likely due to an altered microenvironment in the transplant recipients, leading to 
oncogenic transformation of the normal donor hematopoietic cells.141 
Model of niche-induced leukemogenesis 
Summarizing findings in the past decades defining the contribution of the bone marrow 
niche to leukemogenesis, two different but not mutually exclusive models have been 
proposed: niche-induced and niche-facilitated leukemogenesis (Figure 6). The first studies 
demonstrating microenvironment-induced disruption in hematopoiesis are associated with 
myeloproliferative neoplasm/disease (MPN/MPD). In 2005, Rupec et al. showed that mice 
with ubiquitous deletion of IƙBɑ developed MPN-like phenotypes. But conditional deletion 
of IƙBɑ in myeloid lineage and in fetal liver cells did not result in disease development, 
suggesting the observed MPN is likely initiated by non-hematopoietic cells with inactive 
IƙBɑ.142 Soon after, in a retinoic acid receptor (RAR) ɣ-/- MPN mouse model, myeloproliferation 
was not intrinsic to hematopoietic cells, but due to alterations in the microenvironment as 
only transplantation of wild-type cells into RARɣ-/- recipients resulted in disease development, 
not vice versa.143 A parallel study demonstrated that similar MPN phenotypes were only 
observed when deletion of retinoblastoma protein (Rb) took place in both hematopoietic 
cells and their BMME, as deletion in either one cellular source alone was not sufficient to 
induce any phenotype.144 Likewise, similar transplantation experiments in the mind bomb 1 
(Mib1-/-) mouse model revealed a BMME-dependent development of MPD due to defective 
Notch activation in the non-hematopoietic cells.145 Together, these examples indicated that 
the hyper-proliferation phenotype of MPN is induced by alterations in the BMME; however, 
these findings did not specify the disease-causing niche component and hematopoietic cell 
transformation was not observed. 
Disruption of Dicer1, an endonuclease essential for microRNA biogenesis, in an osterix-
expressing osteoprogenitor cell induced MDS-like phenotype and secondary leukemia with 
novel cytogenetic abnormalities. This study provided the first evidence demonstrating 
that primary alterations in a specific cellular component of the HSPC niche can initiate 
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malignancy in a distinct, parenchymal cell; thus, introducing the concept of “niche-induced 
oncogenesis” in the hematopoietic system.146 Deletion of Dicer1 in osterix+ osteoprogenitors 
led to the downregulation of Sbds, the disease-causing gene of human SDS.146 Interestingly, 
the mouse model of conditional Sbds deletion in osterix+ osteoprogenitors faithfully 
recapitulated the MDS-like hematopoietic phenotypes in human SDS.146 The concept of 
niche-induced oncogenesis is further supported by another study indicating that disease-
relevant mutation in PTPN11, a gene often mutated in Noonan syndrome, specifically in 
mesenchymal progenitor cells (including osterix+ cells) indirectly disrupted the function of 
HSPCs and induced the development of MPN in mice.147 In line with these findings, another 
study has reported that activating mutations in ß–catenin in osteoblasts associated with 
increased Notch signaling, resulted in the development of AML in mice.148 Taken together, 
these data suggest that primary dysfunction in a specific component of the HSPC niche, in 
particular the mesenchymal progenitor cells, can initiate hematological malignancies. 
Model of niche-facilitated leukemogenesis 
In parallel, several other studies have supported the model of “niche-facilitated 
leukemogenesis” (Figure 6). In this proposed model, the malignant hematopoietic 
cells can shape the HSPC niche into a self-reinforcing leukemic niche, which impairs 
normal hematopoiesis, favors the function of LSCs, and therefore contributes to disease 
pathogenesis. In contrast to the previously mentioned “niche-induced” model, an altered 
osteoblastic niche is a result of cell-cell interactions with leukemic cells. In a mouse model 
of chronic myeloid leukemia (CML), severe osteoblastic defects in cell number and function 
were observed, leading to a major bone loss associated with high level of CCL3 in mice 
and human patients.149 In line with this report, data obtained from a transgenic model of 
BCR-ABL1+ CML showed that the HSPC niche was remodeled into a leukemic niche with 
expansion of functionally impaired osteoblasts. Notch, TGF-ß and inflammatory signaling 
were found to be involved in the remodeling process. In addition, CCL3, TPO and direct 
cell-cell contact resulted in the osteoblastic expansion. Exposure of either normal HSCs 
or LSCs to the leukemic osteoblastic niche led to a reduced reconstitution capacity of the 
normal cells, but the function of LSCs remained intact, congruent with the decreased level 
of key HSCs-supporting factors.150 These findings suggest that inhibition of the “remodeling” 
effect of the leukemic cells, which likely shapes the niche in a way most beneficial to LSCs, 
but detrimental to normal HSCs, might have a negative impact on leukemic progression. 
However, further research into this direction is required. 
Another study demonstrating the importance of cooperation between the niche and 
aberrant hematopoietic cells was performed in a xenotransplantation model of MDS. 
Only co-transplantation of MDS-initiating Lin-CD34+CD38- stem cells with patient-derived 
mesenchymal stem/progenitor cells (MSPCs), isolated based on plastic adherence, resulted 
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in the development of MDS-like phenotypes in murine recipients. These patient-derived 
MSPCs presented altered differentiation pattern and distinct global transcriptome profile 
compared to the normal counterparts, probably due to factors such as N-cadherin, ILGFBP2, 
VEGFA and LIF as a result of interacting with the hematopoietic MDS cells.151 
In the meantime, parallel studies have provided us with a better understanding of the 
mechanism underlying how LSCs alter the HSPC niche, specifically the perivascular niche. 
As previously mentioned, the arterioles in the bone marrow are highly innervated by the 
SNS, which plays an essential role in regulating HSCs activity. In a murine (JAK2 V617F+) 
MPN model, the malignant HSCs resulted in neuropathy (loss of neural fibers) and 
depletion of nestin+ mesenchymal cells via the secretion of IL-1ß. The loss of neural fibers 
and mesenchymal elements severely accelerated MPN development. Treatment with 
sympathomimetic agent (ß3-adrenergic agonist) restored the loss of nestin+ mesenchymal 
cells and blocked the development of disease, indirectly via the reduction of MPN cells.152 
These findings were supported by another study reporting leukemia-induced neuropathy 
of the SNS promotes leukemic bone marrow infiltration in a murine AML model of MLL-
AF9 AML. AML development impaired the quiescence of nestin+ cells, promoting the 
differentiation of MSPCs towards osteoblasts, while not favoring the peri-arteriolar niche 
cells with HSC-supporting capacity. Interestingly, leukemogenesis was promoted by the ß2-
adrenergic receptor expressed on the stromal cells of the leukemic bone marrow, suggesting 
that the malignant cells might be able to “hijack” the SNS to integrate the BMME, to foster 
and advance the neoplasm.153 
Taken together, we have gained a more comprehensive understanding of the architecture 
of the BMME at a cellular resolution, which allowed us to interrogate the contribution 
of specific HSPC niche component to disease pathogenesis using different (conditional) 
genetic mouse models. While these experimental tools have advanced our knowledge, 
these experimental conditions are unlikely to be met in human investigations, so the human 
relevance of these findings is yet to be established.
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Preleukemic HSC
Leukemic HSC
Normal Mesenchyme
Aberrant Mesenchyme
Factors supporting normal hematopoiesis
Factors supporting (pre)malignant hematopoiesis
A B
Figure 6. The role of the niche in leukemogenesis. (A) Model of “niche-induced leukemogenesis”: primary 
alteration in the cellular component of the HSPC niche can disrupt normal hematopoiesis, induce transformation 
of normal HSCs to become aberrant pre-leukemic HSCs, and further promote the development of leukemia. (B) 
Model of “niche-facilitated leukemogenesis”: acquisition of genetic abnormalities in normal HSCs transform these 
normal cells to become pre-leukemic. These pre-leukemic HSCs remodel their niche into an aberrant niche that 
contribute to the transformation of the pre-leukemic cells into leukemic HSCs. 
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Role of the HSPC niche in Human MDS
Alterations in the bone marrow environment have long been documented in MDS and 
other myeloid malignancies. The “topography” (localization) of the hematopoietic 
elements within the marrow is often disrupted.154-156 Elevated levels of VEGF and numerous 
inflammatory  cytokines (e.g. IL-6, IL-8, TNFɑ, TGFß etc.) are often observed in the bone 
marrow of MDS patients, which were thought to be the result of the interplay among 
the aberrant hematopoietic cells, activated immune system and the stroma.157,158 Though 
many immunodeficient mouse models have been developed for investigating human 
hematopoietic malignancies via xenograft transplantation, application of this approach has 
proven to be difficult in MDS. In MDS, transplantation studies have consistently shown poor 
engraftment of myelodysplastic cells in immunodeficient mice, and failure to recapitulate 
hematopoietic phenotypes of human MDS.159-162 These observations suggest that MDS 
is a disease of the tissue, that disruption of hematopoiesis goes beyond changes in the 
hematopoietic cells alone. 
So far, our knowledge about the role of the MDS stroma is derived from ex vivo expanded 
stromal cells based on their plastic adherence property – also known as bone marrow 
derived stromal cells (BMDSC). Though the data is highly controversial, BMDSC isolated 
from MDS and AML patients have been identified to carry genetic abnormalities.163,164 Other 
data defining the transcriptional changes of  these BMDSC from MDS patients have revealed 
the following: reduced expression of adhesion molecules165 and transcriptional factors166, 
activation of p38MAPK signalling167 and TNF- modulating genes168, and increased expression 
of a range of cytokines.151 However, how these adherent stromal cells in a dish reflect the 
complex bone marrow architecture of human patients remains largely unknown.
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5. SCOPE AND OUTLINE OF THE THESIS 
Accumulating evidence in the past years has revealed that hematopoietic disorders are 
diseases of the tissue, where the niche cells, immune cells, among other elements, in addition 
to aberrancies in the hematopoietic compartment contribute to disease pathogenesis. 
As mentioned earlier, insights into the biology of the bone marrow niche elements in 
hematopoietic aberrancies have been limited to studies investigating ex vivo expanded 
stromal cells where the relevance to their in situ counterparts remains largely unknown. The 
first goal of this thesis as described in chapter 2, is to characterize the global transcriptome 
of prospectively isolated, directly purified mesenchymal elements from a cohort of low-risk 
MDS (LR-MDS) patients. Our previous work in mouse modeling has supported the concept 
of “niche-induced leukemogenesis” by showing ribosomal stress in osteoprogenitors 
can induce MDS-like hematopoietic abnormalities, recapitulating key phenotypes in SDS 
patients. In chapter 3, we interrogated the molecular mechanism(s) behind this concept 
as well as its relevance to human disease by combining mouse modelling of Sbds deletion 
in osterix+ MPCs and investigating human-equivalent mesenchymal cells in SDS and MDS 
patients. Extending our findings from chapter 2 and chapter 3, in chapter 4, we revealed 
activation of Nuclear Factor-κB (NF-κB) pathway as a biological commonality in LR-MDS 
mesenchyme, supported by ex vivo genetic study demonstrating the inhibitory effect of 
mesenchymal NF-κB signaling in normal hematopoiesis. In chapter 5, we were interested 
in the other side of the coin by using a hematopoietic cell-autonomous model of MDS - the 
Vav-Nup98-Hoxd13 (NHD13) model to investigate the effect of altered HSPCs (NHD13+ MDS 
cells) on their niche and how this niche may affect normal hematopoiesis and contribute 
to bone marrow failure. In the end, the findings in this thesis are summarized in chapter 6, 
along with discussions concerning the relevance of our findings to the field of hematopoietic 
(pre)malignancies, broader relevance to cancer and potential future perspectives. 
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Myelodysplastic syndromes (MDS) have long been considered hematopoietic cell-
autonomous disorders in which disease initiation and progression is exclusively driven by 
hematopoietic cell intrinsic genetic events. Recent experimental findings have challenged 
this view, implicating mesenchymal elements in the bone marrow microenvironment in 
disease pathogenesis. Specifically, genetic perturbation of mesenchymal cells has the ability 
to induce MDS and acute myeloid leukemia (AML), establishing an experimental concept 
of ‘niche-induced’ oncogenesis.(1, 2) Alternatively, primary alterations in hematopoietic 
cells have the ability to alter mesenchymal niche components such that niche cells 
facilitate disease propagation in the context of xenograft transplantation.(3) Together, these 
observations challenge the view that ineffective hematopoiesis and leukemic progression is 
exclusively driven by hematopoietic-cell autonomous events in human MDS. Translation of 
experimental findings to human disease is complicated by a lack of insight in the molecular 
wiring of primary, non-expanded, mesenchymal cells in MDS. Insights into the biology of 
mesenchymal elements in human MDS, and other hematopoietic disorders, thus far, have 
been derived from studies investigating ex vivo expanded mesenchymal cells derived from 
the diseased bone marrow. The hierarchic, biologic and molecular relationship between 
these ex vivo expanded cells and their in situ counterparts, however, has remained largely 
unknown. Here, we describe massive parallel transcriptome sequencing of prospectively 
isolated mesenchymal elements from human low risk MDS (LR-MDS), revealing a common 
molecular signature, distinct from both normal and ex vivo expanded cells, characterized by 
cellular stress and upregulation of genes encoding inflammation-associated secreted factors 
with established inhibitory effects on hematopoiesis.
Mesenchymal cells were prospectively FACS-sorted from bone marrow aspirates of LR-
MDS patients (n=12, Supplementary Table S1) and normal controls (n=10) using previously 
established markers of primary bone marrow mesenchymal cells (Figure 1A).(4) The 
frequency of CD45-/7AAD-/CD235a-/CD31-/CD271+/CD105+ mesenchymal cells in LR-MDS 
was not significantly different from normal bone marrow (Figure 1B) (0.019%±0.0086% vs. 
0.022%±0.0066% of mononuclear cells (MNCs), p=0.819 by unpaired student t-test), and 
these cells comprised a small subset of CD45-/7AAD-/CD235a- ‘niche’ cells (10.41%±4.086% 
vs. 12.30%±5.052, p=0.771) with the major constituent being CD31+ endothelial cells 
(43.80%±7.243% vs. 38.28%±9.424%, p=0.816). 
RNA was extracted from highly purified mesenchymal elements and cDNA synthesis was 
performed using the SMARTer Ultra Low RNA kit for Illumina Sequencing (Clonetech) 
(Supplementary Methods). Quality of RNA-sequencing data was shown to be similar for 
normal and LR-MDS derived samples using various quality parameters including the number 
of aligned bases, base composition, coverage coefficient and full-length transcript coverage 
(from 5’ end to 3’ end) reflecting no systematic 5’-end or 3’-end bias (Supplementary Figure S1). 
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The mesenchymal identity of CD45-/7AAD-/CD235a-/CD31-/CD271+/CD105+ cells was 
confirmed molecularly by whole transcriptome analysis demonstrating significant 
abundance of transcripts encoding defining membrane proteins (Figure 1C), established 
markers of mesenchymal stem cells (Figure 1D)(4, 5), essential ‘niche’ factors governing the 
behavior of hematopoietic stem and progenitor cells (HSPCs) (Figure 1E) and osteolineage 
markers (Figure 1F) compared to endothelial cells. Collectively, the findings demonstrate the 
feasibility of prospective isolation and molecular characterization of highly purified primary 
mesenchymal elements in LR-MDS by massive parallel transcriptome sequencing. 
Principle component analysis (PCA) of all transcriptomes demonstrated uniform clustering 
of normal mesenchymal cells, implying transcriptional homogeneity (Figure 2A). Strikingly, 
distinct and more heterogeneous clustering of mesenchymal transcriptomes was found 
in LR-MDS revealing that these cells are transcriptionally distinct from their normal 
counterparts. Gene set enrichment analysis (GSEA) was subsequently performed to define 
the molecular networks underlying the distinct transcriptional landscape of LR-MDS. Gene 
sets associated with inflammatory response and cellular stress were remarkably enriched 
in LR-MDS (Figure 2B-C; Supplementary Table S2). Cellular stress was reflected by a reduced 
capacity of the CD271+ mesenchymal population in LR-MDS to form colonies (Figure 2D) with 
morphologic features reminiscent of cellular senescence (Figure 2E), as described earlier for 
expanded stromal cells in LR-MDS.(6, 7) Distinct hierarchical clustering and the signatures of 
cellular stress were not age-dependent, as these signatures remained statistically significant 
when examined in an age-matched sub-cohort of patients and controls (Supplementary 
Figure S2). Together, the data indicate that mesenchymal cells in LR-MDS are molecularly 
and functionally distinct from their normal counterparts, characterized by cellular stress, 
reflected by a reduced, ex vivo, capacity to form fibroblast colonies.
Thus far, molecular and biologic insights into the role of mesenchymal cells in the 
pathogenesis of human MDS have been derived from studies using ex vivo expanded, 
plastic adherent stromal cells. The molecular relationship between these expanded cells 
and their in situ mesenchymal counterparts has remained largely unknown. Elucidation of 
the transcriptome of mesenchymal elements in the MDS marrow allows us to compare our 
transcriptional data to sequencing data obtained from expanded cells in an age-matched 
cohort of LR-MDS published earlier (Supplementary Figure S3).(3) 
Comparison of FDR-significant differentially expressed transcripts between the two datasets 
demonstrated limited overlap (Figure 2F), suggesting distinct molecular wiring between 
the two mesenchymal cell sources. To obtain insight into the biologic processes underlying 
differential gene expression, GO (gene ontologies) term analysis was performed focusing on 
cellular biologic processes. To correct for potential experimental differences affecting FPKM 
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values, we normalized expression of all genes in LR-MDS to the expression of the controls 
in the respective data sets as detailed in the Supplementary Methods section. Normalized 
expression was subsequently used to perform GO term analysis and GSEA, comparing sorted 
to expanded cells. 
25 GO terms were significantly (FDR < 0.25) enriched in primary CD271+ mesenchymal cells 
(while no signatures were enriched in the ex vivo expanded mesenchymal cells), many 
of which (8/25) reflected response to external stimuli, chemokine activity and immune 
regulation (Figure 2G). Transcript abundance analysis in CD271+ cells in comparison to 
their normal counterparts indeed revealed significant upregulation of numerous cytokines 
(Supplementary Table S3), including a large number of inflammatory factors, such as IL6 
and IL8, and a wide variety of factors previously demonstrated to be negative regulators 
of hematopoiesis, in particular erythropoiesis and B-lymphopoiesis, cell lineages that are 
typically affected in LR-MDS (Supplementary Table S3). 
To obtain insight into the molecular pathways underlying the biologic processes identified, 
transcriptional network analysis (GSEA) was performed. This  identified 504 gene sets that 
were significantly (FDR < 0.25) enriched in primary sorted LR-MDS stromal cells, whereas 
16 signatures were enriched in expanded LR-MDS stromal cells. Again, gene signatures 
related to inflammation and cellular stress were enriched in CD271+ cells with a remarkable 
abundance of signatures related to EGF, TGFß and TNF signaling (Supplementary Figure S4, 
Table S4). 
Collectively, the data comprise, to our knowledge, the first comprehensive transcriptional 
network analysis of highly purified mesenchymal elements directly isolated from the marrow 
in human hematopoietic disease. They support the view that these cells are intricately 
implicated in MDS disease pathogenesis, stressing the relevance of considering the tissue 
context in generating a comprehensive understanding of the disease. The data further 
support the notion that inflammatory signaling is an important pathophysiologic factor in LR-
MDS and implicate the mesenchyme in this process. Finally, the data complement findings 
derived from ex vivo stromal cells in this disease revealing preferential overexpression 
of inflammatory pathways and secreted factors in FACS-purified CD271+ cells. This likely 
reflects active cross-talk with other cellular elements within the inflammatory bone marrow 
environment in LR-MDS(8), eliciting or maintaining these transcriptional programs, which 
may not be  fully appreciated in ex vivo cultures. 
The finding that secretory programs implicated in negative regulation of hematopoiesis are 
activated in CD271+ cells may be of particular relevance given their close anatomical proximity 
with CD34+ cells(9), potentially harboring the MDS initiating population.(10) The data warrant 
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future investigations unraveling the signaling between cellular elements in the MDS marrow 
driving these secretory programs. We anticipate that elucidation of the transcriptome of 
highly purified mesenchymal elements in MDS will thus be a valuable resource to the 
community, instructing the validation and discovery of novel pathophysiologic factors and 
putative therapeutic targets.(11) 
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Figure 1. Prospective isolation and molecular characterization of mesenchymal cells in LR-MDS. (A) Gating 
strategy to identify and isolate 7AAD-/CD45-/CD235a-/CD271+/CD105+ mesenchymal cells. (B) Frequency of 
mesenchymal cells in normal and MDS samples. (C-F) Transcriptional validation of the mesenchymal identity of 
7AAD-/CD45-/CD235a-/CD271+/CD105+ cells, revealing differential expression in comparison to endothelial subsets 
of (C) defining cell surface markers (CD271, CD105, CD31), (D) known mesenchymal markers (CD73, CD90, CD146), 
(E) established hematopoiesis-supporting cytokines (CXCL12, ANGPT1, KITL) and (F) bone lineage markers (BGLAP, 
RUNX2, SPP1 and ALPL). 
FPKM: fragments per kilobase of exon per million fragments mapped. CD73 (NT5E: ecto-5’-nucleotidase); CD90 
(THY1: Thy-1 T-Cell Antigen); CD146 (MCAM: melanoma cell adhesion molecule); CXCL12 (stromal cell-derived 
factor 1); ANGPT1 (angiopoietin 1); KITL (KIT ligand); BGLAP (osteocalcin); RUNX2 (runt-related transcription factor 
2); SPP1 (osteopontin); ALPL (alkaline phosphatase, liver/bone/kidney). Figure C to figure F: Normal samples 
(n=10); MDS samples (n=12). Black bar: CD271+ mesenchymal cells; white bar: CD31+ endothelial cells. ** FDR < 
.01; *** FDR < .001.
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Figure 2. Mesenchymal cells in LR-MDS display a distinct molecular signature characterized by cellular stress and 
inflammation. (A) Principle component analysis (PCA) on the transcriptomes of normal and LR-MDS mesenchymal 
cells. Patient numbers in Figure 2A refer to LR-MDS patient IDs (Table S1). (B) Example of GSEA plot revealing 
inflammatory response in the mesenchymal cells from LR-MDS. (C) Representative GSEA plot demonstrating 
deregulation of the gene set associated with cellular stress in response to UV in LR-MDS mesenchymal cells. 
Gene set size, NES and FDR value of each gene set is listed. GSEA: gene sets enrichment analysis. NES: normalized 
enrichment score. FDR: false discovery rate. (D) Number of CFU-F colonies formed by normal (n=3) or LR-MDS (n=3) 
CD271+ mesenchymal cells. (E) Representative images of cell clusters and colonies formed by mesenchymal cells 
from healthy control (left panel) and LR-MDS patients (right panel). (F) Comparison of significantly differentially 
expressed genes in FACS-purified CD271+ versus culture-expanded mesenchymal cells in LR-MDS. The total number 
of differentially regulated transcripts in each data set is indicated and the overlapping differentially regulated genes 
in the two datasets are listed. (G) Biologic processes significantly enriched (FDR < 0.25) in FACS-purified CD271+ 
LR-MDS mesenchymal cells in comparison to  expanded stromal cells defined by GO term analysis. ** P < .01
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SUPPLEMENTAL DATA  
SUPPLEMENTARY MATERIAL AND METHODS
Patient and healthy donor bone marrow samples
Patient characteristics (median age: 65, range 38-80) are shown in Table S1. Control 
marrow was obtained from donors for allogeneic transplantation (median age: 45, range 
35-61), after written informed consent. The use of human samples was approved by the 
Institutional Review Board of the Erasmus Medical Center, the Netherlands, in accordance 
with the declaration of Helsinki. 
Flow cytometry analysis 
For cell sorting, bone marrow from patients and normal donors were stained on ice in the 
dark with the following antibodies using optimized dilutions: CD45-PE-Cy7 (1:200), CD235a-
BV421-A (1:100), CD271-PE (1:100), CD105-APC (1:50), CD31-APC-CY7 (1:50). The indicated 
populations of interest were sorted using a FACS ARIAIII Cell Sorter (BD Biosciences). Dead 
cells were gated out using 7AAD (Stem-Kit Reagents) after mononuclear cell selection and 
doublets exclusion. The cells were directly sorted in 800μl Trizol (Ambion) for RNA isolation. 
RNAse free non-stick micro-tubes (Ambion) were used to prevent pre-digestion of RNA.
RNA extraction and RNA quality control
Total sample RNA isolation was performed according to the standard protocol of RNA 
isolation with Trizol and GenElute LPA (Sigma). The RNA pellet was resuspended in 7.5μl of 
RNAse free water (Qiagen) and quality and quantity of the total RNA was checked on a 2100 
Bio-analyzer (Agilent) using the Agilent RNA 6000 Pico Kit. 
RNA sequencing and gene expression profiling 
SMARTer Ultra Low RNA Kit (Clonetech) for Illumina Sequencing was used to prepare 
the cDNA based on the manufacture’s recommendation. Similar quantities of total RNA 
from each sample were used as starting material for the SMARTer procedure. cDNA 
preparation steps were performed according to the user manual in a PCR-clean room to 
avoid contamination. The Agilent 2100 Bio-analyzer and the High Sensitivity DNA kit were 
applied to determine the quantity and quality of the cDNA production. Once the cDNAs 
were obtained, the subsequent library preparation steps, sequencing and alignments 
were performed as previously described.(1, 2) In brief, prior to sequence alignment, the 
SMARTer adapters were trimmed using the cutadapt program.(3) The resulting sequences 
were aligned to the human RefSeq transcriptome using TopHat2.(4) Sequences that could 
not be aligned to the RefSeq transcriptome were aligned to the reference genome (build 
hg19). Normalization and quantification was performed using Cufflinks.(5) The resulting 
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gene expression values are measured as FPKM (Fragments per kilobase of exon per million 
fragments mapped). Fragment counts were determined per gene with HTSeq-count, utilizing 
the strict intersection option, and subsequently used for differential expression analysis 
using the DESeq2(6) package, with standard parameters, in the R environment. Multiple 
testing correction was performed with the Benjamini-Hochberg procedure to control the 
False Discovery Rate (FDR). Principle component analysis was performed on the fragment 
counts using the R environment. Finally gene set enrichment analysis (GSEA) was performed 
on the FPKM values using the curated C2 collection of gene sets within MSigDB.(7) 
Comparison between molecular data from primary and ex vivo expanded mesen-
chymal cells
We performed a direct comparison of transcriptional data obtained from FACS-isolated 
CD271+ mesenchymal cells to transcriptional data obtained by RNAseq from culture-
expanded stromal cells from an age-matched cohort of LR-MDS patients reported earlier.(8) 
BAM files containing the molecular data of ex vivo expanded stromal cells derived from LR-
MDS patients (n=5) and normal controls (n=3)(8) were obtained from the European Genome-
Phenome Archive data base (EGAS00001000716). Gene expression values quantified by the 
FPKM statistic were determined by Cufflinks as previously described (vide supra). Differential 
expression analysis was performed using the DESeq2 package.  
To allow direct comparison of datasets and correct for potential technical/experimental 
variation affecting FPKM values, for both datasets, average gene FPKM values of MDS 
samples were normalized to average FPKM values observed in the normal control samples 
(FPKM MDS/FPKM control)and the normalized (fold-change) value subjected to GO term 
and GSEA.(7)
CFU-F assay
Live CD45-/CD235a-/CD271+ mesenchymal cells from bone marrow samples of LR-MDS 
patients (n=3) and normal controls (n=3) were sorted using a FACSARIA III cell sorter. On 
average, 20 cells per 0.32 cm2 were plated in ɑMEM supplemented with 20% fetal bovine 
serum and 1% penicillin, streptomycin. On day 14, dishes were fixed and stained with 
Giemsa, and CFU-F colonies were counted as previously described.(9) Images of colonies and 
individual cell clusters were acquired on a Leica SP5 confocal laser scan microscope using a 
40x objective. Images were analyzed using ImageJ software. 
2
Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals 
tissue-context dependent activation of inflammatory programs
56
SUPPLEMENTARY REFERENCE
 1.  Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, et al. A single 
oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell. 
2014;157(2):369-81.
 2.  Zambetti NA, Bindels EM, Van Strien PM, Valkhof MG, Adisty MN, Hoogenboezem RM, et al. Deficiency of 
the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice 
by attenuating lineage progression in myelocytes. Haematologica. 2015;100(10):1285-93.
 3.  Marcel M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet journal. 
2011;17:10-2.
 4.  Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes 
in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
 5.  Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression 
analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562-78.
 6. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11(10):R106.
 7.  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment 
analysis: A knowledge-based approach for interpreting genome-wide expression profiles. P Natl Acad Sci 
USA. 2005;102(43):15545-50.
 8.  Medyouf H, Mossner M, Jann JC, Nolte F, Raffel S, Herrmann C, et al. Myelodysplastic cells in patients 
reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem 
Cell. 2014;14(6):824-37.
 9.  Tormin A, Li O, Brune JC, Walsh S, Schutz B, Ehinger M, et al. CD146 expression on primary nonhematopoietic 
bone marrow stem cells is correlated with in situ localization. Blood. 2011;117(19):5067-77.
 10.  Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. 
Leukemia. 2003;17(9):1731-7.
 11.  Broxmeyer HE, Cooper S, Hangoc G, Kim CH. Stromal cell-derived factor-1/CXCL12 selectively counteracts 
inhibitory effects of myelosuppressive chemokines on hematopoietic progenitor cell proliferation in vitro. 
Stem Cells Dev. 2005;14(2):199-203.
 12.  Dimicoli S, Wei Y, Bueso-Ramos C, Yang H, Dinardo C, Jia Y, et al. Overexpression of the toll-like receptor 
(TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes. PLoS One. 
2013;8(8):e71120.
 13.  Nishihara T, Ohsaki Y, Ueda N, Koseki T, Eto Y. Induction of apoptosis in B lineage cells by activin A derived 
from macrophages. J Interferon Cytokine Res. 1995;15(6):509-16.
 14.  Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a 
negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 
2007;110(4):1153-60.
 15.  Bruns I, Lucas D, Pinho S, Ahmed J, Lambert MP, Kunisaki Y, et al. Megakaryocytes regulate hematopoietic 
stem cell quiescence through CXCL4 secretion. Nat Med. 2014;20(11):1315-20.
Chapter 2
57
SUPPLEMENTAL TABLES AND FIGURES
Table S1. Patient characteristics 
Patient ID WHO Cytogenetics BM Blasts IPSS
MDS02   RAEB-1 46, XX[20] 5% 1
MDS01 RCMD-RS 46, XY[20]
Age
63
62 0% 0
MDS03 72 RCMD-RS 46, XX[20] 1%  0.5
MDS04 75 Isolated del(5q) 46, XX, del(5)(q15q33)[10] 1% 0
MDS05 79 RCMD-RS 46, XX[10] 0% 0
MDS06 66 RARS 46, XX[21] 2% 0
MDS09 65 RCMD-RS 46, XX[20] 3% 0.5
MDS08 80 RCMD 46, XY[20] 3% 0.5
MDS12 65 RCMD 46, XX[20] 2% 0
MDS07 56 RARS 46, XX[20] 0% 0
MDS11 38 Isolated del(5q) 46, XX, del(5)(q13q33)
[25]/46,XX[5] 2% 0
MDS10 58 RCMD-RS 45,X,-Y[10]/46,XY[10] 1% 0
Genetic Aberrations
DNMT3A, SRSF2
SRSF2 
no mutations
SF3B1 
TET2, ASXL1 
TET2, DNMT3A, SF3B1 
ASXL1 
EZH2 
1a.
Normal Samples
N10513 (N2)   
N10410 (N1)
Age
40
58
N12723 (N3) 48
N15863 (N4) 42
N14207 (N5) 61
N16237 (N6) 40
N14167 (N9) 48
N08276 (N8) 58
N11703 (N7) 39
N12066 (N10) 35
1b.
Gender
F
F
M
F
M
M
M
F
M
M
SF3B1, RUNX1, TET2 
DNMT3A, SF3B1 
TET2, DNMT3A, SF3B1, Runx1 
no mutations
Supplemental Table 1. Patient characteristics. (A) Bone marrow was obtained at entry of a prospective clinical 
trial (HOVON89, Eudract nr. 2008-002195-10). The patient ID, age, WHO category (MDS WHO classification 2008), 
cytogenetic abnormalities, percentage of blasts in the bone marrow, the International Prognostic Scoring System 
for MDS (IPSS) and genetic aberrations of each patient are listed above (n=12).  (B) Age and gender of each normal 
control sample is listed.
2
Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals 
tissue-context dependent activation of inflammatory programs
58
Supplemental Table 2. Enrichment of transcriptional signatures reflecting inflammatory response and cellular 
stress in mesenchymal cells from LR-MDS patients. 
The size of each individual gene set, normalized enrichment score (NES), nominal p-value and false discovery rate 
(FDR) values are as listed.  
Chapter 2
59
Supplemental Table 3. Differential expression of secreted factors and cytokines in primary LR-MDS mesenchymal 
cells
Differential expression of different cytokines in primary LR-MDS mesenchymal cells comparing to the normal coun-
terparts are listed. This list includes bona fide inflammatory cytokines known to be negative regulators of hema-
topoiesis (a), erythropoiesis (b), B-lymphopoiesis (c), megakaryopoiesis (d)  and with myelosuppressive effects (e).
(10-15) FC: Fold change; FDR: false discovery rate. Fold change, FDR significance and average FPKM value of each gene 
are as listed.   FC: Fold change; FDR: false discovery rate.
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Supplemental Table 4. Signatures that are associated with stress, inflammation, TNF and EGF signaling within the 
top 100 signatures enriched in primary LR-MDS mesenchymal cells in comparison to culture expanded stromal 
cells
Supplemental Figure 1. Comparable quality of RNA sequencing data obtained from MDS and normal mesenchymal 
cells. (A) Number of aligned bases were calculated using aligned data of MDS (orange bars) vs. normal (blue bars) 
stromal samples. (B) Base composition including ribosomal bases (blue), coding bases (orange), UTR bases (yellow), 
intronic bases (green) and intergenic bases (red) is constructed for both MDS and normal stromal cell aligned 
sequencing data. (C) Median coefficient of variation (CV) value was computed indicating the level of coverage for 
LR-MDS and normal stromal cell aligned sequencing data. (D) Comparison of the transcript coverage from LR-MDS 
CD271+ cells and control CD271+ cells. Presented here are superimposed plots displaying the average read coverage 
from the total RNA of each sample library. The x-axis represents gene length normalized to 100%, where 0 is the 
5’-end and 100 is the 3’end of each transcript. 
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Figure S1
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Figure S2
Supplemental Figure 2. Molecular signature of mesenchymal cells from LR-MDS patients compared to age-
matched controls. (A) Patient and control characteristics including median age and gender. (B) PCA. (Normal: 
orange; patient: green). The age and gender of each sample is indicated in the plot. (C) Representative GSEA plot 
indicating enriched stress response in LR-MDS mesenchymal cells compared to age-matched controls. NES and 
FDR value of each signature are listed. (D) List of GSEA signatures reflecting cellular stress in LR-MDS stromal cells 
in the age-matched cohort. GSEA: gene sets enrichment analysis. NES: normalized enrichment score. FDR: false 
discovery rate.
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Figure S3 
Supplemental Figure 3. Comparison of molecular profile between primary and expanded LR-MDS stromal cells(8) 
(A) Scheme illustrating the strategy of directly comparing RNA-seq data from primary mesenchymal cells to RNA-
seq data obtained from culture expanded stromal cells in LR-MDS. (B) Age distribution of LR-MDS patients for the 
primary and expanded stromal cell data sets. (C) Gene sets differentially expressed (FDR< 0.25) in primary CD271+ 
cells or ex vivo expanded MSCs from patients with LR-MDS.
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Figure S4
Supplemental Figure 4. Gene signatures of inflammation and stress enriched in primary LR-MDS mesenchymal 
cells in comparison to expanded stromal cells. Representative GSEA plot demonstrating enrichment of gene sets 
associated with inflammation (A), stress (B) and EGF, TGFß, TNF signaling (C-E) in primary LR-MDS mesenchymal 
cell comparing to expanded stromal cells. These plots are associated with Supplemental Table S4. 
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SUMMARY
Mesenchymal niche cells may drive tissue failure and malignant transformation in the 
hematopoietic system but the underlying molecular mechanisms and relevance to human 
disease remain poorly defined. Here, we show that perturbation of mesenchymal cells in a 
mouse model of the preleukemic disorder Shwachman-Diamond syndrome (SDS) induces 
mitochondrial dysfunction, oxidative stress and activation of DNA damage responses in 
hematopoietic stem and progenitor cells. Massive parallel RNA sequencing of highly purified 
mesenchymal cells in the SDS mouse model and a range of human preleukemic syndromes 
identified p53-S100A8/9-TLR inflammatory signaling as a common driving mechanism of 
genotoxic stress. Transcriptional activation of this signaling axis in the mesenchymal niche 
predicted leukemic evolution and progression-free survival in myelodysplastic syndrome 
(MDS), the principal leukemia predisposition syndrome. Collectively, our findings identify 
mesenchymal niche-induced genotoxic stress in heterotypic stem and progenitor cells 
through inflammatory signaling as a targetable determinant of disease outcome in human 
preleukemia.
Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution 
in human pre-leukemia
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INTRODUCTION
Genotoxic stress results in the accumulation of DNA lesions in hematopoietic stem and 
progenitor cells (HSPCs) over the lifespan of an organism, contributing to tissue failure and 
malignant transformation (Jaiswal et al., 2014; Rossi et al., 2007). The pathophysiological 
insults underlying genomic stress in HSPCs, however, remain incompletely understood. 
Perturbed signaling from their surrounding microenvironment may be implicated, but this 
has not been experimentally defined. 
Components of the bone marrow microenvironment have emerged as key regulators of 
normal and malignant hematopoiesis (Arranz et al., 2014; Hanoun et al., 2014; Medyouf 
et al., 2014; Schepers et al., 2015; Walkley et al., 2007). We, and others, have shown that 
primary alterations of the mesenchymal niche can induce myelodysplasia and promote 
the emergence of acute myeloid leukemia (AML) with cytogenetic abnormalities in HSPCs 
(Kode et al., 2014; Raaijmakers et al., 2010), thus introducing a concept of niche-driven 
oncogenesis in the hematopoietic system. 
To provide insights into the mechanisms that underlie this concept, as well as their relevance 
for human disease, we modeled the human leukemia predisposition disorder Shwachman-
Diamond syndrome (SDS), caused by constitutive homozygous or compound heterozygous 
loss of function mutations in the SBDS gene, required for ribosome biogenesis (Boocock et 
al., 2003; Finch et al., 2011). SDS is characterized by skeletal defects in conjunction with a 
striking propensity to develop myelodysplastic syndrome (MDS) and AML at a young age, 
with a cumulative probability of >30% at the age of 30 years and a median onset at 18 
years (Alter, 2007; Donadieu et al., 2012). Hematopoietic cell intrinsic loss of Sbds does not 
result in MDS or leukemia (Rawls et al., 2007; Zambetti et al., 2015), supporting the notion 
that cell-extrinsic factors contribute to malignant transformation. Deletion of Sbds from 
mesenchymal cells expressing the mesenchymal progenitor marker osterix (Sp7) in the bone 
marrow induced apoptosis in HSPCs and myelodysplasia, but the molecular mechanisms 
driving these observations and their relevance for human disease remained to be defined 
(Raaijmakers et al., 2010).
Here, we identify the endogenous damage-associated molecular pattern (DAMP) molecules 
S100A8 and S100A9, secreted from mesenchymal niche cells, as drivers of mitochondrial 
dysfunction, oxidative stress and DNA damage response (DDR) activation in HSPCs, with 
clinical relevance to the pathogenesis and prognosis of human bone marrow failure and 
leukemia predisposition syndromes.
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RESULTS
Deletion of Sbds from mesenchymal progenitor cells (MPCs) recapitulates skeletal 
abnormalities of human SDS
SDS is characterized by bone abnormalities including low-turnover osteoporosis with 
reduced trabecular bone volume, low numbers of osteoblasts, and reduced amount of 
osteoid, leading to increased risk of fractures (Toiviainen-Salo et al., 2007). The cellular 
subsets driving these abnormalities and the underlying molecular mechanisms have 
remained largely undefined. We have previously shown that Cre-mediated deletion of Sbds 
from osterix+ MPCs (Sbdsf/f Osxcre/+ mice, hereafter OCSf/f or mutants) disrupts the architecture 
of the marrow and cortical bone (Raaijmakers et al., 2010). Here, we first sought to better 
define the skeletal defects in these mice and their relevance to human disease.
OCSf/f mice presented growth retardation and reduced femur length compared to control 
Sbdsf/+ Osxcre/+ (OCSf/+) mice (Figure 1A and 1B) as observed in human patients (Aggett et 
al., 1980; Ginzberg et al., 1999). The runted phenotype was associated with a significantly 
limited lifespan, with lethality observed after the age of 4 weeks. Analyses were therefore 
performed in three week-old mice. The femur trabecular area was profoundly reduced in 
OCSf/f mice, with decreased bone volume, low number of trabeculae, increased trabecular 
spacing and reduced numbers of osteoblasts compared to controls (Figure 1C-1G, and 
1I). The cortical bone of OCS mutants was also affected, as indicated by low bone mineral 
density values (Figure 1C-1D and 1H), attenuating the mechanical properties of the bone, 
which was found less resistant to fracture in three-point bending test (Figure 1J). A tendency 
for reduced stiffness in the long bones was also observed (Figure 1K). Taken together, the 
structural and mechanical defects indicate that Sbds deficiency in MPCs causes osteoporosis 
with a propensity for fracturing, in line with observations in SDS patients (Ginzberg et al., 
1999; Mäkitie et al., 2004; Toiviainen-Salo et al., 2007). Impaired osteogenesis did not reflect 
a contraction of the bone progenitor cell pool as shown by frequency of CFU-F and Osx::GFP+ 
cells (Figure S1A and S1B), but rather impairment of terminal osteogenic differentiation as 
suggested by transcriptional profiling of prospectively isolated osterix-expressing (GFP+) 
cells (Figure S1C). Transcriptional data confirmed deregulated expression of genes related 
to ribosomal biogenesis and translation (Figure S1D and S1E), in line with the established 
role of Sbds in ribosome biogenesis. Collectively, this data supports a view in which bone 
abnormalities in SDS are caused by deficiency of Sbds in MPCs, which attenuates terminal 
differentiation towards matrix-depositing osteoblastic cells with a compensatory increase in 
the most primitive mesenchymal compartment. 
Chapter 3
73
Sbds deficiency in the hematopoietic niche induces mitochondrial dysfunction, 
oxidative stress and activation of the DNA damage response in HSPCs
Having established that the OCS mice represent a bona fide model for bone abnormalities 
in human disease, we next investigated the hematopoietic consequences of these 
environmental alterations. HSPC number was unaltered in OCS mice (Figure S2A-S2C) 
and HSPCs displayed global preservation of their transcriptional landscape after exposure 
to the Sbds-deficient environment (Figure S2D-S2F). Transcriptional network analysis, 
however, revealed significant overlap with signatures previously defined as predicting 
leukemic evolution of human CD34+ cells (Li et al., 2011), including pathways signaling 
mitochondrial abnormalities (Figure 2A; Table S1). Mitochondrial dysfunction was confirmed 
by measuring the mitochondrial membrane potential (Δψ), indicating hyperpolarization 
of the mitochondria (Figure 2B and 2C). Mitochondrial hyperpolarization can result in 
reverse electron transfer, leading to the production of superoxide radicals, which can 
be further converted into other reactive oxygen species (ROS) (Murphy, 2009). In line 
with this, a marked increase in intracellular ROS levels was found in OCS mutant HSPCs 
(Figure 2D), more specifically superoxide radicals derived from mitochondria as shown by 
dihydroethidium (DHE) staining (Figure S2G) (Owusu-Ansah et al., 2008; Stowe and Camara, 
2009). ROS can undermine the genomic integrity of HSPCs by inducing DNA damage (Ito et 
al., 2006; Walter et al., 2015; Yahata et al., 2011), to which normal HSPCs react by activating 
the DDR and DNA repair pathways (Rossi et al., 2007). Indeed, HSPCs (LKS-SLAM) cells 
from OCSf/f mice displayed accumulation of Ser139-phosphorylated H2AX histone (γH2AX), 
which forms at the sites of DNA damage (Figure 2E; Figure S2H). Treatment of OCS mutant 
animals with the ROS scavenger N-acetylcysteine (NAC) resulted in partial reduction in the 
accumulation of gH2AX (Figure S2I and S2J). Congruent with genotoxic effects of the mutant 
microenvironment, HSPCs displayed transcriptional modulation of DDR and DNA repair 
pathways (Table S2), including nucleotide excision repair programs, associated with ROS-
induced lesions (Curtin, 2012) and signatures related to the master regulator of DDR and cell 
checkpoint activation ataxia telangiectasia and Rad3-related (ATR). Activation of the G1-S 
cell cycle checkpoint, resulting in cell cycle arrest, was suggested by depletion of S-phase 
transcriptional signatures (Figure 2F; Table S1), in vivo BrdU/Ki67 labeling (Figure 2G and 2H; 
Figure S2K) and downregulation of the Myc pathway, a critical regulator for this restriction 
point and the coordination of S–G2–M progression (Figure 2I; Table S3). Apoptosis of mutant 
HSPCs, as an alternative outcome of checkpoint activation, was earlier demonstrated 
(Raaijmakers et al., 2010). Together, the data indicate that the Sbds-deficient environment 
induces mitochondrial dysfunction, oxidative stress, DNA damage and genotoxic stress in 
HSPCs leading to activation of DDR pathways and G1-S checkpoint activation, reminiscent of 
a model in which mitochondrial dysfunction underlies an escalating cycle of increased ROS 
and genotoxic damage (Sahin and Depinho, 2010). 
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Short term exposure to the genotoxic environment did not attenuate HSPC function in DNA 
repair proficient cells, as demonstrated by competitive transplantation experiments (Figure 
S3A-S3C), suggesting efficient DNA-repair or elimination of functionally impaired HSPCs by 
the DDR-driven apoptosis and cell cycle arrest. Congruent with this notion, alkaline comet 
assays on sorted HSPCs failed to demonstrate structural DNA damage (Figure S3D and S3E).
Activation of the p53 pathway drives bone abnormalities and genotoxic stress in 
OCS mice
Next, we sought to define the molecular programs underlying the bone and hematopoietic 
alterations in OCS mice. A proposed common molecular mechanism for the pathogenesis 
of ribosomopathies involves activation of the p53 tumor suppressor pathway (Raiser et al., 
2014). The p53 protein was overexpressed in GFP+ MPCs in OCS mutants, with activation 
of downstream transcriptional pathways and upregulation of canonical targets (Figure 3A-
3C). To assess the pathophysiological role of p53 activation in MPCs, we intercrossed OCS 
with Trp53-floxed mice (Marino et al., 2000), generating a double conditional knock-out 
model where the deletion of p53 is localized in the Sbds-deleted stromal compartment 
(Sbdsf/f Trp53f/f Osxcre/+ mice; hence OCSf/f p53Δ) (Figure 3D). Genetic recombination of the 
Trp53 locus was detected only in bone cells-containing samples, demonstrating the tissue 
specificity of p53 deletion in this model (Figure 3E). Genetic deletion of p53 from Sbds-
deficient MPCs rescued the osteoporotic phenotype (Figure 3F-3J), but not cortical bone 
mineralization (Figure 3K), while it had only modest effects on bone mass in OCS control 
mice (Figure S4), in line with earlier observations (Wang et al., 2006). Rescue of the skeletal 
phenotype was linked to amelioration of genotoxic stress in HSPCs as demonstrated by a 
reduction of superoxide radicals derived from mitochondria and DNA damage (Figure 3L 
and 3M).
Identification of the damage-associated molecular pattern genes S100A8 and 
S100A9 as candidate niche factors driving genotoxic stress in human leukemia 
predisposition syndromes 
To identify human disease-relevant niche factors, downstream of p53 activation, driving 
genomic stress in HSPCs, we compared the transcriptomes of GFP+ MPCs from OCS mice to 
those from prospectively FACS-isolated mesenchymal CD271+ niche cells (Tormin et al., 2011) 
from human SDS patients (Figure 4A; Table S4). The mesenchymal nature of CD271+ cells was 
confirmed by CFU-F capacity and differential expression of mesenchymal, osteolineage and 
HSPC-regulatory genes (Chen et al, 2016). RNA sequencing showed the presence of SBDS 
mutations (Figure 4B; Figure S5; Table S4) associated with reduced SBDS expression (Figure 
4C), confirming molecular aspects of SDS in previous studies (Finch et al., 2011; Woloszynek 
et al., 2004). Virtually identical transcriptional signatures of disrupted ribosome biogenesis 
and translation were found in human niche cells (Figure 4D) and in GFP+ cells from OCS mice 
(Figure S1E), confirming faithful recapitulation of human molecular disease characteristics 
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in the mouse model. Forty genes were differentially expressed both in the mouse model 
and human SDS, 25 of which were overexpressed, with a remarkable abundance of genes 
encoding proteins implicated in inflammation and innate immunity (Figure 4E). 
To further delineate candidate genes driving genomic stress and leukemic evolution from 
this gene set, we performed whole transcriptome sequencing of CD271+ cells in two related 
human bone marrow failure and leukemia predisposition disorders: (1) low-risk MDS, the 
principal human preleukemic disorder in which cell cycle exit (senescence), accumulation 
of ROS, DNA damage and apoptosis have been described (Head et al., 2011; Peddie et al., 
1997; Xiao et al., 2013), reminiscent of HSPC phenotypes in OCS mice, and (2) DBA, like SDS, 
a ribosomopathy characterized by bone marrow failure, but with a much lower propensity 
to evolve into AML (<1% with longer latency than observed in SDS and MDS) (Vlachos et 
al., 2012) (Table S4). We reasoned that genes specifically overexpressed in mesenchymal 
niche cells from disorders with as strong propensity for leukemic evolution (SDS and MDS) 
might represent strong candidate drivers of genotoxic stress. Eleven such genes were found 
(Figure 4F), among which the damage-associated molecular pattern (DAMP) genes S100A8 
and S100A9, which were  significantly (P<0.05) differentially expressed in GFP+ cells from 
OCS mutant mice (Figure 4E-4G) and also represent a bona fide downstream transcriptional 
target of p53 (Li et al., 2009). Ex vivo shRNA experiments confirmed that upregulation of 
both p53 and S100A8/9 are direct, cell-intrinsic consequences of Sbds downregulation in 
mesenchymal precursor (OP9) cells (Figure S6A).
Niche-derived S100A8/9 induces genotoxic stress in murine and human HSPCs 
S100A8 and S100A9 belong to a subclass of proinflammatory molecules referred to as DAMP 
or alarmins. DAMPs are endogenous danger signals that are passively released or actively 
secreted in the microenvironment after cell death, damage or stress and bind pattern 
recognition receptors (PRR) to regulate inflammation and tissue repair (Srikrishna and 
Freeze, 2009). S100A8 and S100A9 proteins were overexpressed in mouse Sbds-deficient 
MPCs (Figure 5A and 5B) and increased plasma concentration of S100A8/9 indicated 
secretion of the heterodimer (Figure 5C). Its canonical receptor TLR4 (Vogl et al., 2007) is 
expressed in murine HSPCs (Figure S6B) and the canonical downstream signaling NF-κB and 
MAPK pathways were activated in HSPCs from OCSf/f mice (Figure S6C). 
Exposure of HSPCs (LKS) cells to recombinant murine S100A8/9 resulted in increased DNA 
damage (number of γH2AX and 53BP1 foci) (Figure 5D; Figure S6D), which was replication-
independent (Figure 5E), and apoptosis (Figure 5F), associated with activation of TLR 
signaling (Figure 5G; Table S5), recapitulating the in vivo HSPC phenotype (Raaijmakers et 
al., 2010). In vivo, blockage of TLR4 by neutralizing antibodies resulted in a reduction of 
γH2AX foci in LKS cells from OCSf/f mice (Figure 5H).
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To provide formal experimental support for the view that S100A8/9 production by ancillary 
cells in the bone marrow microenvironment is sufficient to drive genotoxic stress in HSPCs 
in a paracrine manner, we next transplanted CD45.1+ wild type hematopoietic cells into 
S100A9-GFP transgenic (S100A9Tg) mice, overexpressing both S100A8 and S100A9 under 
control of the MHC class I H2K promoter (Cheng et al., 2008) (Figure 6A). S100A8/9 (GFP) 
was expressed in a mesenchymal (CD45- CD31- Ter119- CD51+ Sca1-) niche population, 
previously shown to contain the Osterix-expressing cells (Schepers et al, 2013) (Figure 6B 
and 6C). The S100A8/9+ microenvironment induced accumulation of superoxide radicals 
(DHE) and DNA-damage (γH2AX) in wild type (CD45.1+) HSPCs (Figure 6D-6F), in particular 
in immunophenotypic HSCs, indicating that secretion of S100A8/9 from ancillary cells in 
the microenvironment is indeed sufficient to induce genotoxic stress in HSCs in a paracrine 
manner.
Translating these findings to human disease, exposure of human cord blood CD34+ HSPCs to 
human recombinant S100A8/9 at clinically relevant concentrations (Chen et al., 2013 and 
Supplemental Experimental Procedures) resulted in DNA damage (increased γH2AX foci), 
apoptosis and impaired HSPC function (CFU-C) (Figure S7). 
Activation of the p53-S100A8/9-TLR axis in mesenchymal niche cells predicts 
leukemic evolution and clinical outcome in human low-risk MDS
To further define the biologic and clinical significance of these findings, we performed 
transcriptome sequencing of CD271+ niche cells in a prospective, homogeneously treated 
cohort of low-risk MDS patients (n = 45, Figure 7A; Table S6).  Expression of S100A8 and 
S100A9 was strongly correlated (Figure 7B, 7C), with a subgroup of MDS patients (17/45; 
38%) demonstrating significant overexpression of S100A8 and S100A9 (Modified Thompson 
Tau outlier test) (Figure 7B and 7D), independent of established prognostic factors as defined 
by the revised International Prognostic Scoring System (IPSS-R) and the MD Anderson risk 
score (LR-PSS) (Table S6). Transcriptional pathway analysis (GSEA) comparing mesenchymal 
cells overexpressing S100A8/9 (n = 17) to those of niche S100A8/9- patients (n = 28) 
revealed activation of p53 and TLR programs in S100A8/9+ mesenchymal cells (Figure 7E), 
in line with experimental data from the mouse model pointing at the existence of a p53-
S100A8/9-TLR axis. Leukemic evolution, defined as the development of frank AML or excess 
of blasts to WHO RAEB1/ RAEB2 (refractory anemia with excess of blasts), occurred in 5/17 
(29.4%) of niche S100A8/9+ patients (3 AML, 2 RAEB1/RAEB2) vs. 4/28 (14.2%) in niche 
S100A8/9- patients (2AML, 2 RAEB1/RAEB2). Time to leukemic evolution was significantly 
shorter in niche S100A8/9+ patients (average 3.4 (1-7.5) vs 18.5 (7-40); P = 0.03 by Exact 
Wilcoxon rank sum test) resulting in a significantly shorter progression-free survival of niche 
S100A8/9+ patients (median 11.5 vs 53 months, P = 0.03) (Figure 7F and 7G). Collectively, 
the data establish activation of p53-S100A8/9 signaling in mesenchymal niche cells as an 
independent predictor of disease outcome in human MDS. 
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DISCUSSION
Genomic stress and the ensuing DNA damage play a pivotal role in the attenuation of normal 
hematopoiesis in ageing and disease. Mutations accumulate in HSPCs over the lifespan of 
an organism, but the (patho)physiological sources of genomic stress in HSPCs and their 
relationship with human bone marrow failure remain incompletely understood. Here, we 
show that specific inflammatory signals from the mesenchymal niche can induce genotoxic 
stress in heterotypic stem/progenitor cells and relate this concept to the pathogenesis of 
two human bone marrow failure and leukemia predisposition syndromes, SDS and MDS. 
The data indicate that the mesenchymal niche may actively contribute to the formation of a 
‘mutagenic’ environment, adding to our understanding of how a premalignant environment 
facilitates cancer initiation and evolution. The data argue that this may not only occur 
through facilitated selection and expansion of genetic clones that stochastically emerge in 
a permissive environment, but that the mesenchymal niche may be an active participant 
in driving the genotoxic stress underlying tissue failure and malignant transformation of 
parenchymal cells. 
Notably, leukemic transformation was not observed in mice with targeted deficiency of Sbds 
in mesenchymal cells. Earlier, in a related mouse model of targeted Dicer1 deletion in MPCs, 
leukemic transformation was a rare event (Raaijmakers et al., 2010). In the light of our 
current findings, these observations are likely explained by several factors. First, prolonged 
exposure to a mutagenic niche, beyond the limited lifespan of OCS mice, may be necessary 
for the accumulation of genetic damage required for full transformation. Additionally, the 
data argue that DNA repair-proficient HSPCs are able to cope with the mutagenic stress 
induced by their environment through activation of the DDR (as shown by molecular 
activation of cell cycle checkpoints and apoptosis), preventing the accumulation of stable 
genetic damage (as demonstrated by comet assays) and maintaining the functional integrity 
of HSPCs (as shown by repopulation assays).
We propose that in SDS (and possibly other congenital bone marrow failure syndromes) 
genetically aberrant hematopoietic and niche elements cooperate in driving bone marrow 
failure and leukemic evolution. Our mouse models of SDS support a view in which 
hematopoietic cell autonomous loss-of-function of Sbds drives neutropenia (Zambetti 
et al., 2015), while niche alterations in this disease drive myelodysplastic alteration and 
genotoxic stress. It is conceivable that loss-of-function mutations in Sbds in HSPCs further 
sensitizes HSPCs to the genotoxic effects of the Sbds-deficient environment, perhaps 
through attenuation of DNA damage repair mechanisms. It will thus be of considerable 
interest to test the hypothesis that a mutagenic environment cooperates with aberrant 
HSPCs, compromised in their ability to cope with inflammatory genotoxic stress, in leukemia 
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evolution. In this context, the propensity of Sbds-deficient cells to accumulate ROS (Ambekar 
et al., 2010), and their reduced ability to cope with various cellular stressors such as mitotic 
spindle destabilizing agents, endoplasmic reticulum stress activators, topoisomerase 
inhibitors and UV irradiation (Austin et al., 2008; Ball et al., 2009) is noteworthy. 
The current findings add to emerging insights into the role of innate immune TLR-signaling 
in the pathogenesis of human MDS. TLR4 and other TLRs are overexpressed in HSPCs from 
MDS patients (Maratheftis et al., 2007; Wei et al., 2013) and TLR4 expression was shown 
to correlate with apoptosis in CD34+ hematopoietic cells. TLR signaling is constitutively 
activated in MDS mice with deletion of chromosome 5 (del5q) (Starczynowski et al., 2010) 
and multiple TLR downstream signaling pathways have been shown to be activated in MDS 
and related to loss of progenitor cell function (Ganan-Gomez et al., 2015). 
Our findings implicate the DAMP S100A8/9 derived from the mesenchymal niche as a 
driver of TLR signaling in this disease. The unbiased identification of S100A8/9 seems to 
independently converge with an earlier report implicating S100A8/9 in the pathogenesis of 
MDS (Chen et al., 2013). In this study it was shown that the plasma concentration of S100A9 
was significantly increased in MDS patients (Chen et al., 2013) and S100A8/9 was shown to 
drive expansion and activation of myeloid-derived suppressor cells (MDSCs) that contributed 
to cytopenia and myelodysplasia in a murine model of S100A9 overexpression through 
secretion of suppressive cytokines. It is therefore an intriguing possibility that additional, 
indirect, biologic effects of S100A8/9 contribute to the hematopoietic phenotype of OCS 
mice. This may include engagement of other cognate receptors of the protein, including 
expansion of MDSCs through CD33 signaling (Chen et al., 2013). 
In our study S100A8/9 was aberrantly overexpressed in a rare population of mesenchymal 
niche cells, both in the mouse model and human disease. Typically, expression of the protein 
is found in myeloid cells, raising the question why S100A8/9 production by (rare) niche 
cells is more relevant to the biology of HSPC than secretion from myeloid/erythroid cells. 
While the answer to this question remains speculative in the absence of in vivo targeted 
overexpression studies, it is noteworthy that, in contrast to most cytokines, chemokines and 
other pro-inflammatory molecules, the local accumulation of S100A8/9 in the environment 
is very high (up to 100μg/ml and about 50 to 100-fold higher than systemic concentrations), 
likely caused by attachment to extracellular matrices such as proteoglycans (Vogl et 
al., 2014). This implicates that the exposure of HSPCs to S100A8/9 is projected to relate 
strongly to their anatomical proximity to a producing cell. CD271+ mesenchymal cells are 
directly adjacent to CD34+ HSPC in human bone marrow (Flores-Figueroa et al., 2012). This 
notion of ‘spatial relevance’ may also be congruent with recent observations that aberrant 
overexpression of S100A8/9 in hematopoietic (erythroid) cells within the erythroid island 
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in a model of human 5q- syndrome leads to a predominant erythroid, anemic, phenotype 
(Schneider at al., 2016).
The mechanisms of S100A8/9 induced DNA damage remain to be fully elucidated. Our 
experiments using NAC to reduce ROS burden suggest an incomplete association between 
oxidative stress and DNA damage, suggesting that S100A8/9 secretion may attenuate 
genomic integrity through additional mechanisms. Similarly, it is conceivable that other 
ligands secreted from mesenchymal cells contribute to the induction of DNA damage in 
HSPCs in the mouse model. We found a striking abundance of transcripts encoding other 
DAMPs and cytotoxic proteins in both the mouse model and mesenchymal elements isolated 
from SDS patients. Ongoing investigations will have to assess whether other selected ligands 
can evoke genomic stress in heterotypic HSPCs and in such a fashion contribute to the 
generation of a mutagenic environment in these disorders.
Finally, our findings establish molecular characteristics of the mesenchymal environment as 
an important determinant of disease outcome in humans. S100A8/9 expression, associated 
with activated p53 and TLR signaling, in mesenchymal cells predicted leukemic evolution 
and progression-free survival in a cohort of homogeneously treated low-risk MDS patients. 
This is of considerable clinical relevance because low-risk MDS is a heterogeneous disease-
entity with a subset of patients having a particular dismal prognosis not identified by current 
risk-stratification strategies (Bejar et al., 2012). Gene expression of S100A8/9 may identify 
a substantial subset of patients with a survival typically associated with ‘high-risk’ patients 
and, if confirmed in larger independent cohorts, could guide therapeutic decision making in 
MDS. The data thus provide a strong rationale for niche–instructed therapeutic targeting of 
inflammatory signaling in human preleukemic disease.
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EXPERIMENTAL PROCEDURES
Mice and in vivo procedures
OCS, Trp53f/f and S100A9Tg mice have been previously described (Cheng et al., 2008; Jonkers 
et al., 2001; Raaijmakers et al., 2010). PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased 
from Charles River. Animals were maintained in specific pathogen free conditions in the 
Experimental Animal Center of Erasmus MC (EDC). For in vivo cell cycle analysis, OCS mice 
received intraperitoneal injections of BrdU (1.5 mg in PBS, BD Biosciences) and sacrificed 
after 15 h. For TLR4 studies, 2 week-old mice were intraperitoneally injected with a double 
dose (100 µg and 35 µg, 48 h interval) of TLR4-neutralizing antibody (clone MTS510, 
eBioscience) or isotype control (clone eBR2a, eBioscience) and sacrificed after 60h. For NAC 
rescue studies, 2-week-old mice received daily intraperitoneal injections of NAC (Sigma-
Aldrich, 320 mg/kg in saline) until the day of the analysis and at least for 5 days. All mice 
were sacrificed by cervical dislocation. Animal studies were approved by the Animal Welfare/
Ethics Committee of the EDC in accordance with legislation in the Netherlands (Approval No. 
EMC 2067, 2714, 2892, 3062).
μCT analysis
Femur bones were isolated, fixated in 3% PFA/PBS for 24 h and stored in 70% ethanol. μCT 
analysis was performed using a SkyScan 1172 system (SkyScan) using previously described 
settings (Tudpor et al., 2015). Bone microarchitectural parameters relative to the trabecular 
and the cortical area were determined in the distal metaphysis and the mid-diaphysis of 
each femur, respectively, using software packages from Bruker MicroCT (NRecon, CtAn and 
Dataviewer). 
Human bone marrow samples
Bone marrow aspirates were obtained from SDS and DBA patients during routine follow-up. 
All MDS patients were treated with lenalidomide (10 mg/day, d 1-21 in a 4-week schedule) 
in the context of an ongoing prospective clinical trial for patients with low or intermediate-1 
risk MDS according to IPSS criteria (HOVON89; www.hovon.nl; www.trialregister.nl as 
NTR1825; EudraCT No. 2008-002195-10). Bone marrow specimens were collected at study 
entry and disease diagnosis and staging confirmed by central board reviewing. Leukemic 
evolution was assessed according to WHO criteria; development of RAEB1 (refractory anemia 
with excess of blast) or RAEB-2 (if RAEB1 at entry) was considered progression of disease. 
Leukemia (AML) was diagnosed according to standard WHO criteria (≥20% myeloblasts in 
blood/bone marrow). Bone marrow cells from allogeneic transplantation donors were used 
as normal controls. Patients and healthy donor characteristics are described in Table S4 and 
S6. All specimens were collected with informed consent, in accordance with the Declaration 
of Helsinki
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Gene expression profiling
Osx::GFP cells from bone cell suspensions of OCS mice were sorted in TRIzol Reagent (Life 
Technologies) and RNA was extracted according to the manufacturer’s recommendations. 
Linear amplification of mRNA was performed using the Ovation Pico WTA System (NuGEN). 
cDNA was fragmented and labelled with  Encore™ Biotin Module (NuGEN). The biotinylated 
cDNA was hybridized to the GeneChip Mouse Genome 430 2.0 Array (Affymetrix eBioscience). 
Signal was normalized and differential gene expression analysis was performed with the 
limma package (Ritchie et al., 2015). Gene expression array data derived from murine 
Osterix:GFP cells is available at ArrayExpress (www.ebiac.uk/arrayexpress) under accession 
number E-MTAB-5023. RNA sequencing experiments were performed as previously described 
(Zambetti et al., 2015). Human transcripts were aligned to the Ref Seq transcriptome (hg19) 
and analyzed with DESeq2 (Love et al., 2014), while mouse transcripts were aligned to the 
Ensembl transcriptome (mm10) and analyzed with EdgeR (Robinson et al., 2010) in the R 
environment. FPKM values were calculated using Cufflinks (Trapnell et al., 2010). Principal 
component analysis was performed in the R environment on the raw fragment counts 
extracted from the BAM files by HTSeq-count (Anders et al., 2015). RNA-Seq data derived 
from murine CD48-/CD48+ LSK cells have been deposited at the European Nucleotide Archive 
(ENA, http://www.ebi.ac.uk/ena/), which is hosted by the EBI, under accession number 
PRJEB15060. RNA-seq data derived from human LR-MDS, SDS and DBA specimens have 
been deposited at the European Genome-phenome Archive (EGA, https://www.ebi.ac.uk/
ega/), which is hosted by the EBI, under accession number EGAS00001001926. For Gene Set 
Enrichment Analysis (Subramanian et al., 2005) (GSEA, Broad Institute), normalized intensity 
values (microarray data) and FPKM values (RNA sequencing) were compared to the curated 
gene sets (C2) and the Gene Ontology gene sets (C5) of the Molecular Signature Database 
(MsigDB) using the Signal2Noise metric and 1000 gene set-based permutations. For HSPCs 
GO-term analysis, genes with significantly differential expression (P<0.05) were interrogated 
using g:Profiler web-based software (Reimand et al., 2011; Reimand et al., 2007).
Immunofluorescence microscopy
HSPCs were harvested in PBS+0.5%FBS, cytospun on a glass slide for 3 min at 500 rpm using 
a Cytospin 4 centrifuge (Thermo Scientific) and fixed in 3% PFA/PBS for 15 min on ice. After 3 
washing steps in PBS, cells were permeabilized for 2 min in 0.15% Triton-X100/PBS. Aspecific 
binding sites were blocked by incubation in 1%BSA/PBS for 1 h at room temperature. Cells 
were next stained overnight at 4°C with either anti-phospho-histone H2A.X (Ser139) mouse 
monoclonal antibody (clone JBW301, Merck Millipore, diluted 1:1000 in 1%BSA/PBS) or 
with anti-53BP1 rabbit polyclonal antibody (Novus Biologicals, diluted 1:1000 in 1%BSA/
PBS). Slides were washed twice in PBS for 5 min and incubated for 1 h at 37°C with either 
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Alexa Fluor 488-conjugated goat anti-mouse antibody (Cat. A10667, Life Technologies) or 
goat anti-rabbit antibody (Cat. A11008, Life Technologies), both diluted 1:200 in 1%BSA/
PBS. After 2 washes in PBS, slides were mounted in VECTASHIELD Mounting Medium with 
DAPI (Vector Laboratories). Z-series images were acquired with a Leica TCS SP5 confocal 
microscope (63X objective lens) using the LAS software (Leica Microsystems). γH2AX and 
53BP1 foci were counted manually from the maximum projection view.
Survival analysis
The low-risk MDS patient subgroup with S100 niche signature was defined by the Modified 
Thompson Tau test for outlier detection. In brief, S100A8 statistics from the control cases 
were combined to define the rejection region, demarcating FPKM values to be considered as 
outliers. MDS cases with S100A8 FPKM values within the rejection region were thus defined 
as niche-signature+. To determine the significance difference in time to progression we used 
the Wilcoxon signed rank test accounting for tied observations. Event-free survival was 
determined by specifying leukemic progression or death as events. Patients experiencing a 
non-hematological related death (e.g., cardiac failure), where censored on the date of this 
event. Patients remaining alive were censored on the date of last consultation. Kaplan-Meier 
curves were used to estimate the survival functions through time. Statistical differences in 
the survival distributions was assessed with the Mantel-Cox log-rank test. All calculations 
were performed in the R environment. 
Statistics
Statistical analysis was performed using Prism 5 (GraphPad Software). Unless otherwise 
specified, unpaired, 2-tailed Student’s t test (single test) or 1-way analysis of variance 
(multiple comparisons) were used to evaluate statistical significance, defined as P<0.05. All 
results in bar graphs are mean value ± standard error of the mean.
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SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, five figures, 
and six tables.
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FIGURE LEGENDS
Figure 1. Deletion of Sbds in MPCs recapitulates skeletal defects in human SDS. (A-B) Impaired growth in OCSf/f 
mice: (A) body weight (n = 9) and (B) femur length (n = 5). (C-H) Femur μCT analysis of OCSf/+ (n = 5) and OCSf/f (n = 
4) mice. (C) Representative 2D-images. Left: longitudinal view. Right: cortical bone. (D) 3D-image. (E) Bone volume 
per tissue volume (BV/TV). (F) Trabecular number (Tb. N). (G) Trabecular spacing (Tb. Sp). (H) Cortical bone mineral 
density (BMD). (I) Goldner osteoblast staining (OCSf/+, n = 6; OCSf/f, n = 8). Left: representative images (arrows: 
osteoblasts; with white dashed line in the magnified region). Right: number of osteoblasts per bone perimeter 
(N.Ob/B.Pm). (J-K) 3-point bending test indicating (J) reduced resistant to fracture and (K) decreased stiffness of 
OCSf/f bone (OCSf/+, n = 5; OCSf/f, n = 4). *P<0.05. **P< 0.01. ***P<0.001. Data are mean ± SEM. See also Figure S1.
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Figure 2. Sbds-deficient mesenchymal cells induce genotoxic stress in HSPCs. (A) Transcriptional network analysis 
indicating mitochondrial dysregulation in mutant HSPCs. NES: Normalized Enrichment Score. (B-C) Increased 
mitochondrial potential (TMRM) in HSPCs: (B) representative plots; (C) mean fluorescence intensity (MFI) (n = 3). 
(D) ROS quantification by CM-H2DCFDA (OCSf/+, n = 6; OCSf/f, n = 7). (E) Increased γH2AX levels in mutant HSPCs. 
Left, representative FACS analysis. Right, MFI values (n = 4). (F-I) Activation of DNA damage response in mutant 
HSPCs. (F) Transcriptional repression of G1-S checkpoint progression. (G, H) In vivo BrdU staining confirming 
impaired S-phase transition (n = 4). (I) Downregulation of Myc signaling. GSEA data shown is from CD48- LKS cells. 
a.u., arbitrary units.  †††FDR<0.001. *P<0.05. **P<0.01. ***P<0.001. Data in bar graphs are mean± SEM. See also 
Figure S2, S3, S6 and Table S1-S3.
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Figure 3. Activation of p53 in MPCs drives skeletal and hematopoietic abnormalities in OCS mutants. (A) p53 
protein (FACS) accumulates in GFP+ cells from OCSf/f mice (n = 3). (B-C) Activation of p53 in mutant GFP+ cells 
as demonstrated by (B) enrichment of a p53 GSEA signature and (C) overexpression of canonical p53 targets (n 
= 3). (D) Schematic representation of the p53 floxed allele with indication of primers used to assess genotypes 
(p10.1-p10.2) and genomic deletion (p1.1-p10.2). (E) Specific deletion of p53 in bone-containing tissue in OCSf/f 
p53Δ mice (genomic PCR). (F-J) Non-compiled µCT images  indicating normalization of bone mass in OCSf/f mice 
upon genetic deletion of p53 (p53+, n = 3; p53Δ, n = 5). Tb. Pf , Trabecular bone pattern factor. (K) Bone imineral 
density in OCSf/f mice is not rescued by p53 deletion. (L-M) Effects of p53 deficiency on OCS HSPCs. Tendency for 
reduced oxidative stress as assessed by DHE analysis (L) and significant reduction of γH2AX levels (M) in HSPCs from 
OCSf/f p53Δ mice (n = 3). MFI: mean fluorescence intensity. a.u., arbitrary units.  *P < 0.05. **P <0.01. ***P <0.001. 
Data are mean ± SEM. See also Figure S4.
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Figure 4. Identification of S100A8 and S100A9 as candidate drivers of genotoxic stress in leukemia predisposition 
syndromes. (A) Representative mesenchymal CD271+ FACS gating. (B) Pathognomonic 183-184 TA>CT mutation 
in niche cells from a representative SDS patient (IGV plot). (C) Reduced SBDS expression in SDS niche cells. (D) 
Disruption of ribosome biogenesis and translation in SDS CD271+ cells (GSEA). (E) Inflammation-related transcripts 
are upregulated in niche cells from SDS patients and OCSf/f mice. (F) Significantly differentially expressed genes in 
SDS (n = 4), MDS (n = 9) and DBA (n = 3) in comparison to normal CD271+ cells. (G) Expression of S100A8 and S100A9 
in mesenchymal cells from SDS, low-risk MDS, and DBA patients. *P<0.05. ***P<0.001. †††FDR-adjusted P<0.001. 
See also Figure S1, S5 and Table S4.
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Figure 5. S100A8/9 induces genotoxic stress in murine HSPCs through TLR4 signaling. (A-B) Increased S100A8 and 
S100A9 levels in OCSf/f GFP+ cells. (A) representative plots. (B) MFI values (n = 5). (C) Increased plasma concentration 
of S100A8/9 by ELISA (OCSf/+, n = 5; OCSf/f, n = 4). (D) Left: representative γH2AX pictures after HSPCs in vitro 
exposure. Positive control: 8-Gy irradiated Lin- c-Kit+ Sca-1- cells. Negative controls: heat-inactivated S100A8/9 (H.I. 
ctr). Right: number of γH2AX foci (n = 3). (E) S100A8/9 has no effect on cell cycle (n = 2). (F) Increased apoptosis 
in S100A8/9-exposed LKS (n = 3). (G) Activation of TLR signaling (GSEA). (H) TLR4-blocking antibodies limit DNA 
damage in OCSf/f mice (n = 4). *P<0.05. *P<0.01. ***P<0.001. Data are mean ± SEM. See also Figure S6 and S7; 
Table S5.
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Figure 6. Niche derived S100A8/9 induces oxidative and genotoxic stress in HSPCs. (A) Schematic representation 
of wild type HSPCs transplantation in S100A9Tg mice. BM: bone marrow. (B-C) Mesenchymal cells from S100A9Tg 
mice express the S100A9-IRES-GFP construct. (B) Gating strategy defining CD51+ Sca-1+ mesenchymal ‘stem’ cells 
(MSC) and CD51+ Sca-1- osteolineage cells in the microenvironment (C) Expression of GFP in S100A9Tg-derived 
mesenchymal compartments (n = 3). (D) Transplantation efficiency as assessed by CD45.1+ cell chimerism in the 
bone marrow (BM) of transplanted mice (n = 4). (E) Accumulation of superoxide radicals in HSPCs exposed to 
S100A8/9-overexpressing microenvironment. Left, representative plot. Right, DHE MFI values (n = 4). (F) Increased 
levels of γH2AX in immunophenotypically-defined HSCs. Left, representative plot. Right, DHE MFI values (n = 4). 
*P<0.05. **P<0.01. Data are mean ± SEM.
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Figure 7. Activation of the p53-S100A8/9-TLR axis in mesenchymal niche cells predicts leukemic evolution 
and clinical outcome in human low-risk MDS. (A) Representative examples of FACS-isolated CD271+ niche cells 
in human MDS. (B) Correlation plot of S100A8 and S100A9 expression levels in human low-risk MDS (n = 45). 
(C) Expression of the defining gene NGFR (CD271) in mesenchymal  cells (S100 niche +, n = 17; S100 niche -, 
n = 28). (D) Representative staining of S100A8 and S100A9 in endosteal (CD271+) stromal cells. Intramedullary 
staining reflects expression of S100A8/9 in myeloid cells. (E) GSEA analysis indicating enrichment of p53 and TLR 
signatures in S100A8/9-overexpressing CD271+ cells. Two representative GSEA plots are shown. NES: Normalized 
Enrichment Score. (F) Kaplan-Meier survival curve showing progression-free survival (G). Statistical analysis 
indicating significantly reduced time to progression and progression-free survival (PFS). Data are mean ± SEM. See 
also Table S6.
Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution 
in human pre-leukemia
3
96
SUPPLEMENTAL DATA ITEMS
Figure S1. Related to Figure 1; Figure 4. Impairment of terminal osteogenic differentiation in OCSf/f mice. 
(A) Increased CFU-F numbers (n = 3) with (B) unaltered frequency of Osx::GFP+ cells (n = 4) in OCSf/f mice. (C) 
Depletion of transcripts defining terminal osteogenic differentiation (osteocalcin, Bglap) and dentin matrix acidic 
phosphoprotein 1 (Dmp1), critical for proper mineralization of bone, and enrichment of markers of bone progenitor 
cells or early osteoblasts (Runx2 and Col1a1) in GFP+ cells from OCSf/f mice. No statistically significant difference 
was observed in the expression of osterix (Sp7).  (D) Significant (FDR<0.25) enrichment of ribosome and peptide 
chain elongation signatures in OCSf/f GFP+ cells (GSEA) with (E) representative plots. *P<0.05. **P<0.01. Data are 
mean ± SEM.
Figure S2. Related to Figure 2. Oxidative and genotoxic stress in HSPCs from OCSf/f mice. (A-C) unaltered HSPC 
numbers in OCSf/f mice: (A) representative FACS plots, (B) bone marrow cellularity and (C) subset frequency (OCSf/+, 
n = 8 in A-B, n = 7 in C; OCSf/f, n = 7). LK: Lin- c-Kit+ Sca-1- cells. LKS: Lin- c-Kit+ Sca-1+ cells. MPP: multipotent 
progenitors, CD48- CD150- LKS cells. SLAM: CD48- CD150+ LKS cells. (D) FACS isolation of CD48+ and CD48- HSPC 
subsets for RNA-seq (OCSf/+ CD48-, n = 3; other groups, n = 4). (E) RNA-seq validation confirming CD48 and Ptprc 
(CD45) expression and the Sbds-proficient status of HSPCs from mutant mice. (F) Principal component analysis 
indicating global preservation of the transcriptome in HSPCs from OCSf/f mice. (G) Superoxide radical accumulation 
in HSPCs from OCSf/f mice as shown by DHE staining. (H) Increased number of γH2AX foci in HSPCs from mutants 
(n= 2; pooled data). (I-J) NAC treatment attenuates oxidative (I) and (non-significantly) genotoxic stress (J) of OCSf/f 
mice. NAC- controls were either treated with saline or not injected. (OCSf/+ + NAC, n = 3; OCSf/f + NAC, n = 3;, n = 4; 
other groups, n = 5). (K) Ki67 analysis of OCS mice indicating no change in the frequency of G0 HSPCs (OCSf/+, n = 3; 
OCSf/f, n = 4). *P<0.05. **P<0.01. ***P<0.001. †††FDR-adjusted P<0.001. Data are mean ± SEM.
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Figure S3. Related to Figure 2. Niche-induced DNA damage does not affect HSPC function. (A) Schematic 
representation of the competitive transplantation. BM: bone marrow. (B) Peripheral blood frequency of CD45.2+ 
cells 16 weeks after transplantation. (C) Bone marrow frequency of CD45.2+ cells (21-32 weeks after transplantation). 
Every circle represents one recipient mouse. (D) Manual scoring system applied to comet assay analysis. (E) Comet 
assay showing similar frequency of highly damaged HSPCs in OCSf/+ and OCSf/f mice (n = 5). +IR: 8-10 Gy irradiated 
positive control (LK cells). ***P<0.001. Data are mean ± SEM.
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Figure S4. Related to Figure 3. Bone effects of Trp53 ablation in OCS mutant and control mice. (A-D) Normalization 
of µCT parameters  in OCSf/f p53Δ mice shown as fold change (p53+, n = 3; p53Δ, n = 5). (E-F) Modest increase in bone 
mass upon genetic deletion of p53 in OCS control mice, defined as Osxcre/+ Sbdsf/+ or Osxcre/+ Sbds+/+ (p53f/+, n = 8; 
p53f/f, n = 3). *P<0.05. **P<0.01. ***P<0.001.  Data are mean ± SEM.
Figure S5. Related to Figure 4. SBDS mutations in mesenchymal cells from SDS patients. (A-B) Detection of 
258+2 T>C mutation in SDS patients. (A) Representative IGV plot. Note that the coverage level after the cryptic site 
(dashed box) is reduced in SDS, indicating an 8-bp deletion. (B) Quantification of 258+2 T>C mutation as frequency 
of spliced reads with 8-bp deletion. Every circle represents a patient. (C) Nucleotide sequence in positions 183-184 
from SDS patients and healthy donors.
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Figure S6. Related to Figure 2; Figure 5. A p53-S100A8/9-TLR axis induces DNA damage in HSPCs. (A) Sbds-knock 
down in OP9 cells induces expression of S100a8, S100a9 and activation of p53 pathway. Left, expression analysis 
by qPCR (data normalized against shControl, n = 3). Right, representative Western Blot analysis showing p53 
accumulation upon Sbds-knock down. (B, C) TLR4 expression and activation of NF-κB and MAPK pathways in HSPCs 
from OCSf/f mice (GSEA). NES: normalized enrichment score. (D) Ex-vivo treatment with S100A8/9 induces 53BP1 
foci of DNA damage in murine HSPCs (LKS cells), Left, representative images. Right, cumulative dot plots (n = 2). 
***P <0.001. Data in bar graphs are mean ± SEM.
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Figure S7. Related to Figure 5. S100A8/9 drives genomic stress in human HSPCs. (A-C) Treatment of human CD34+ 
HSPCs with recombinant S100A8/9. (A) Induction of γH2AX foci (n = 3). (B-C) Increased frequency of apoptotic cells. 
(B) Representative plot. (C) Quantification (n = 3).  (D) Reduced colony forming capacity of HSPCs as assessed by 
CFU-C assay (n = 4 independent experiments in triplicate). Data are mean ± SEM. *P<0.05. **P<0.01. ***P<0.001.
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of 
signatures previously identified as predictive for leukemia evolution. Provided as an Excel file. Upregulation of 
G-protein-coupled receptors and cell adhesion-communication, and downregulation of mitochondrial oxidative 
phosphorylation, ribosome biogenesis, aminoacyl-tRNA synthetase activity, proteasomal degradation, citric acid 
cycle, cell cycle deregulation and hematopoietic stem cell programs. Normalized enrichment score (NES) and False 
Discovery Rate-adjusted q-value (FDR) are omitted when FDR > 0.25.
Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
Enriched in OCS mutants
G-protein coupled receptors
G_PROTEIN_COUPLED_RECEPTOR_PROTEIN_SIGNALING_
PATHWAY
C5 1.63 0.180
Cell adhesion-communication
REACTOME_GAP_JUNCTION_ASSEMBLY C2
1.84 0.170
PID_INTEGRIN_CS_PATHWAY C2 1.78 0.213
SA_MMP_CYTOKINE_CONNECTION C2 1.75 0.230
KEGG_CELL_ADHESION_MOLECULES_CAMS C2 1.70 0.236
Enriched in OCS controls
Mitochondria and oxidative phosphorylation
MOOTHA_VOXPHOS C2 -2.49 <0.001 -1.93 0.001
WONG_MITOCHONDRIA_GENE_MODULE C2 -2.46 <0.001 -2.19 <0.001
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_
SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_
PRODUCTION_BY_UNCOUPLING_PROTEINS_
C2 -2.44 <0.001 -2.02 <0.001
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT C2 -2.43 <0.001 -1.91 0.002
KEGG_OXIDATIVE_PHOSPHORYLATION C2 -2.37 <0.001 -1.75 0.012
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT C2 -2.13 <0.001 -1.95 0.001
MOOTHA_MITOCHONDRIA C2 -2.12 <0.001 -1.96 0.001
HOUSTIS_ROS C2 -1.58 0.047 -1.34 0.211
REACTOME_RNA_POL_I_RNA_POL_III_AND_
MITOCHONDRIAL_TRANSCRIPTION
C2 -1.50 0.076
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_
TURQUOISE_DN
C2 -1.48 0.083
MOOTHA_HUMAN_MITODB_6_2002 C2 -2.01 <0.001
GALLUZZI_PREVENT_MITOCHONDIAL_PERMEABILIZATION C2 -1.30 0.248
MITOCHONDRIAL_MEMBRANE_PART C5 -2.21 <0.001 -1.83 0.016
MITOCHONDRIAL_INNER_MEMBRANE C5 -2.15 <0.001 -1.99 0.003
MITOCHONDRIAL_PART C5 -2.13 <0.001 -2.07 0.001
MITOCHONDRIAL_MEMBRANE C5 -2.07 <0.001 -2.02 0.003
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Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
MITOCHONDRIAL_ENVELOPE C5 -1.98 0.002 -2.01 0.003
MITOCHONDRIAL_MATRIX C5 -1.97 0.002 -1.81 0.020
MITOCHONDRIAL_LUMEN C5 -1.96 0.002 -1.81 0.019
MITOCHONDRIAL_RIBOSOME C5 -1.87 0.008 -1.64 0.060
MITOCHONDRION C5 -1.85 0.010 -2.01 0.002
MITOCHONDRIAL_RESPIRATORY_CHAIN C5 -1.81 0.015 -1.87 0.013
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS C5 -1.54 0.121 -1.50 0.133
ELECTRON_CARRIER_ACTIVITY C5 -1.73 0.034
MITOCHONDRIAL_TRANSPORT C5 -1.55 0.099
Ribosomes
BILANGES_SERUM_RESPONSE_TRANSLATION C2 -1.64 0.028
REACTOME_DEADENYLATION_DEPENDENT_MRNA_DECAY C2 -1.63 0.032
REACTOME_ELONGATION_ARREST_AND_RECOVERY C2 -1.58 0.046
REACTOME_TRANSLATION C2 -2.47 <0.001
KEGG_RIBOSOME C2 -2.42 <0.001
REACTOME_PEPTIDE CHAIN ELONGATION C2 -2.42 <0.001
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_
THE_EXON_JUNCTION_COMPLEX
C2 -2.37 <0.001
REACTOME_FORMATION_OF_THE_TERNARY_COMPLEX_
AND_SUBSEQUENTLY_THE_43S_COMPLEX
C2 -2.19 <0.001
MCGOWAN_RSP6_TARGETS_UP C2 -1.76 0.011
STRUCTURAL_CONSTITUENT_OF_RIBOSOME C5 -2.33 <0.001
RIBOSOME C5 -2.04 0.001 -1.68 0.045
RIBOSOME_BIOGENESIS_AND_ASSEMBLY C5 -2.02 0.001 -1.78 0.023
ORGANELLAR_RIBOSOME C5 -1.89 0.007 -1.63 0.067
RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS_AND_
ASSEMBLY
C5 -1.83 0.012 -2.11 0.002
RIBOSOMAL_SUBUNIT C5 -1.78 0.019 -1.62 0.071
TRANSLATION C5 -1.56 0.118
PROTEIN_POLYMERIZATION C5 -1.53 0.126
RIBONUCLEOPROTEIN_COMPLEX C5 -2.09 0.001
PROTEIN_RNA_COMPLEX_ASSEMBLY C5 -1.98 0.003
TRANSLATIONAL_INITIATION C5 -1.73 0.034
TRANSLATION_REGULATOR_ACTIVITY C5 -1.71 0.039
TRANSLATION_FACTOR_ACTIVITY_NUCLEIC_ACID_BINDING C5 -1.70 0.044
TRANSLATION_INITIATION_FACTOR_ACTIVITY C5 -1.67 0.048
REGULATION_OF_TRANSLATIONAL_INITIATION C5 -1.55 0.100
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Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
tRNA biosynthesis
REACTOME_CYTOSOLIC_TRNA_AMINOACYLATION C2 -1.85 0.004
REACTOME_TRNA_AMINOACYLATION C2 -1.72 0.015
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS C2 -1.64 0.030
TRNA_METABOLIC_PROCESS C5 -1.69 0.044
Proteasomal pathway
KEGG_PROTEASOME C2 -2.18 <0.001 -1.99 0.001
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_
LIGASE_COP1
C2 -2.07 <0.001 -2.01 <0.001
BIOCARTA_PROTEASOME_PATHWAY C2 -1.92 0.002 -2.14 <0.001
WONG_PROTEASOME_GENE_MODULE C2 -1.83 0.005
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_
PROTEASOME_DEGRADATION
C2 -1.42 0.138
PROTEASOME_COMPLEX C5 -1.47 0.168 -1.52 0.113
Cell cycle regulation
REACTOME_SYNTHESIS_OF_DNA C2 -2.44 <0.001 -2.25 <0.001
REACTOME_S_PHASE C2 -2.42 <0.001 -2.31 <0.001
CHICAS_RB1_TARGETS_LOW_SERUM C2 -2.28 <0.001
ISHIDA_E2F_TARGETS C2 -2.27 <0.001 -2.11 <0.001
REACTOME_MITOTIC_G1_G1_S_PHASES C2 -2.27 <0.001 -2.37 <0.001
REACTOME_G1_S_TRANSITION C2 -2.26 <0.001 -2.31 <0.001
REACTOME_M_G1_TRANSITION C2 -2.26 <0.001 -2.17 <0.001
REACTOME_DNA_STRAND_ELONGATION C2 -2.23 <0.001 -2.05 <0.001
KEGG_DNA_REPLICATION C2 -2.21 <0.001 -2.02 <0.001
RAHMAN_TP53_TARGETS_PHOSPHORYLATED C2 -2.18 <0.001 -1.90 0.002
REACTOME_CDK_MEDIATED_PHOSPHORYLATION_AND_
REMOVAL_OF_CDC6
C2 -2.17 <0.001 -2.00 0.001
REACTOME_ASSEMBLY_OF_THE_PRE_REPLICATIVE_COMPLEX C2 -2.15 <0.001 -2.20 <0.001
KONG_E2F3_TARGETS C2 -2.14 <0.001 -2.19 <0.001
REACTOME_DNA_REPLICATION C2 -2.14 <0.001 -2.29 <0.001
REACTOME_CDT1_ASSOCIATION_WITH_THE_CDC6_ORC_
ORIGIN_COMPLEX
C2 -2.13 <0.001 -2.10 <0.001
REACTOME_CYCLIN_E_ASSOCIATED_EVENTS_DURING_G1_S_
TRANSITION_
C2 -2.13 <0.001 -2.13 <0.001
MARKEY_RB1_ACUTE_LOF_DN C2 -2.11 <0.001 -2.27 <0.001
REACTOME_CELL_CYCLE_CHECKPOINTS C2 -2.10 <0.001 -2.11 <0.001
WHITFIELD_CELL_CYCLE_LITERATURE C2 -2.08 <0.001 -2.25 <0.001
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Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
EGUCHI_CELL_CYCLE_RB1_TARGETS C2 -2.03 <0.001 -1.97 0.001
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE C2 -2.03 <0.001
REACTOME_CELL_CYCLE_MITOTIC C2 -2.02 <0.001 -2.34 <0.001
REACTOME_LAGGING_STRAND_SYNTHESIS C2 -2.02 <0.001 -1.88 0.003
REACTOME_CELL_CYCLE C2 -2.01 <0.001 -2.18 <0.001
REACTOME_MITOTIC_M_M_G1_PHASES C2 -2.00 <0.001 -2.23 <0.001
SCIAN_CELL_CYCLE_TARGETS_OF_TP53_AND_TP73_DN C2 -1.98 0.001 -1.81 0.006
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_24HR C2 -1.90 0.002 -2.12 <0.001
KAUFFMANN_DNA_REPLICATION_GENES C2 -1.87 0.003 -1.96 0.001
IGLESIAS_E2F_TARGETS_UP C2 -1.86 0.003 -1.32 0.235
CHANG_CYCLING_GENES C2 -1.85 0.004 -2.10 <0.001
TANG_SENESCENCE_TP53_TARGETS_DN C2 -1.82 0.006 -1.86 0.003
MARKEY_RB1_CHRONIC_LOF_UP C2 -1.78 0.008 -1.42 0.134
REACTOME_G2_M_CHECKPOINTS C2 -1.78 0.008 -1.71 0.017
ZHOU_CELL_CYCLE_GENES_IN_IR_RESPONSE_6HR C2 -1.77 0.009 -2.19 <0.001
REACTOME_CYCLIN_A_B1_ASSOCIATED_EVENTS_DURING_
G2_M_TRANSITION
C2 -1.68 0.022 -1.39 0.160
REACTOME_E2F_MEDIATED_REGULATION_OF_DNA_
REPLICATION
C2 -1.64 0.028 -1.88 0.003
MOLENAAR_TARGETS_OF_CCND1_AND_CDK4_DN C2 -1.62 0.033 -2.32 <0.001
REACTOME_G1_S_SPECIFIC_TRANSCRIPTION C2 -1.62 0.034 -1.94 0.001
BIOCARTA_P53_PATHWAY C2 -1.59 0.044 -1.31 0.246
VERNELL_RETINOBLASTOMA_PATHWAY_UP C2 -1.58 0.045 -1.96 0.001
REACTOME_MEIOTIC_RECOMBINATION C2 -1.57 0.049
KANNAN_TP53_TARGETS_DN C2 -1.56 0.052
IWANAGA_E2F1_TARGETS_INDUCED_BY_SERUM C2 -1.54 0.059 -1.40 0.155
KEGG_CELL_CYCLE C2 -1.51 0.068 -1.88 0.003
BIOCARTA_MCM_PATHWAY C2 -1.49 0.079 -1.54 0.068
REACTOME_G0_AND_EARLY_G1 C2 -1.48 0.086 -1.86 0.003
PID_E2F_PATHWAY C2 -1.47 0.088 -1.85 0.004
MARKEY_RB1_CHRONIC_LOF_DN C2 -1.44 0.110
CHICAS_RB1_TARGETS_GROWING C2 -1.42 0.121 -1.72 0.015
REACTOME_MITOTIC_PROMETAPHASE C2 -1.38 0.153 -1.84 0.004
REACTOME_G1_PHASE C2 -1.37 0.155 -1.65 0.030
BIOCARTA_CELLCYCLE_PATHWAY C2 -1.35 0.173 -1.65 0.029
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN C2 -1.30 0.220
WHITFIELD_CELL_CYCLE_G2 C2 -1.30 0.224 -1.60 0.044
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Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
SANCHEZ_MDM2_TARGETS C2 -1.28 0.249
BENPORATH_PROLIFERATION C2 -2.15 <0.001
REACTOME_SCFSKP2_MEDIATED_DEGRADATION_OF_P27_
P21
C2 -2.14 <0.001
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_
MITOTIC_PROTEINS
C2 -2.03 <0.001
REN_BOUND_BY_E2F C2 -1.89 0.002
REACTOME_PROCESSIVE_SYNTHESIS_ON_THE_LAGGING_
STRAND
C2 -1.92 0.001 -1.72 0.016
REACTOME_MITOTIC_G2_G2_M_PHASES C2 -1.69 0.021
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_
COMPLEX
C2 -1.93 0.001 -1.68 0.022
CEBALLOS_TARGETS_OF_TP53_AND_MYC_UP C2 -1.67 0.025
REACTOME_RECRUITMENT_OF_MITOTIC_CENTROSOME_
PROTEINS_AND_COMPLEXES
C2 -1.63 0.033
REICHERT_MITOSIS_LIN9_TARGETS C2 -1.61 0.039
PID_P53REGULATIONPATHWAY C2 -1.59 0.047
BIOCARTA_G1_PATHWAY C2 -1.55 0.060
SA_G1_AND_S_PHASES C2 -1.51 0.082
WHITFIELD_CELL_CYCLE_G2_M C2 -1.48 0.099
WHITFIELD_CELL_CYCLE_M_G1 C2 -1.48 0.099
WHITFIELD_CELL_CYCLE_G1_S C2 -1.47 0.101
BIOCARTA_G2_PATHWAY C2 -1.46 0.112
GEORGES_CELL_CYCLE_MIR192_TARGETS C2 -1.45 0.116
WHITFIELD_CELL_CYCLE_S C2 -1.40 0.155
REGULATION_OF_CYCLIN_DEPENDENT_PROTEIN_KINASE_
ACTIVITY
C5 -1.99 0.001
REPLICATION_FORK C5 -1.85 0.010 -1.45 0.169
DNA_REPLICATION C5 -1.83 0.012 -1.58 0.088
CELL_CYCLE_PROCESS C5 -1.74 0.031 -1.51 0.127
INTERPHASE C5 -1.67 0.057 -1.45 0.171
CELL_CYCLE_PHASE C5 -1.64 0.070 -1.40 0.209
CELL_CYCLE_GO_0007049 C5 -1.64 0.070 -1.43 0.174
MITOTIC_CELL_CYCLE C5 -1.63 0.070 -1.51 0.122
DNA_DEPENDENT_DNA_REPLICATION C5 -1.59 0.097 -1.52 0.113
INTERPHASE_OF_MITOTIC_CELL_CYCLE C5 -1.58 0.104 -1.50 0.128
M_PHASE C5 -1.54 0.122 -1.34 0.250
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Gene set MSigDB 
collection
CD48- LKS CD48+ LKS
NES FDR NES FDR
M_PHASE_OF_MITOTIC_CELL_CYCLE C5 -1.52 0.125 -1.55 0.098
CELL_PROLIFERATION_GO_0008283 C5 -1.46 0.176
MITOSIS C5 -1.43 0.197 -1.56 0.096
DNA_METABOLIC_PROCESS C5 -1.46 0.160
Metabolism
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_
TRANSPORT
C2 -2.19 <0.001 -2.08 <0.001
MOOTHA_TCA C2 -1.67 0.024 -1.78 0.008
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE C2 -1.61 0.037 -1.87 0.003
KEGG_CITRATE_CYCLE_TCA_CYCLE C2 -1.55 0.054 -1.79 0.007
REACTOME_GLUCOSE_METABOLISM C2 -1.33 0.190
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_
TCA_CYCLE
C2 -1.71 0.017
Hematopoietic stem cells
IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR C2 -1.67 0.023 -2.02 <0.001
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_QTL_CIS C2 -1.45 0.103
PARK_HSC_AND_MULTIPOTENT_PROGENITORS C2 -1.39 0.145 -1.53 0.070
BYSTRYKH_HEMATOPOIESIS_STEM_CELL_AND_BRAIN_QTL_
CIS
C2 -1.32 0.227
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Table S2. Related to Figure 2. Stress and DNA damage dysregulation in the transcriptome of HSPCs from OCSf/f mice. 
Genes with significantly different expression (P<0.05) between OCSf/+ and OCSf/f mice within the CD48- or CD48+ 
populations were interrogated for GO and Reactome term enrichment using g-profiler. P-val: p-value. NS: not 
significant (P≥0.05).
Table S3. Related to Figure 2. Myc-related signatures depleted in OCSf/f HSPCs. 
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Table S4. Related to Figure 4. Human normal donor and patient characteristics. 
 
aAll SDS patients were genetically characterized by compound heterozygosity c.183_184TA>CT/c.258+2T>C. Patients 
did not receive G-CSF treatment and were not diagnosed with MDS or AML at the time of bone marrow sampling. 
All patients presented with pancreatic insufficiency (serum trypsinogen level <6 µg/L) and growth retardation (≤ 2 
SD). All patients but SDS438 were neutropenic at sampling (absolute neutrophil counts, ANC < 1.5×109/l); SDS438 
had ANC = 1.62×109/l).
bSee Table S6 for further patient characteristics.
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Table S5. Related to Figure 5. In vitro exposure of HSPCs to S100A8/9 activates transcriptional signatures related 
to TLR signaling and cellular stress/apoptosis. 
Table S6. Related to Figure 7. MDS patient characteristics. Provided as an Excel file. All patients were treated with 
lenalidomide in the context of an ongoing prospective clinical trial (details in Experimental Procedures). Patient 
characteristics at study entry are listed.  Progression free survival is calculated from date of study-entry.  Hb, 
hemoglobin. PLT, platelets. WBC, white blood cells. ANC, absolute neutrophil count. S100A8 and S100A9 expression 
is obtained by RNA-sequencing data. P-values were calculated by Mann-Whitney (MW) test.
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Patient ID WHO Cyto-
genetics
IPSS Genetic 
Abnormalities
S100 niche 
signature +
MDS020 RCMD-RS 46,XX[20] 0 SRSF2 mutation
MDS486 CMML-1 46,XX,t(3;3)(q21;q26)[10] 0.5 SF3B1 mutation
MDS610 RCMD-RS 46,XX[20] 0.5 TET2, DNMT3A, SF3B1 and RUNX1 mutation
MDS627 RCMD 46,XY[20] 0 TET2 and ASXL1 mutation 
MDS008 RCMD 46,XX[20] 0.5 ASXL1 and EZH2 mutation
MDS092       RAEB-1 46,XX,del(5)(q1?5q3?5)[15] 0.5 sequenced: no mutations found
MDS174     RCMD-RS 47,XY,+19[9]/46,XY[11] 1 SETBP1 and  U2AF1 mutation
MDS176 RCMD-RS 46,XY[22] 0 Not Sequenced
MDS019 RCMD-RS 46,XX[20] 0 SF3B1 mutation
MDS061 RAEB-1 46,XY[20] 0.5 DNMT3A, SF3B1 and TET2 mutation
MDS069 CMML-1 46,XY,der(13)t(1;13)(q11;p11)[10] 1.0 ASXL1, IDH2, SF3B1 and TET2 mutation
MDS079 RCMD 47,XY,t(2;14)(q3?7;q2?2),idic(21)
(p1?2),+idic(21)(p1?2)[8]
1.0 ASXL1 mutation
MDS135 RCMD-RS 46,XX[20] 0 ASXL1, TET2 mutation
MDS183 MDS-U 47,XX,+8[12] 0.5 ASXL1, IDH2  and SRSF2 mutation
MDS203 RCMD-RS 46,XY,del(5)(q13q31)[7]/47,XY,del(5)
(q13q31),+8[4]/46,XY[1]
0.5 ASXL1 and SF3B1 mutation
MDS206 Del(5q) 46,XX,del(5)(q13q33)[7}/46,XX[13] 0 SF3B1 and TET2 mutation
MDS010 RCMD 46,XY[20] 0 sequenced: no mutations found
S100 niche 
signature -
MDS006 RAEB-1 46,XX[20] 1 DNMT3A and SRSF2 mutation
MDS118 RARS 46,XX[20] 0 TET2, DNMT3A and SF3B1 mutation
MDS159 Del(5q) 46,XX,del(5)(q15q33)[10] 0 sequenced, no mutations found
MDS209 RCMD-RS 46,XX[10] 0 SF3B1 mutation
MDS222 RARS 46,XX[21] 0 SF3B1 and 2 TET2 mutations
MDS025 RCMD-RS 46,XY[20] 0 SF3B1 mutation
MDS433 RCMD-RS 45,X,-Y[10]/46,XY[10] 0 sequenced: no mutations found
MDS646 RAEB-1 46,XX[20] 1 ASXL1 mutation
MDS893 RARS 46,XX[20] 0 SF3B1 mutation
MDS111 RCMD 46,XX[20] 0 sequenced: no mutations found
MDS623 RCMD 46,XY[20] 0.5 sequenced: no mutations found
MDS247 RCMD-RS 46,XY[20] 0 DNMT3A and SF3B1 mutation
MDS150     RCMD-RS 46,XX[20] 0.5 not sequenced
MDS158     RCMD-RS 46,XX[20] 0 DNMT3A, SF3B1 and TET2 mutation
MDS172      RARS 46,XY[20] 0 SF3B1 and 2 TET2 mutations
MDS022 RAEB-1 46,XY[20] 1.0 sequenced: no mutations found
MDS053 RARS 45,X,-Y][7]/46,XY[3] 0.0 SF3B1, TET2 mutation
MDS055 RCMD 46,XY,der(22)(t(1;22)(q12;p11)
[16]/46,XY,SL,del(20)(q12)[3]
0.5 sequenced: no mutations found
MDS093 RCMD 46,XY[20] 0.5 TET2 mutation
MDS101 RCMD-RS 46,XY[21] 0.0 ASXL1, DNMT3A and SF3B1 mutation
MDS121 RCMD 46,XY[20] 0.5 sequenced: no mutations found
MDS144 RCMD 47,XY,+19[6]/48,idem,+21[3]/46,XY[4] 1.0 ASXL1, U2AF1 mutation
MDS167 RCMD 46,XY[21] 0.0 SF3B1 mutation
MDS182 RCMD 46,XY,del(5)(q13q33)[10]/46,XY[10] 0.0 DNMT3A, TET2 mutation
MDS201 RCMD-RS 46,XX[20] 0.0 SF3B1 mutation
MDS001 RCMD-RS 46,XY[20] 0.0 SF3B1 mutation
MDS007 RCMD-RS 46,XY[20] 0.0 SF3B1, TET2 mutation
MDS013 Del(5q) 46,XX,del(5)(q13q33)[15]/46,XX[1] 0.0 sequenced: no mutations found
Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution 
in human pre-leukemia
3
112
SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Mice genotyping and sample collection
DNA was extracted from mouse toes with DirectPCR Lysis Reagent (Viagen Biotech). 
Genotyping and Cre-mediated recombination were verified on genomic DNA samples using 
the primers listed in the table below. Mouse bone marrow and bone fraction cells were 
isolated as previously described (Raaijmakers et al., 2010). Red blood cells (RBC) were 
lysed with ACK lysing buffer (Lonza) before surface markers staining. Peripheral blood was 
collected from the submandibular vein in K2EDTA-coated microtainers (BD) and analyzed 
using a Vet ABC counter (Scil Animal Care).
Genotyping primers used in the study. 
Bone mineral density and 3-point bending test analysis
Cortical BMD was calculated from μCT cortical data on the basis of a calibration scanning 
obtained using two phantoms with known density (0.25 g/cm3 and 0.75 g/cm3; Bruker 
MicroCT) under identical conditions as for the femurs. For the bending test, femurs were 
placed in a custom-modified Single Column Lloyd LRX System bending device (Lloyd 
Instruments) and analyzed as previously reported (van der Eerden et al., 2013) using 
CtAnalyzer software (Bruker MicroCT).
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Goldner’s Masson trichrome staining
Femurs were embedded in methylmetacrylate as indicated before (Derkx et al., 1998). 
Sections of 6 μm were deacrylated, hydrated and stained accordingly to the previously 
described protocol (Gruber, 1992). Images of the metaphysial area were captured with a 
Nikon Eclipse E400 system (Nikon) using a 20X objective lens. Data was analyzed using Image 
J software (http://imagej.nih.gov/ij/). Briefly, the bone surface was manually selected and 
the perimeter length calculated. Osteoblasts were manually identified based on staining 
and morphology. The frequency of osteoblasts was calculated as percentage of osteoblast 
area in the bone surface and as number of osteoblasts per mm of bone. 
CFU-F assay
Primary bone fraction cells were resuspended in growth medium, consistent of αMEM, 
20% FBS (Life Technologies), and Penicillin-Streptomycin solution (Life Technologies), and 
cultured under hypoxic conditions (5% O2, 5% CO2) in 24-well plates (seeding density: 6.5 x 
104 cells/cm2). After 24h, the medium was changed to eliminate non-adherent cells. Colonies 
were stained after 7 days of culture. Briefly, medium was removed and cells were fixed 
5’ in methanol, stained in a 1:20 dilution of Giemsa staining (Merck Millipore) in distilled 
water and rinsed with tap water. Colonies were counted with an Olympus CK2 inverted 
microscope, using a 10X magnification. 
Primary cell isolation and flow cytometry
All FACS antibodies incubations were performed in PBS+0.5%FCS for 20 min on ice. To 
identify hematopoietic stem and progenitor cells (HSPCs), bone marrow cells were first 
co-stained with a cocktail of biotin-labelled antibodies against the following lineage (Lin) 
markers: Gr1 (RB6-8C5), Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), CD4 (GK1.5), 
CD8 (53-6.7) and B220 (RA3-6B2) (all from BD Biosciences). After washing, cells were 
incubated with Pacific Orange-conjugated streptavidin (Life Technologies) and the following 
antibodies: Pacific Blue anti-Sca1 (D7), FITC or PE anti-CD48 (HM48-1), PE-Cy7 anti-CD150 
(TC15-12F12.2) (all from Biolegend), APC anti-c-Kit (2B8, BD Biosciences). Dead cells were 
excluded based on 7AAD staining.
To analyze differentiated cells and define chimerism, we used FITC anti-Gr1 (RB6-8C5), 
APC anti-Mac1 (M1/70), PE anti-B220 (RA3-6B2), APC-Cy7 anti-CD45.1 (A20), PE-Cy7 anti-
CD45.2 (104), all from Biolegend. To identify stromal cells, bone fraction cell suspension 
was stained with the following antibodies: APC-Cy7 anti-CD45.2 (104), BV510 anti-Ter119 
(TER-119), PE-Cy7 anti-CD105 (MJ7/18), PE anti-CD51 (RMV-7), Pacific Blue anti-Sca1 (D7) 
(all from Biolegend), PE-CF594 anti-CD31 (MEC 13.3, BD Biosciences). 
For human mesenchymal cell isolation, bone marrow aspirates were diluted 1:25 with red 
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blood cell lysis solution (NH4Cl 0.155 M, KHCO3 0.01 M, EDTA-Na2.2H2O 0.1 M, pH 7.4) 
and incubated for 10 min at room temperature. Cells were collected by centrifugation and 
washed once with PBS+0.5%FBS. For FACS sorting, immunostaining was performed with the 
same protocol used for murine bone marrow, using PE CD271 (ME20.4) and PE-Cy7 CD45 
(HI30) antibodies (Biolegend). CD271+ cells did not contain erythroid cells based on staining 
with BV421 CD235a (GA-R2, BD Biosciences).
Apoptosis was assayed with FITC Annexin V Apoptosis Detection Kit I (BD Biosciences) 
according to the recommendation of the manufacturer. 
The content of p53 in stromal cells was analyzed after cell surface antibody staining and 
cell permeabilization, obtained with Cytofix/Cytoperm Fixation/Permeabilization Solution 
Kit (BD Biosciences), by incubating cells with Alexa Fluor 647 anti-p53 (1C12) diluted in 1X 
Perm/Wash buffer (BD Biosciences). 
γH2AX levels were assessed in cells fixed and permeabilized with Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD Biosciences) by incubating cells with Alexa Fluor 647 anti-
γH2AX (N1-431, BD Biosciences) diluted in 1X Perm/Wash buffer (BD Biosciences).
All FACS events were recorded using a BD LSR II Flow Cytometer and analyzed with FlowJo 
7.6.5 software (Tree Star). Cells were sorted with a BD FACSAria III.
SBDS mutation analysis
Mutations in SBDS were evaluated in the RNA sequencing data of SDS patients and 
healthy controls using the Integrative Genomics Viewer (IGV) (Robinson et al., 2011). The 
c.183_184TA>CT mutation was quantified by annotating the number of reads presenting 
each of the four different nucleotides for both the positions 183 and 184. Because of its 
intronic position, the c.258+2T>C mutation was assessed by quantifying the usage of the 
251-252 cryptic donor site (Boocock et al., 2003). Specifically, we quantified the fraction of 
spliced reads with an 8-bp deletion (nucleotides 251-258) as an indication of the mutated 
genotype.
Mitochondrial membrane potential quantification
After staining cells for surface antigens, cells were washed in PBS+0.5%FBS and centrifuged. 
Cells were resuspended in PBS+0.5%FBS  and tetramethylrhodamine methyl ester (TMRM, 
ThermoFisher Scientific) was added from a 50 mM stock solution in DMSO to a final non-
quenching concentration of 100 nM. After incubation for 20 min at 37°C, cells were washed 
with PBS+0.5%FBS and analyzed. Cells treated with 1 μM p-trifluoromethoxy carbonyl 
cyanide phenyl hydrazone (FCCP) were used as positive control for membrane depolarization.
ROS detection
After surface antigen staining, cells washed in PBS+0.5%FBS and centrifuged. A stock 
solution of 2.5 μg/μl 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate 
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acetyl ester (CM-H2DCFDA, Life Technologies) in DMSO was diluted with PBS+0.5%FBS to a 
final concentration of 3 ng/μl. Cells were resuspended with the CM-H2DCFDA solution and 
stained for 20 min at 37°C, washed in PBS+0.5%FBS and analyzed.
For dihydroethidium (DHE) studies, the compound (Sigma-Aldrich) was reconstituted 
to a 100 mM solution in DMSO. After surface antigen staining and washing, cells were 
resuspended in 500 µl of diluted DHE solution (1:100,000 in HBSS) and incubated at 37°C for 
30 min, then washed in PBS+0.5%FBS and analyzed.
Cell cycle analysis
Mice labeled in vivo by BrdU were sacrificed and bone marrow cells were stained for 
surface antigen. BrdU staining was performed using the FITC BrdU Flow Kit (BD Biosciences) 
following the manufacturer’s instructions.
For Ki67-based cell cycle analysis, cultured or freshly isolated cells were first stained for 
surface markers and then fixed and permeabilized with Cytofix/Cytoperm Fixation/
Permeabilization Solution Kit (BD Biosciences). After washing, cells were incubated with 
FITC anti-Ki67 (B56, BD Biosciences) diluted in 1X Perm/Wash buffer (BD Biosciences) for 
20 min and then washed. Cells were resuspended in PBS+0.5%FBS and 7AAD was added to 
detect DNA.
Alkaline comet assay
HSPCs were resuspended in 0.7% low melting agarose (Sigma-Aldrich) in PBS at a 
concentration of 105 cells/ml. 50 μl of cell suspension were spread on CometSlides (Trevigen) 
and the agarose was allowed to solidify for 30 min at 4°C. Slides were incubated for 1 h 
at 4°C in lysis buffer (1% Triton-X100 freshly added to 2.5M NaCl, 100 mM EDTA, 10 mM 
Tris/pH10 solution) protected from light and placed in an electrophoresis tray. After 20 min 
incubation in alkaline solution (200mM NaOH, 1mM EDTA, freshly prepared), unwound 
DNA was run in the same solution for 30 min at 1 V/cm. After electrophoresis, slides were 
washed twice in distilled water for 5 min, fixated in 70% ethanol for 5 min and allowed to 
dry at 37°C. DNA was stained for 5 min in SYBR Gold (Life Technologies), washed in distilled 
water and allowed to dry in the dark. Images were captured with a Leica DMRXA fluorescent 
microscope (10X magnification). DNA damage severity was manually quantified according 
to the score system depicted in Figure S3D. 
Bone marrow transplantation
For serial (competitive) transplantation studies, bone marrow cells from OCS and BL6.SJL 
mice were isolated and RBC-depleted as described above. BL6.SJL cells were mixed in a 1:1 
ratio with cells from OCSf/+ or OCSf/f mice. 9 week-old B6.SJL mice were lethally irradiated 
(8.5Gy) and transplanted with a total of 106 bone marrow cells. 
For transplantation in S100A9Tg mice, donor bone marrow cells were isolated from 12-week 
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old BL6.SJL mice and transplanted into lethally irradiated (8.5Gy) C57BL/6 or S100A9Tg mice 
(F10 backcross in C57BL76). Each mouse received 2x106 bone marrow cells by tail vein 
injection and was sacrificed one month after transplantation. 
In all transplantation experiment, recipients received antibiotics in the drinking water for 2 
weeks after transplantation.
S100A8/9 measurements
To quantify intracellular levels of S100A8/9 proteins, bone fraction cell suspensions were 
first stained for surface markers and next fixated and permeabilized with Cytofix/Cytoperm 
Fixation/Permeabilization Solution Kit (BD Biosciences) according to the manufacturer’s 
instructions. Cells were then resuspended in 1X Perm/Wash buffer (BD Biosciences) and 
incubated for 20 min with polyclonal rabbit antibodies against mouse S100A8 or S100A9 
(Vogl et al., 2014). After washing, cells were incubated for 20 min with Pacific Orange-
labelled goat anti-rabbit secondary antibody (Life Technologies) diluted in 1X Perm/Wash 
buffer, washed and resuspended in PBS+0.5%FBS and analyzed by FACS.
To analyze the concentration of S100A8/9 in the plasma, peripheral blood was collected 
in Microtainer PST tube (BD) and centrifuged to collect the plasma fraction. Samples were 
stored at -80°C until the moment of analysis. S100A8/9 was quantified by ELISA as previously 
described (Vogl et al., 2014).
Immunohistochemical staining of low-risk MDS and age-matched controls (biopsies obtained 
for disease staging from lymphoma patients without evidence of intramedullary localization) 
were performed on 5 µm bone marrow sections, which were deparaffinized in xylene and 
hydrated in a graded series of alcohol. Antigen retrieval was achieved by microwave treatment 
in citrate buffer (10mM pH 6.0) and blocking of the endogenous peroxidases was performed 
with 3% H2O2 in PBS. Sections were blocked using 10% normal human and goat serum 
(DAKO) in Teng-T solution followed by overnight incubation at 4°C with primary antibody 
anti-S100A8 and S100A9 (Vogl et al., 2014) diluted 1:500, CD271 (Sigma-Aldrich) diluted 
1:200, or normal rabbit immunoglobulin (DAKO) diluted accordingly. Immunoreactions were 
detected using biotinylated secondary antibody (goat anti-rabbit, 1:2000 dilution) with 
Vectastain ABC Elite Kit (Vector Laboratories) and 3,3’-diaminobenzidine tetrahydrochloride 
(Sigma-Aldrich). For all stainings, nuclei were counterstained with haematoxylin (Vector 
Laboratories). Images of the stained tissue were acquired using a Leica DM5500B upright 
microscope with 40x lenses and LAS-AF image acquisition software. 
Sbds-knockdown and expression analysis in OP9 cells
OP9 cells were grown in DMEM+10%FBS+1%PenStrep. Sbds RNA interference was achieved by 
lentiviral transduction. Briefly, short hairpin RNAs against Sbds (shSbds1:TRCN0000108586; 
and shSbds4:TRCN0000316346) and a commercial non-target control (shControl: SHC002 
[SHC]), cloned in the pLKO.1 backbones, were selected from the Mission TRC shRNA library 
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(Sigma-Aldrich). Lentiviral shRNAs were produced in HEK293T cells after cotransfection of 
shControl, shSbds1, or shSbds4 together with the packaging plasmids pSPAX2 and pMDG.2. 
OP9 cells were infected with lentivirus for 72 hours in the presence of 4 µg/mL polybrene 
and selected 72 hours with 2 µg/mL puromycin.
RNA isolation, conversion to cDNA and qPCR were performed accordingly to previously 
described methods (Zambetti et al., 2015), using the SuperScript II Reverse Transcriptase 
(Thermo Fisher Scientific) for conversion to cDNA. For qPCR, expression levels were 
obtained using the ddCt method using GAPDH as internal control and shControl sample 
as calibrator. The following primers were used: Sbds-Fw: GCGCTTCGAAATCGCCTG; 
Sbds-Rv: TCTGGTCGTCTGTCCCAAATG; S100a8-Fw: ATCACCATGCCCTCTACAAGAATG; 
S100a8-Rv: GTCCAATTCTCTGAACAAGTTTTCG; S100a9-Fw: AAGCTGCATGAGAACAACCCA; 
S100a9-Rv: CCCAGAACAAAGGCCATTGA; Cdkn1a-Fw: CCTGGTGATGTCCGACCTG; 
Cdkn1a-Rv: CCATGAGCGCATCGCAATC; Bax-Fw: CCGGCGAATTGGAGATGAACT; Bax-Rv: 
CCAGCCCATGATGGTTCTGAT.
For protein analysis, cells were lysed in Carin lysis buffer (20 mM Tris-HCl pH 8.0, 138 mM NaCl, 
10mM EDTA, 100 mM NaF, 1% NP-40, 10% glycerol, 2mM sodium vanadate) supplemented 
with 0.5 mM DTT and the protease inhibitor SigmaFast (Sigma-Aldrich). 32 µg of protein 
per condition were denatured and separated on a Novex NuPage 4-12% Bis-Tris Gradient 
gel (Life Technologies) and transferred to Protran BA83 blotting paper (GE Healthcare 
Sciences). After blocking, membranes were incubated overnight at 4°C with the following 
primary antibodies: goat polyclonal anti-SBDS (Santa Cruz, S-15, 1:200); rabbit polyclonal 
anti- p53 (Leica, CM5, 1:2000). Beta-actin was used as a loading control (mouse monoclonal 
anti-beta-actin, clone AC-15, Sigma-Aldrich, 1:10,000 dilution). After washing, blots were 
incubated with the following secondary antibody: IRDye 800CW Donkey anti-Goat IgG (H + 
L), IRDye® 800CW Donkey anti-Rabbit IgG (H + L), and IRDye 800CW Donkey anti-mouse IgG 
(H + L) (all from Li-COR and diluted 1:10,000). After final washing steps, Western blots were 
scanned and processed using an Odyssey Infrared Imager (Li-COR Biosciences).
HSPCs in vitro culture, S100A8/9 exposure and CFU-C assay
LKS and Lin- c-Kit+ Sca-1- cells were sorted from wild type C57BL/6 mice and cultured in 
a serum-free medium, with the following composition: X-Vivo 15 (Lonza), 1% detoxified 
BSA, 50 μM β-mercaptoethanol (Life Technologies), 1:100 GlutaMAX™ Supplement (Life 
Technologies), 20 ng/ml recombinant murine SCF (Peprotech), 100 ng/ml recombinant 
murine Flt3-Ligand (Peprotech), 1:100 penicillin-streptomycin mixture (Life Technologies). 
The medium was supplemented with recombinant murine S100A8/9, produced with the 
same methods described earlier (Vogl et al., 2006), at a final, clinically relevant concentration 
of 25-50 μg/ml, in the range of concentrations measured in the bone marrow supernatants 
of MDS patients (List, 2014). A heat-inactivated control was obtained by incubating S100A8/9 
at 80°C for 30 min; the protein was cooled-down and next added to the HSPC medium 
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with the same concentration and volume as S100A8/9. LKS and Lin- c-Kit+ Sca-1- cells were 
cultured in 96-well plates at a cell density of 2.5x104 cells/well.
For human studies, cryopreserved CD34+ cells were used, which were isolated from cord 
blood obtained under informed consent by Ficoll gradient and MACS separation (Miltenyi 
Biotec). Thawed cells were resuspended in StemSpan SFEM II (STEMCELL Technologies) and 
recombinant human S100A8/9 was added (R&D systems) at a final concentration of 50 μg/
ml. For the control medium, an equal volume of vehicle (PBS) was added. Cells were seeded 
in flat bottom 96 well-plates (5x104 cells/well).
For both mouse and human studies, cells were harvested at 4h for γH2AX and cell cycle 
studies and at 24 h for apoptosis assay.
To assess the effect of S100A9 on HSPC function, CD34+ cord blood cells were resuspended in 
SFEM1 medium (Stemcell Technologies) containing SCF (50 ng/ml) and human recombinant 
S100A9 (2.5 μg/ml,ProSpec) or PBS control and seeded in 96-well plates (2x104 cells/
well). After one week of preconditioning (37ºC, 5% CO2), cells were pooled. 2,000 cells per 
condition were resuspended in 400 µl IMDM and transferred to 3.6 ml of MethoCult H84434 
(Stemcell Technologies). Cells were plated in triplicate on 1 cm² petri-dishes (1 ml/dish) and 
incubated at 37ºC/5% CO2. Colonies were counted after 12-14 days. 
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KEY POINTS:
1.  Activation of NF-κB signaling in mesenchymal cells is a biologic commonality in LR-MDS.
2. Activation of NF-κB in mesenchymal cells leads to transcriptional overexpression of 
inflammatory factors including negative regulators of hematopoiesis.
3. Activation of NF-κB attenuates HSPC numbers and function ex vivo.
ABSTRACT
Myelodysplastic syndromes (MDS) are bone marrow failure states characterized by 
ineffective hematopoiesis and the propensity for malignant transformation. Accumulating 
evidence supports a contribution of the mesenchymal microenvironment to disease 
pathogenesis. Mesenchymal inflammation has been demonstrated to play an important role 
but the underlying programs driving these inflammatory alterations remain incompletely 
understood.
Here, we show that activation of NF-κB signaling in mesenchymal cells is a biologic 
commonality in low-risk MDS, driving transcriptional activation of inflammatory programs 
and attenuating HSPC function. Gene set enrichment analysis of the transcriptome of highly 
purified mesenchymal cells from 45 low-risk MDS patients revealed activation of NF-κB 
signaling and upregulation of putative downstream genes encoding inflammatory factors. 
Overexpression of the NFκBIA gene, reflecting activation of the NF-κB pathway, supported 
the notion that the pathway is overexpressed in mesenchymal cells in the vast majority of 
patients. Experimental activation of NF-κB signaling in mesenchymal precursor cells ex vivo, 
recapitulated transcriptional activation of inflammatory factors and negative regulators of 
hematopoiesis observed in patient cells. Finally, mesenchymal activation of NF-κB attenuated 
normal HSPC function in co-culture systems.
 
Collectively, the data provide human disease relevance to murine studies implicating NF-κB 
activation in ancillary cells in bone marrow failure and support the notion that NF-κB is a 
potential therapeutic target in MDS.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective 
hematopoiesis and the propensity for leukemic transformation. Cumulating evidence has 
challenged the traditional view that MDS is exclusively driven by hematopoietic cell intrinsic 
factors. Mesenchymal cells in the bone marrow (BM) microenvironment have emerged as 
key players in disease pathogenesis, as either initiating or contributing factors.1-5 We have 
earlier demonstrated that the transcriptional landscape of highly purified mesenchymal 
elements from human low risk MDS (LR-MDS) is distinct from normal mesenchymal cells and 
characterized by cellular stress and the upregulation of inflammatory molecules with known 
inhibitory effects on normal hematopoiesis.5 Specifically, mesenchymal overexpression of the 
alarmins S100A8/9 was shown to drive genotoxic stress in hematopoietic stem/progenitor 
cells (HSPCs) and are related to leukemic evolution in a subset of LR-MDS patients.4 An 
important question emerging from these findings is the nature of the upstream drivers of 
cellular stress and inflammatory programs in LR-MDS mesenchyme. Here, we show that 
activation of NF-κB in mesenchymal cells is a biologic commonality in LR-MDS, driving 
transcriptional activation of inflammatory programs and attenuating HSPC function.
RESULTS AND DISCUSSION
Mesenchymal NF-κB activation is a biologic commonality  in LR-MDS 
We earlier reported on the elucidation of the transcriptome of highly purified mesenchymal 
cells isolated from LR-MDS patients (n=45) by massive parallel RNA sequencing4, suggesting 
inflammation in these mesenchymal elements. In order to identify candidate master 
regulatory pathways upstream of inflammatory programs in LR-MDS, we performed Gene 
Set Enrichment Analysis (GSEA) comparing the transcriptomes of these 45 patients to 
mesenchymal cells purified from healthy controls (n=10).5 In total, 120 gene signatures 
were significantly enriched in the LR-MDS mesenchyme, while 8 signatures were enriched 
in normal mesenchymal cells. Among the signatures upregulated in LR-MDS patients was 
a remarkable abundance of signatures related to the activation of the Nuclear Factor-
kappa B (NF-κB) family of transcription factors in LR-MDS (Figure 1A, 1B). To corroborate 
the notion of activation of this pathway and provide better insight into the heterogeneity 
within the population, we assessed the expression levels of NF-κB inhibitor NFκBIA (also 
known as IκB-ɑ), which forms an autoregulatory loop with activated NF-κB transcription 
factors and therefore directly reflects activation of NF-κB signaling.6-8 Overexpression 
of NFκBIA was found in the vast majority of patients, suggesting that mesenchymal NF-
κB activation is probably not specific to a subgroup of patients but a general feature in 
LR-MDS (Figure 1C). To confirm functional activation of NF-κB in mesenchymal elements 
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in LR-MDS, we demonstrated increased phosphorylation of p65, a component of the 
activated NF-κB complex, in intramedullary located CD271+ mesenchymal cells (Figure 1D) 
as well as in bone-lining CD271+ stromal cells (Figure 1E-F). Moreover, our earlier report 
has demonstrated that many of the overexpressed inflammatory cytokines and negative 
regulators of hematopoiesis (including IL6, IL8, CXCL4, CCL3, INHBA, FTH1, LTF and CCL5)5 in 
LR-MDS mesenchyme are bona fide NF-κB downstream targets. 
 To begin understanding whether activation of NF-κB signaling is an intrinsic 
feature of the mesenchyme, or rather dependent on the tissue context, we compared the 
transcriptome of ex vivo expanded mesenchymal cells from LR-MDS patients (n=5)3 to the 
transcriptome of the n=45 mesenchymal cells directly sorted from LR-MDS bone marrow. 
This analysis revealed significant enrichment of NF-κB pathway and genes encoding 
inflammatory factors in then tissue-sorted cells (Figure S1), suggesting that activation of NF-
κB in mesenchymal cells is dependent on signaling in the diseased marrow.
Activation of NF-κB in mesenchymal cells induces transcriptional upregulation of 
inflammatory cytokines
While the genes encoding inflammatory factors and negative regulators of hematopoiesis5 
are bona fide downstream targets of NF-κB signaling in other systems, we next wanted to 
provide experimental support for the view that NF-κB activation specifically in mesenchymal 
precursor cells results in upregulation of these targets. To this end, we designed a strategy 
of activating NF-κB signaling in OP9 mesenchymal progenitor cells by stably overexpressing 
the constitutively active form of IKK2 (FLAG-IKK2SE), a kinase upstream regulator of NF-
κB, via a lentiviral vector (Figure 2A, Figure S2A-C).9-11 OP9 cells, like CD271+ cells5 express 
osteolineage commitment markers as well as HSPC regulatory factors and robustly support 
the expansion of human HSPCs.12 NF-κB activation in OP9 cells resulted in overexpression of 
the canonical NF-κB downstream targets and several negative regulators of hematopoiesis, 
including Il6, Cxcl2 (murine homologue of IL8), Ccl3, Inhba, Fth1, Ltf, Ccl5 and Cxcl4 (Figure 
2B). Interestingly, activation of NF-κB in OP9 cells also resulted in transcriptional upregulation 
of the alarmins S100a8 and S100a9 (Figure 2B) recently described by us to drive genotoxic 
stress in HSPCs associated with increased likelihood of leukemic transformation.4 Similar 
to results in OP9 cells, activation of NF-κB in human mesenchymal cells (HS5 cell line and 
expanded bone-marrow-derived primary mesenchymal cells) (Figure S2D) also resulted in 
upregulation of NF-κB downstream targets including negative regulators of hematopoiesis 
such as IL6, IL8, CCL3, S100A9, INHBA, and CCL5. (Figure S2E). Together, the data link the 
transcriptional landscape of inflammatory alterations in mesenchymal cells to activation of 
NF-κB in LR-MDS. 
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Figure 1. Activation of NF-κB mediated signaling in LR-MDS mesenchymal cells. (A) Representative GSEA plots 
demonstrating activation of NF-κB signaling in mesenchymal cells from LR- MDS. (B) Summary of gene sets impli-
cating NF-κB activation in mesenchymal cells from 45 LR-MDS patients. Gene set size, NES, and FDR value of each 
gene set are as listed. GSEA: gene sets enrichment analysis. NES: normalized enrichment score. FDR: false discovery 
rate. (C) Gene expression level (in FPKM) of NFKBIA in normal and LR-MDS samples. (D) Representative images 
showing immunofluorescence staining of CD271 and phospho-p65 in both age-matched control (left panel) and 
LR-MDS patient (ight panel) bone marrow slides confirming activation of NF-κB in mesenchymal cells. The white 
arrow indicates the absence or presence of nuclear phospho-p65 signal (red) in CD271+ (green) mesenchymal cells. 
The nuclei were counterstained with DAPI. (E) Representative photomicrographs of the distribution of CD271+ 
mesenchymal cells (left panels). These cells are enriched at the endosteal surface (marked by bone-lining area) 
and have a spindle-shaped morphology. Representative immuno-histochemical analysis of phospho-p65 (middle 
and right panels) in age-matched controls  (top) and LR-MDS  (bottom) patients, demonstrating NF-κB activation 
in spindle-shaped endosteal cells in LR-MDS. (F) The percentage of phospho-p65+ bone lining cells as a fraction 
of the total bone lining cells in LR-MDS (n=4) compared to age-matched controls (n=3). *** P < .001 * P < .05 FPKM: 
fragments per kilobase of exon per million fragments mapped. NFKBIA: NF-Kappa-B Inhibitor Alpha  
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Mesenchymal activation of NF-κB attenuates HSPC numbers and function
As earlier reported, in human MDS, the majority of CD34+ HSPCs is in direct contact with 
CD271+ mesenchymal cells.13 To assess the effect of NF-κB activation in mesenchymal cells 
on the biology of normal HSPC, we performed co-culture experiments with cord blood 
CD34+ HSPCs and OP9 cells transduced with IKK2SE or empty vector (EV) (Figure 2C). Co-
culture for 7 days on IKK2SE-transduced OP9 cells resulted in significantly reduced numbers 
of immunophenotypically-defined HSPC in comparison to EV-transduced mesenchymal cells 
(Figure 2D). This included the fraction enriched for long-term hematopoietic stem cells (LT-
HSCs) defined by the markers CD34+CD38-CD45-CD90-, as well as primitive (CD34+CD38-) and 
committed CD34+CD38+ progenitor cells (Figure 2D). In addition, reduced HSPC number was 
reflected in a reduced number of CFU-Cs (Figure 2E), indicating attenuation of progenitor 
function in this setting. 
Collectively, in this brief communication, we demonstrate that mesenchymal NF-κB activation 
is a biological commonality in LR-MDS patients leading to transcriptional upregulation 
of inflammatory programs associated with negative regulation of hematopoiesis and 
attenuation of HSPC numbers and function. 
Demonstration of mesenchymal activation of NF-κB provides human disease relevance to a 
number of murine studies implicating NF-κB activation in ancillary cells to the pathogenesis 
of hematopoietic disease. NF-κB activation in non-hematopoietic cells has been shown 
to induce ‘MDS-like’ myeloproliferative disease (MPD) in mice.14 In another study, NF-κB 
activation in bone marrow mesenchymal cells and endothelial cells, as a result of elevated 
levels of the microRNA miR-155, generated a persistent pro-inflammatory state of the bone 
marrow niche leading to a MPD-like disease in a Notch/RBPJ loss-of-function mouse model.15 
In addition to a potential role in driving myeloid hematopoietic disease, other studies have 
implicated stromal NF-κB activation in the survival and chemoresistance of malignant cells 
in chronic lymphocytic leukemia (CLL) and AML.16,17 Our experimental data demonstrate 
that NF-κB activation in the mesenchyme attenuates normal hematopoiesis, which is of key 
relevance as a common feature of LR-MDS is characterized by cytopenia. The implication 
of mesenchymal NF-κB activation in the pathogenesis of MDS may also point towards 
common mechanisms between the pathogenesis of MDS and oncogenesis in other systems. 
NF-κB mediated chronic tissue inflammation has been shown to drive cancer initiation and 
progression via secretion of cytokines and soluble factors in models of several other forms 
of cancer,18-20 including skin, prostate and colon cancer.21-23 In these models, activation of 
NF-κB signaling, specifically in fibroblasts, promoted malignant features in heterotypic (pre)
cancerous cells, supporting the hypothesis that mesenchymal inflammation may facilitate 
tumorigenesis in the hematopoietic system as well.
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Figure 2. Activated NF-κB signaling in mesenchymal cells attenuates HSPC number and function. (A) Western 
blot analysis showing the overexpression of Flag-IKK2SE and nuclear phospho-p65, the phosphorylated (active) 
form of NF-κB, in IKK2SE transduced OP9 cells in comparison to empty vector (EV)-transduced or wild-type cells 
(B) Expression level of NF-κB downstream targets (Il6, Cxcl2) and disease-relevant negative regulators of hemato-
poiesis4,5 in OP9 cells transduced with IKK2SE. Fold change relative to EV is presented. (n=3 for each transcript) (C) 
Experimental strategy of co-culture experiments with cord blood CD34+ HSPCs and OP9 stromal cells transduced 
with either EV or IKK2SE. The co-culture took place for 7 days before analysis. (D) The absolute number of immuno-
phenotypically defined HSPCs subsets (Lin-CD34+CD38+ progenitors, Lin-CD34+CD38- HSPCs, Lin-CD34+CD38-CD45-
CD90- LT-HSCs) on day 7 after co-culturing with OP9-EV or OP9-IKK2SE (n=4). (E) The total number of CFU-C after 7 
days co-culture (n=4). *** P < .001  ** P < .01  * P < .05
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The activation of NF-κB signaling in mesenchymal cells in most LR-MDS patients raises 
intriguing questions about the events driving this activation. This includes the question 
whether mesenchymal cell-intrinsic alterations or extrinsic events are driving NF-κB 
activation. While the answer to this question remains speculative in the absence of 
experimental evidence (and may vary between patients), our finding that NF-κB activation 
separates in situ mesenchymal elements from their ex vivo expanded counterparts may 
argue for cell-extrinsic determinants. This notion is supported by recent findings where 
activation of the NF-κB pathway in CD34+ HSPCs is implicated in MDS pathogenesis24 and 
CD271+ mesenchymal cells co-localize with CD34+ HSPC in the bone marrow section of MDS 
patients.13 It is therefore reasonable to hypothesize that activated NF-κB pathway in HSPCs 
signals to the adjacent mesenchymal elements, resulting in NF-κB activation in mesenchymal 
cells. As NF-κB activation is likely maintained through autocrine/paracrine feedback signaling 
networks, other cellular types that anatomically localize with the activated HSPCs and 
mesenchymal elements are probably involved as well, suggesting diverse cellular components 
may participate in this crosstalk. The combined findings suggest that in LR-MDS, activation 
of NF-κB occurs in both hematopoietic and mesenchymal cells, likely through autocrine and 
paracrine feedback signaling networks, leading to a NF-κB-mediated inflammatory milieu 
in the LR-MDS bone marrow and an overexpression of a repertoire of secreted negative 
hematopoietic regulators. Among these, was S100A8/9, recently shown by us to induce NF-
κB activation and genotoxic stress in HSPC and to be associated with an increased likelihood 
of leukemic transformation. Regulation of S100A8/9 in mesenchymal cells, however, is likely 
to be more complex in order to explain the heterogeneity of overexpression between LR-
MDS patients and may include upstream TP53 activation.4 
Taken together, the findings support the notion that mesenchymal factors, in addition to 
hematopoietic cell autonomous characteristics, may be therapeutically targeted in LR-
MDS and warrant ongoing experiments defining the contribution of NF-κB activation and 
inflammation to ineffective hematopoiesis and leukemic evolution in MDS.
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SUPPLEMENTARY MATERIALS 
SUPPLEMENTARY MATERIAL AND METHODS
Patient and healthy donor bone marrow samples
Bone marrow samples from LR-MDS patients and healthy donors were obtained as 
previously described, including the clinical characteristics of the patients and information 
about the healthy donors.1,2 In short, all 45 patients were part of the HOVON89 clinical trial 
(HOVON89; www.hovon.nl; www.trialregister.nl as NTR1825; EudraCT No. 2008-002195-10) 
where patients with low or intermediate-1 risk MDS based on IPSS criteria were recruited. 
The healthy controls were obtained from donors for allogeneic transplantation. All samples 
were collected with informed consent, approved by the Institutional Review Board of the 
Erasmus Medical Center, the Netherlands, in accordance with the declaration of Helsinki. 
Flow cytometry analysis 
Sorting of the mesenchymal cells from the bone marrow of patients and normal donors 
were performed by FACS as previously described.1,2 The cells were directly sorted in 800μl 
Trizol (Ambion) for RNA isolation. 
For immunophenotyping of CD34+ HSPCs after 7 days of co-culture, the following antibodies 
were used based on earlier work with optimized dilutions: Lin-APC (1:25), CD34-PE-Cy7 
(1:30), CD38-PercP-Cy5.5 (1:60), CD90-PE (1:30) and CD45RA-APC-H7 (1:30).3 Live cells were 
selected based on the DAPI (1:5000) gate. The gating strategy defining the different subsets 
of HSPCs is illustrated in supplemental Figure 2F-G. The OP9 stromal cells were excluded 
based on ZsGreen expression, as the transduced OP9 cells (higher than 99% efficiency) were 
ZsGreen (GFP) positive (Figure S2C). The data was acquired using a LSRII flow cytometer (BD) 
and analyzed using FlowJo software.
Counting of the cells after 7 days of co-culture was accurately obtained with flow-count 
fluorosphere beads (Beckman Coulter), in combination with the following antibodies: CD34-
PE-Cy7 (1:30) and CD45-PB (1:50). The gating strategy is shown in Figure S2H. The data was 
acquired using a LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software. 
The number of cells was calculated based on the following formula: CD34+ cells per μl = 
(Live CD34+ events x bead concentration)/number of acquired single beads/(volume beads/
volume cells). The number of total mononuclear cells (MNCs) determined by cell counting 
with beads and frequency of each HSPCs subpopulation from immunophenotyping were 
combined to obtain the number of cells present in individual subpopulations. 
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RNA extraction and RNA quality control
Total sample RNA isolation was performed according to the standard protocol of RNA 
isolation with Trizol and GenElute LPA (Sigma). In the end, the RNA pellet was resuspended 
in 7.5μl of RNAse free water (Qiagen) and quality and quantity of the total RNA was checked 
on a 2100 Bio-analyzer (Agilent) using the Agilent RNA 6000 Pico Kit. 
RNA sequencing and gene expression profiling 
RNA sequencing and the downstream data processing were as previously described.1,2 
In short, SMARTer Ultra Low RNA Kit (Clonetech) for Illumina Sequencing was used to 
prepare the cDNA based on the manufacture’s protocol. Once the cDNAs were obtained, 
the subsequent library preparation steps, sequencing and alignments were performed 
as earlier described, using a range of tools including the cutadapt program, TopHat2 and 
cufflinks.4 The resulting gene expression values are measured as FPKM (Fragments per 
kilobase of exon per million fragments mapped). Fragment counts were determined per 
gene with HTSeq-count, utilizing the strict intersection option, and subsequently used for 
differential expression analysis using the DESeq2 package, with standard parameters, in the 
R environment. Multiple testing correction was performed with the Benjamini-Hochberg 
procedure to control the False Discovery Rate (FDR). Finally gene set enrichment analysis 
(GSEA) was performed on the FPKM values using the curated C2 collection of gene sets 
within MSigDB.5 
Direct comparison between gene expression data from purified and ex vivo expanded 
LR-MDS mesenchymal cells was performed as previously described.2 In brief, BAM files 
containing the molecular data of ex vivo expanded stromal cells derived from LR-MDS 
patients (n=5)6 were obtained from the European Genome-Phenome Archive data base 
(EGAS00001000716). Gene set enrichment analysis (GSEA) was then performed comparing 
our gene expression data of the purified LR-MDS mesenchymal cells (n=45) to the gene 
expression data of expanded stromal cells (n=5).5 
Immunohistochemistry and immunofluorescence 
Immunohistochemical and immunofluorescence stainings of LR-MDS and control paraffin-
embedded bone marrow slides were performed as previously described (supplemental 
Methods).7 CD271 and phospho-p65 antibodies were used to mark the stromal cells 
of interest with their corresponding phospho-p65 status. Immunohistochemical single 
staining facilitated the enumeration of phospho-p65+ bone lining stromal cells; whereas 
the immunofluorescence double staining demonstrated the co-localization of CD271+ and 
phospho-p65+ cells in patient and control sections. 
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All the bone marrow sections (5-µm) were deparaffinized in xylene and hydrated in a graded 
series of alcohol. Antigen retrieval was achieved by microwave treatment in citrate buffer 
(10mM pH 6.0) and blocking of the endogenous peroxidases was performed with 3% H2O2 
in PBS. For IHC staining, sections were blocked using 10% normal human and goat serum 
(DAKO) in Teng-T solution (10 mM Tris, 5 mM EDTA, 0.15 M SodiumCl, 0.25 % gelatine, 0.05 
% Tween-20) followed by an overnight incubation at 4°C with primary antibody: rabbit anti-
human phospho Serine 276 of p65 (p-p65, active form; Santa Cruz Biotechnology) diluted 
1:400, CD271 (Sigma Aldrich) diluted 1:200, or normal rabbit immunoglobulin (DAKO) 
diluted accordingly. Immunoreactions were detected using biotinylated secondary antibody 
(goat anti-rabbit, 1:2000 dilution) with Vectastain ABC Elite Kit (Vector Laboratories) and 
3,3’-diaminobenzidine tetrahydrochloride (Sigma Aldrich). For all stainings, nuclei were 
counterstained with haematoxylin (Vector Laboratories). Images of stained tissues were 
acquired using a Leica DM5500B upright microscope with 40x lenses and LAS-AF image 
acquisition software (Leica). The number of phospho-p65+ bone lining cells were manually 
quantified using ImageJ software from x40 photomicrographs of blindly selected trabecular 
bone area. Unpaired t-test was performed and p < .05 was considered significant.
For IF staining, sections were blocked with 10% normal human, goat and horse serum 
(DAKO) in Teng-T solution followed by an overnight incubation at 4°C with a primary antibody 
directed against phospho Serine 276 of p65. The next day, biotinylated goat anti-rabbit 
secondary antibody and streptavidin-Dylight 594 (1:200, Vector Laboratories) were incubated 
consecutively. This was followed by an additional incubation with a primary mouse anti-
human antibody directed against CD271 (1:100, eBioscience) followed by conjugated horse 
anti-mouse Dylight 488 (1:200, Vector Laboratories). Counterstain with DAPI and mounting 
were performed using Vectashield mounting medium (Vector Laboratories, H-1200). Control 
slides with single stains for the primary antibodies CD271 or phospho-p65 combined with 
all conjugated secondary antibodies were performed as a background control. Images were 
acquired on a Leica SP5 confocal laser scan microscope equipped with Diode/Argon/HeNe 
lasers using a 40x planapochromat oil immersion objective. Images were analyzed using 
ImageJ software.
Lentiviral transduction of OP9, HS5 and primary expanded stromal cells  
The plasmid containing mutant form of IKK-2 (FlagIKK-2 S177E S181E; referred hereafter as 
IKK2SE), which has previously been demonstrated to result in constitutive NF-κB activation, 
was obtained from Addgene.8,9 The Flag-IKK2SE fragment was recloned into the pHAGE ires 
ZsGreen lentiviral vector (kindly provided by Dr. R. Delwel). Stable transduction of OP9 cells 
with pHAGE-EV and IKK2SE was performed and transduction efficiency was determined by 
FACS measuring ZsGreen expression of the cells (Figure S2C). Overexpression of IKK2SE was 
confirmed by Western blotting against Flag-tag and the subsequent activation of NF-κB was 
verified using an antibody against the active form of NF-κB: phospho-p65 (Ser 536; Cell 
Signaling).
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Lentivirus for both pHage-EV or pHage IKK2SE (Flag-tagged IKK2 S177E S181E) was produced 
in 293T cells, by means of transient transfection of the pHage EV or pHage IKK2SE, together 
with the packaging plasmids pSPAX and pMD2.G. OP9 cells were transduced with equal 
titer lentivirus and 3 days later OP9-EV or OP9-IKK2SE were used for subsequent co-culture 
experiments.
The same transduction procedures were carried out for human HS5 stromal cell line and 
primary expanded stromal cells. 
Luciferase Reporter Assay
We performed NF-κB responsive luciferase reporter assays to test the functionality of the 
recloned pHage IKK2SE construct. HEK293T cells were transiently co-transfected with a 
luciferase vector containing three NF-κB responsive elements together with either pHage EV 
or pHage IKK2SE. Cells were harvested after 48 hours and luciferase activity was measured 
with the Dual-Luciferase Reporter Assay System (Promega) using a Victor3 plate reader 
(PerkinElmer). As a control for the luciferase assay pMIG EV and pMIG HA-IKK2SE were used 
(Figure S2A and S2B). Luciferase vector containing 3x NF-κB responsive elements and pMIG 
HA-IKK2SE were kindly provided by Dr. H. Schepers and J.J. Schuringa.10
Western Blotting 
Protein extracts were made by lysing cells in Carin lysis buffer (20 mM Tris-HCl pH 8.0, 138 
mM NaCl, 10mM EDTA, 100 mM NaF, 1% Nonidet P-40, 10% glycerol, 2mM NA-vanadate) 
supplemented with 0.5 mM DTT and the protease inhibitor SigmaFast (Sigma Aldrich)and 
Equal amounts of proteins were denatured  and separated on a Novex NuPage 4-12% Bis-
Tris Gradient gel (Life Technologies) and transferred to Protran BA83 blotting paper (GE 
Healthcare Sciences). Primary antibodies mouse anti-Flag (1:1000) (Sigma Aldrich) or Rabbit 
anti-phospho p65 S536 (1:1000) (Cell Signaling) were incubated overnight at 4°C after 
necessary blocking step. Flag antibody was used to confirm transfection or transduction 
efficiency; whereas phospho-P65 was used to demonstrate phospho-p65 overexpression in 
IKK2SE transduced cells. As secondary antibodies (1:10000 for both) donkey anti-mouse 800 
or goat anti-rabbit 800 (Li-COR Biosciences) were used. GAPDH (Santa Cruz Biotechnologies) 
was used as a loading control (primary: rat anti-GAPDH (1:1000), secondary: donkey anti-rat 
680 (1:10000). After the final incubation, Western blots were scanned and processed using 
an Odyssey Infrared Imager (Li-COR Biosciences).
Quantitative PCR
Total RNA of OP9-EV, OP9-IKK2SE, HS5-EV, HS5-IKK2SE, primary stroma-EV, primary stroma-
IKK2SE cells was isolated 3 days after transduction using Trizol reagent (Ambion), followed 
by cDNA synthesis using SuperScript II Reverse Transcriptase II kit (Invitrogen). Q-PCR was 
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performed using Fast SYBR Green master mix (Applied Biosystems) on a 7500 Fast Real-Time 
PCR system (Applied Biosystems) with the following primer sets: 
Murine: Il6: Fw 5’-TCGGAGGCTTAATTACACA-3’ Rv 5’-CTGGCTTTGTCTTTCTTGTT-3; Cxcl2 
(murine homologue of IL8): Fw 5’-GCGCCCAGACAGAAGT-3’ Rv 5’-CGGGTGCTGTTTGTTTT-3’; 
Ccl3: Fw 5’-TTCTCTGTACCATGACACTCTGC-3’ Rv 5’-CGTGGAATCTTCCGGCTGTAG-3’; 
Inhba: Fw 5’-TCACCATCCGTCTATTTCAGCA-3’ Rv 5’-CTTCCGAGCATCAACTACTTTCT-3’; 
Fth1: Fw 5’-CAAGTGCGCCAGAACTACCA-3’ Rv 5’-GCCACATCATCTCGGTCAAAA-3’; Ltf: 
Fw 5’-TGAGGCCCTTGGACTCTGT-3’ Rv 5’-ACCCACTTTTCTCATCTCGTTC-3’ Ccl5: Fw 
5’-GCTGCTTTGCCTACCTCTCC-3’ Rv 5’-TCGAGTGACAAACACGACTGC-3’; validated all-in-one 
murine Cxcl4 (PF4) primers (Genecopoeia). 
Human: IL6: Fw 5’-CCCCCAGGAGAAGATTC-3’ Rv 5’- GCTGCTTTCACACATGTTACT-3’; 
IL8: Fw 5’- CCGGAAGGAACCATCT-3’ Rv 5’-TTGGGGTGGAAAGGTT-3’; CCL3: Fw 
5′-GCAACCAGTTCTCTGCATCA-3′ Rv 5′-TGGCTGCTCGTCTCAAAGTA-3′; INHBA: Fw 
5’-ACGGGTATGTGGAGATAGAGGA-3’ Rv 5’- GGACTTTTAGGAAGAGCCAGACT-3’; CCL5: Fw 
5’-CGCTGTCATCCTCATTGCTA-3’ Rv 5’-CCATTTCTTCTCTGGGTTGG-3’; S100A9: Fw 5’-TTC 
AAA GAG CTG GTG CGA AAA G-3’ Rv 5’-GCA TTT GTG TCC AGG TCC TCC-3’; Ikk2SE: Fw 
5’-GGTGAGCAGATTGCCATCAAG-3’ Rv 5’- ACCCTCAGTTCGCTGGTCTCG-3’ 
The expression level of each molecule was normalized against the housekeeping gene 
Hprt (in OP9) or GAPDH (in HS5 or primary expanded stromal cells) and the fold change of 
the expression level of each gene in IKK2SE-transduced cells was calculated relative to EV 
transduced cells.
Isolation and culture of cord blood CD34+ cells 
Informed consent was obtained to use cord blood provided by the Sanquin Bloedbank 
(the Netherlands). Cord blood mononuclear cells were isolated by Ficoll lymphoprep (Axis-
shield) density gradient centrifugation. CD34+ cells were selected by MiniMacs (Miltenyi 
Biotec) followed by LS and MS MACS separation columns (Miltenyi Biotec) to achieve 
optimal purity. In the co-culture setting, 15.000 CD34+ cells per 1.9cm2 were directly plated 
on either a OP9-EV or a OP9-IKK2SE monolayer (Figure 2C). The OP9-EV and OP9-IKK2SE 
monolayers were at comparable confluence on day 1 and 7 of coculture (data not shown). 
Culture medium consisted of ɑMEM supplemented with 20% fetal bovine serum (FBS), 
1% penicillin/streptomycin, 50 ng/ml stem cell factor (SCF), 50 ng/ml FLT3 and 50 ng/ml 
thrombopoietin. All experiments were carried out in triplicates. Cultures were kept at 37°C 
in a 5% CO2 incubator for 7 days until analysis.  
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CFU-C
On day 7 of the co-culture, 4000 mononuclear cells (MNCs) from each condition were 
collected and resuspended in IMDM medium. This cell suspension was added to MethoCult™ 
GF H84434, which allows the growth of colonies from all three lineages, (StemCell 
Technologies) and triplicate dishes were plated. The methocult plates were kept at 37°C in a 
5% CO2-incubator for 2 weeks until colony counting.
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Supplemental Figure 1. Enrichment of NF-κB signatures in purified (n=45) LR-MDS mesenchymal cells in 
comparison to expanded (n=5) stromal cells. (A) Representative GSEA plot demonstrating enrichment of NF-κB 
signatures in purified LR-MDS mesenchymal cell comparing to expanded stromal cells. (B) A list of NF-κB signatures 
enriched in purified MDS mesenchyme comparing to the expanded counterparts. NES: normalized enrichment 
score; FDR: False Discovery Rate. 
Supplemental Figure 2. Activation of NF-κB signaling in OP9, HS5 and expanded primary stromal cells. (A) 
Western blot analysis showing the overexpression of Flag-IKK2SE transfected 293T cells in comparison to pHage-
empty vector (EV) transfected 293T cells. As a reference for the protein size of Flag-IKK2SE, lysates of pMIG EV 
and pMIG HA-IKK2SE transfected 293T cells were included. (B) Level of NF-κB luciferase response in pHage-EV and 
pHage-Flag IKK2 transfected 293T cells (right panel). NF-κB luciferase response in pMIG EV and pMIG HA-IKK2SE 
transfected 293T cells were included as a positive control. (C) Transduction efficiency of phage EV and pHage-Flag 
IKK2SE in OP9 cells measured by ZsGreen expression comparing to non-transfected OP9 cells. (D) Expression level 
of IKK2SE in HS5 and expanded primary mesenchyme transduced with either EV or IKK2SE. (E) Expression level of 
NF-kB downstream targets and disease-relevant negative regulators of hematopoiesis in HS5 mesenchymal cell 
lines (left panel) and expanded primary mesenchyme (right panel) transduced with EV or IKK2SE. Fold change 
relative to EV is presented. (F-G) Representative FACS plots showing the immunophenotypically defined HSPCs 
subsets after exposing to OP9-EV/IKK2SE in both direct cell contact (F) and transwell system (G). The presented 
plots were gated on live/OP9-/Lin- mononuclear cells (MNCs). The HSPCs subfractions are defined as: CD34+CD38+ 
progenitor population, CD34+CD38- HSPCs and CD34+CD38-CD45-CD90- LT-HSCs (long-term hematopoietic stem 
cells). (H) Representative FACS plot demonstrating the cell counting approach by flow-count fluorosphere beads. 
Information concerning total number of beads and MNCs were obtained during acquiring on LSRII. OP9 cells were 
gated out from the MNCs by ZsGreen expression and live cells were selected by 7AAD staining. CD45 and CD34 
antibodies were applied to identify the frequency of CD34+ HSPCs  
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ABSTRACT 
Mounting evidence suggest that alterations in the bone marrow microenvironment (BMME) 
may contribute to disease pathogenesis in myelodysplastic syndromes (MDS). Mice with 
hematopoietic cell autonomous expression of the transgene NUP98-HOXD13 (NHD13) 
present a bona fide model of MDS. Here, we used NHD13 mice to address the question 
whether primary alterations in hematopoietic cells in MDS can induce alterations in the 
BMME that result in the attenuation of normal hematopoiesis. NHD13 mice have reduced 
numbers of HSPCs but transplantation of normal HSPCs in NHD13 recipients did not result 
in altered differentiation. Secondary transplant experiments revealed normal numbers and 
function of wildtype HSPC after exposure to the NHD13+ BMME. Together, the findings in 
this particular mouse model of MDS do not support the notion that hematopoietic cells in 
MDS induce long-term effects on niche cells attenuating normal hematopoiesis.
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INTRODUCTION 
It is increasingly evident that the bone marrow microenvironment (BMME) plays a pivotal 
role in the disease pathogenesis of a wide range of hematopoietic malignancies, including 
myelodysplastic syndromes (MDS).1-9 MDS is the principal pre-leukemic malignancy that is 
characterized by ineffective hematopoiesis, dysplasia, cytopenia and a high propensity for 
clonal evolution to acute myeloid leukemia (AML).10,11 Summarizing data derived from genetic 
mouse models studying the contribution of the BMME to leukemogenesis, two concepts 
have been proposed including “niche-induced ” and “niche-facilitated” leukemogenesis. On 
one hand, primary alterations in the specific cellular component of the BMME can induce 
the development of MDS and  secondary AML in mice1. Several models have demonstrated 
that genetic alterations of mesenchymal niche cells can drive the pathogenesis of MDS by 
inducing myelodysplasia and leukemic transformation of hematopoietic cells. Vice versa, 
whether hematopoietic elements in MDS can drive alterations in niche cells and how this 
would contribute to MDS pathogenesis remains understudied. Xenotransplantation models 
demonstrated that only when MDS hematopoietic cells co-inject with MDS stroma, efficient 
engraftment of MDS cells can be achieved.3 In human MDS patients, a series of in vitro 
experiments showed that stromal cells isolated from MDS patients are dysfunctional.12-15 
However, the cellular and molecular mechanisms underlying the remodeling effect of MDS 
cells on their niche and the contribution of such remodeled niche to leukemogenesis remain 
incompletely understood. Here, we used the hematopoietic cell-autonomous model of 
MDS – the Vav-NUP98-HOXD13 (NHD13) model to investigate the effects of altered HSPCs 
on its BMME and how this may contribute to bone marrow failure and leukemogenesis. 
To this end, NHD13 serves as an ideal model as the expression of the disease-causing 
fusion gene NUP98-HOXD13 is driven by the hematopoietic-cell specific Vav1 promoter 
and these mice recapitulate key clinical features in MDS patients including multilineage 
cytopenias and dysplasia with a high penetrance of leukemic transformation.16-18 
MATERIAL AND METHODS 
Mice and Transplant Experiments
All mice were maintained by the Experimental Animal Facility of Erasmus Medical Center 
(EDC) in specific pathogen free conditions. Wild-type and NHD13 mice in the C57BL/6 
background were purchased from Jackson laboratory. B6.SJL (CD45.1) mice were purchased 
from Charles River. For the transplantation experiments, donor cells were freshly isolated 
whole bone marrow cells after red blood cell lysis with ACK buffer (Lonza). For the competitive 
transplant, 500,000 donor cells were isolated from 9 months old NHD13 mice and mixed in a 
1:1 ratio with wildtype (WT) competitor CD45.1+ cells isolated from 8 weeks old B6.SJL mouse. 
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The recipients were followed for 28 weeks. Recipient mice that died earlier were analyzed 
as described. For the non-competitive transplantation, 1 million CD45.1+ healthy donor cells 
isolated from 8 weeks old B6.SJL mouse were injected into CTRL (7 or 10 months old) or 
NHD13 (7 or 10 months old) recipients. After 7 weeks, the CD45.1+ cells from primary CTRL 
or NHD13 recipients were FACS sorted and competitively injected into healthy secondary 
recipients mixed with CD45.2 WT competitor cells. All recipients received lethal irradiation 
of 9 Gy and received antibiotic water for the first 2 weeks post transplantation. All mice were 
sacrificed by cervical dislocation and all the animal experiments were approved by the Animal 
Welfare/Ethics Committee of the EDC in accordance with legislation in the Netherlands. 
The work-flow of the transplant recipients includes blood counts, bone marrow cellularity, 
spleen isolation and analysis, flow cytometric analysis of CD45.1/CD45.2 chimerism, stem 
cell composition and differentiation in the peripheral blood and bone marrow as previously 
described.1,19,20 Flow cytometric analysis defining the BM niche components including 
arterial and sinusoidal endothelial cells (CD45-Ter119-CD31+Sca1-, CD45-Ter119-CD31+Sca1-
CD31+Sca1+), osteoblasts (CD45-Ter119-CD51+Sca1-) and mesenchymal stem cells (MSCs: 
CD45-Ter119-CD51+Sca1+) are performed as previously described.20,21 
RESULTS 
Loss of the HSPC compartment in NHD13 mice 
NHD13 mice recapitulate key characteristics of human MDS including leukopenia, macrocytic 
anemia, thrombocytopenia, and dysplasia, (Figure 1A and data not shown) fulfilling the 
Bethesda criteria22 for MDS in mice, as previously reported.16,17 Immunophenotypic analysis 
reveals a myeloid bias in the peripheral blood of 4-6 months old NHD13 mice: an increase 
in the frequency of Gr1+Mac1+ myeloid cells is accompanied by lower frequency of B220+ 
lymphoid cells (Figure 1B). In addition, the biphenotypic B220+Mac1+ and B220+Gr1+ 
cells are elevated in the bone marrow (BM) of NHD13 mice (Figure 1C), as previously 
reported, with undefined functional relevance.17,23,24 Earlier work has demonstrated an 
immunophenotypic reduction in the different subsets of hematopoietic stem progenitor 
cells (HSPCs) in 5 months’ old NHD13 mice.17,21 To examine if this phenotype persists as 
MDS progresses, we investigated the different HSPC subsets in 10 months’ old NHD13 
mice at the late MDS stage. It is worth noting that the BM of these mice are normocellular 
comparing to age-matched control (CTRL) mice (data not shown). Based on flow cytometry 
analysis (Figure 1D), we observed a significant decrease in the LKS (Lin-C-kit+Sca-1+) 
population, nearly complete depletion of the short-term (LKSCD48-CD150-) and long-
term HSCs (LKSCD48-CD150+, also known as the LKSSLAM).  Together, the data reveal a 
progressive loss of the HSPC compartment upon disease progression in NHD13 mice. 
Investigating the cellular architecture of the niche in NHD13+ mice, we observed increased
Chapter 5
147
A. RBCs
0
5
10
15 ***
HGB
6
8
10
12
14 **
MCVs
45
50
55
60
65
70 ***
CTRL NHD13
10
12
/L
m
m
ol
/l
CTRL NHD13 CTRL NHD13
B.
FL
C.
B
22
0
B
22
0
Gr1 Mac1
31.5% 3.58%
13.6% 51.9%
29.0% 5.58%
11.2% 54.3%
11.4% 11.6%
22.3% 54.8%
10
10
10
10
10
1
2
3
4
5
0
10
10
10
10
2
3
4
5 11.8% 11.1%
22.2% 54.8%
0
5
10
15
20
**
%
 o
f w
ho
le
 M
N
C
s 
in
 b
on
e 
m
ar
ro
w
0.0580
B220+Mac1+ B220+Gr1+ 
CTRL NHD13 CTRL NHD13
CTRL
NHD13
Gated on live MNCs
cK
it
Sca-1
C
D
48
CD150
D.
49.2% 3.68%
26.1% 21.0%
82.1% 14.1%
ST-HSC
0.00%
LKSSLAM
3.85%
LK 19.6%
LKS 1.17%
LK 28.7%
LKS 0.33%
CTRL
NHD13
0.0
0.4
0.8
20
40
60
%
 o
f L
in
- C
el
ls
**
** **
Gated on live Lin- cells
LK LKS ST-HSC LKSSLAM
CTRL
NHD13
PLTs
0
500
1000
1500
2000
CTRL NHD13
10
9
/L
p=0.06
WBCs
0
5
10
15
***
10
9 /
L
NHD13CTRL
0
20
40
60
80
100
*
*
%
 o
f w
ho
le
 M
N
C
s 
in
 p
er
ip
he
ra
l b
lo
od
CTRL NHD13 CTRL NHD13
Mac1+Gr1+
Myeloid cells 
B220+
Lymphoid cells
Figure 1. NHD13 mice develop cytopenia accompanied by the loss of HSPCs. (A) 4-6 months old NHD13 mice 
develop bone marrow failure as indicated by leukopenia, macrocytic anemia and thrombopenia. (B) NHD13+ 
mice present myeloid skewing with higher frequency of Mac1+ Gr1+ myeloid cells and lower frequency of B220+ 
lymphoid cells. (C) In NHD13+ mice, hematopoietic cells with bi-phenotypic characteristics (B220+Mac1+ cells 
and B220+Gr1+ cells) are observed starting from 4 months. Representative FACS plots are shown on the left. (D) 
Representative FACS plots showing the HSPC compartment of CTRL and NHD13 mice (left panel) at 10 months. Bar 
graph demonstrating the loss of immunophenotypically defined HSPCs in NHD13 mice (right panel) (n=3 pairs).  
MNCs: mononuclear cells; WBCs: white blood cells; RBCs: red blood cells; HGB: hemoglobin; MCVs: mean 
corpuscular volume; PLTs: platelets; LK: lin-c-kit+; LKS: lin-c-kit+sca-1+; ST-HSC: short-term HSC (lin-c-kit+sca-1+CD48-
CD150-); LKSSLAM: long-term HSC (lin-c-kit+sca-1+CD48-CD150+); * p<0.05; **p<0.01; ***p<0.0001
frequencies of different niche components including arteriolar and sinusoidal endothelial 
cells, osteoblasts and mesenchymal stem cells (Figure S1), congruent with earlier findings.21 
The functional relevance of this expansion in niche subsets remains to be defined, 
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The BMME exposed to NHD13+ hematopoietic cells does not impair normal 
hematopoiesis 
Next, we wanted to investigate whether the altered cellular composition in the BM niche, 
induced by NHD13+ hematopoietic cells contribute to the loss of HSPC in the NHD13+ models. 
To test this, we performed a competitive transplantation assay with donor CD45.2+ NHD13 
cells (9 months old, late MDS stage) and competitor wild-type (WT) BM cells obtained from 
congenic B6.SJL mice that express CD45.1 into lethally irradiated age-matched (5 months) 
control (CTRL, n=5) or NHD13 recipients (n=6) (Figure 2A). We followed these recipients 
for approximately 28 weeks post transplantation. All CTRL recipients survived until 
analysis (Figure 2B). 3/6 NHD13 recipients died earlier at week 16, 17 and 21 respectively, 
indicating a higher mortality rate when cells were competitively transplanted into NHD13 
recipients. The cause of death is likely due to the development of CD45.2-derived leukemia 
characterized by leukocytosis, anemia and thrombocytopenia in the blood, infiltration of 
CD45.2+ myeloblasts in the bone marrow and spleen, accompanied by splenomegaly (Figure 
S2). Whether this leukemia arises from residual NHD13+ hematopoietic cells (surviving 
conditioning) or are of donor origin remains speculative. However, of the three NHD13 
recipients that survived until analysis, CD45.2+ NHD13 donor cells were outcompeted by 
the WT competitor cells, indicated by the nearly 100% CD45.1 chimerism in the BM of both 
CTRL and NHD13 recipients (Figure 2C).
To examine if the CD45.1+ competitor cells are affected by the NHD13 BMME, we 
evaluated the differentiation capacity and HSPC composition of CD45.1+ cells in both CTRL 
and NHD13 recipients. Both the differentiation capacity (Figure 2D) and the stem cell 
composition (Figure 2E) of the WT competitor cells are not strongly affected by the NHD13 
BMME, except a trend of two-fold expansion in the LKS fraction (Figure 2E). 
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Figure 2. The BMME of NHD13+ mice does not attenuate lineage progression of normal hematopoiesis. (A) Scheme 
of the competitive transplantation of NHD13 hematopoietic cells (CD45.2+) and wildtype competitor hematopoietic 
cells (CD45.1+) into either CTRL  (n=5) or NHD13 recipients (n=6). (B) Survival curves of CTRL and NHD13 recipients 
demonstrating reduced survival of NHD13 recipients. Premature death was observed in 3/6 NHD13+ recipients, 
likely due to the development of acute leukemia of CD45.2 NHD13+ origin as indicated in supplementary figure 
1. (C) Chimerism of CD45.1 WT competitor cells in the BM and SPL of CTRL (n=5) and NHD13 recipients (n=3) 
that survived until the time of analysis. (D) In the NHD13 recipients that survived, the differentiation capacity 
of competitor CD45.1+ cells is comparable to the cells in CTRL recipients. (E) The CD45.1+ HSPC composition in 
frequency (left panel) and cell number (right panel) in both CTRL and NHD13 recipients.  * p<0.05
SPL: spleen 
The BMME of NHD13+ mice does not affect HSPC number and function
To further investigate the effect of the BMME exposed to NHD13+ cells (at late MDS stage) on 
normal hematopoietic cells, we performed a non-competitive transplantation experiment 
where WT CD45.1+ donor cells were introduced into 10 months old lethally irradiated CTRL 
(n=6) or NHD13 recipients (n=6) (Figure 3A). Seven weeks post-transplant, CD45.1 cells 
were isolated from recipient mice and used for secondary transplant to assess HSC function. 
Peripheral blood analysis of primary recipients at 7 weeks revealed moderate leukopenia 
and macrocytic anemia in NHD13 recipients (Figure 3B), reminiscent of the MDS phenotype 
in NHD13 mice. This cytopenia was, at least partially, explained by limited chimerism of 
CD45.1+ cells (reached only 50% in the peripheral blood and less than 20% in the BM of 
NHD13 recipients) (Figure 3C), suggesting an incomplete engraftment of WT donor cells into 
lethally irradiated 10 months old NHD13 recipients. The differentiation status (Figure 3D) 
and HSPC composition (Figure 3E) of the engrafted CD45.1+ donor cells in NHD13 recipients, 
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however, was not affected, in line with observations in the competitive transplant (figure 
1). To assess the function of normal CD45.1 HSCs exposed to the NHD13 environment, we 
conducted a secondary transplantation experiment by isolating the CD45.1+ donor cells 
from either CTRL or NHD13 primary recipients and competitively introduced these CD45.1+ 
cells with WT CD45.2+ competitor cells into healthy secondary recipients (Figure 3A). We 
followed these secondary recipients monthly for four months. CD45.1+ cells isolated from 
the NHD13 primary recipients consistently showed a competitive advantage comparing to 
their counterparts from the CTRL primary recipients (Figure 3F), perhaps reflecting the (non-
significant) increase of HSPC frequencies (Figure 3E).
In parallel, we performed similar primary and secondary transplantation experiments 
with 7 months old CTRL and NHD13 recipients (n=7 pairs) (less advanced MDS stage). In 
these recipients, efficient engraftment was observed accompanied by full rescue of the 
peripheral blood parameters (Figure S3A-C). Similarly, CD45.1 differentiation capacity and 
HSPC composition were not affected in the younger NHD13 recipients (Figure S3D, S3E) and 
CD45.1+ donor cells isolated from NHD13 recipients at the intermediate MDS stage showed 
a competitive advantage in the secondary transplant recipients (Figure S3F). Together, these 
data suggest that the NHD13 MDS BMME does not attenuate normal hematopoiesis. 
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Figure 3. The BMME of NHD13+ mice does not affect HSPC number and function. (A) Scheme of primary 
transplantation of CD45.1+ normal hematopoietic cells into 10 months old CTRL (n=6) or NHD13 (n=6) recipients 
for 7 weeks, followed by secondary competitive transplantation of the isolated CD45.1+ BM cells into WT secondary 
recipients (n=6 pairs) with 16 weeks follow-up. (B) Whole blood counts of primary CTRL and NHD13 recipients (C) 
Peripheral blood (PB) and BM chimerism of CD45.1+ cells in the primary recipients at 7 weeks, indicating insufficient 
CD45.1 engraftment. (D) Differentiation capacity of CD45.1+ BM hematopoietic cells in CTRL and NHD13 recipients. 
(E) The composition of immunophenotypically defined BM CD45.1+ HSPCs in frequency (left panel) and cell number 
(right panel) in primary control and mutant recipients. (F) Chimerism of CD45.1+ cells isolated from CTRL or NHD13 
primary recipients in the PB of secondary recipients for 16 weeks of follow-up period. 
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DISCUSSION
The hematopoietic cell autonomous effects of the disease-causing transgene Nup98-Hoxd13 
have been extensively studied in the NHD13 MDS mouse model. However, the impact of the 
NHD13+ MDS cells on their BMME and the contribution of this BMME to leukemogenesis 
and bone marrow failure in this model remains incompletely understood. Here, we 
conducted transplantation experiments to test the hypothesis that NHD13+ hematopoietic 
cells affect the BMME in such a way that they attenuate normal hematopoiesis but failed 
to provide experimental support for this view. The data derived from both competitive and 
non-competitive transplantation assays suggest that the BMME of NHD13+ mice does not 
impair the number and function of normal HSPCs, indicating the loss of the NHD13+ HSPCs 
in NHD13 mice is probably a cell autonomous effect caused by the transgene, although 
niche interactions specific to genetically aberrant NHD13+ hematopoietic cells cannot be 
completely excluded. 
In the non-competitive transplantation assay, we introduced normal CD45.1+ donor cells 
into primary CTRL or NHD13 recipients, at late (10 months) or less advanced (7 months) 
MDS stage. In the 10 months old primary NHD13 recipients, poor engraftment of 
CD45.1+ donor cells were observed. The small pool of engrafted donor HSPCs displayed a 
compensatory expansion in the primitive compartment to support hematopoiesis, partially 
rescuing the peripheral blood parameters. The increased donor HSPC fraction was reflected 
in a competitive advantage in reconstituting healthy secondary recipients. In the NHD13 
recipients at the less advanced (7 months) MDS stage, efficient CD45.1 engraftment was 
achieved and these cells resulted in higher chimerism in secondary recipients as well. The 
exact reason behind this discrepancy in the engraftment efficiency remains unclear. Since 
these two experiments were performed in parallel, irradiation effects are unlikely to be the 
cause. It could be that at a later MDS stage, the NHD13 cells are more resistant to irradiation 
or the BMME becomes less favorable for the engraftment of normal hematopoietic cells. 
In either case, regardless of the MDS stage, or engraftment efficiency, the NHD13 BMME 
shows no durable adversary effects on normal hematopoiesis. 
Interestingly, we observed increased mortality and leukemic progression when NHD13+ 
and WT cells were competitively transplanted into NHD13+ recipients (in comparison 
to WT recipients). The finding is reminiscent of recent data reported by the Calvi lab21, 
although we cannot exclude the possibility that reduced survival was caused by leukemic 
transformation of residual CD45.2 NHD13+ hematopoietic cells that survived conditioning by 
irradiation. Investigating the CD45.1+ competitor cells in the NHD13 recipients that survived 
until analysis, the differentiation capacity and HSPC composition of these cells seemed to 
be preserved in the NHD13 recipients in our studies. However, in Calvi’s report, a myeloid 
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bias of the CD45.1+ competitor cells in NHD13 recipients was described. This discrepancy 
could be due to differences in transplantation procedures, such as the irradiation scheme 
given to the recipients (one time 9 Gy vs. 5 Gy split dose) or the post-transplant follow-
up time (28 weeks vs 16 weeks). These factors may influence the level of residual MDS 
cells in the NHD13 recipients, potentially affecting the healthy competitor cells in addition 
to the BMME. Or in our study, the longer follow-up time may allow the competitor cells 
to correct the myeloid/lymphoid bias. Interestingly, however, we did observe an increased 
frequency of CD45.1 biphenotypic cells (expressing both myeloid and lymphoid markers) 
in the NHD13+ environment (data not shown). The relevance of this remains to be shown 
but it is noteworthy that cells with this phenotype have been associated with dysplasia and 
leukemic transformation.16,17,25
Taken together, our data do not support the initial hypothesis, but instead suggest that the 
BMME of NHD13+ mice does not attenuate normal hematopoiesis, at least in the particular 
transplantation settings described here. This indicates that MDS pathogenesis in this model 
may be more cell intrinsic. Previous work has demonstrated that NHD13 MDS can be 
transferred to WT recipients and the NHD13+ HSPCs are characterized by elevated apoptosis, 
accumulation of reactive oxygen species (ROS) and DNA damage response,26,27 suggesting 
NHD13+ MDS can be cell autonomously propagated. In the meantime, our main conclusion 
should be seen in the light of several experimental limitations. Here, we only investigated 
one particular MDS model driven by the nup98-hoxd13 gene fusion (infrequently reported 
in patients with therapy-related AML,) so the conclusion of NHD13+ BMME has no effect on 
normal hematopoiesis cannot be extrapolated to other pre-leukemic models. In addition, 
in this particular model, the disease-facilitating effect (remains to be proven) of the altered 
niche cells are short-term and may rely on continuous contacts with MDS cells. Once this 
contact is disrupted, the BMME no longer has an adversary effect, likely suggesting NHD13+ 
MDS cells do no elicit epigenetic or genetic alterations in their niche. 
Niche alterations in a hematopoietic cell - autonomous mouse model of MDS do not impair normal 
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Supplemental Figure 1. Cellular composition of the BM niche in CTRL and NHD13+ mice. Frequency of the BM 
niche components in both CTRL and NHD13+ mice as a percentage of the total BM MNCs. The investigated niche 
components include sinusoidal endothelial cells (SEC: CD45-Ter119-CD31+Sca1-), arteriolar endothelial cells (AEC: 
CD45-Ter119-CD31+Sca1-CD31+Sca1+), osteoblasts (OBCs: CD45-Ter119-CD51+Sca1-) and mesenchymal stem cells 
(MSCs: CD45-Ter119-CD51+Sca1+). 
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Supplemental Figure 2. Development of acute leukemia of CD45.2 NHD13+ origin in NHD13+ recipient mice. 
Figures show data from one NHD13 recipient with leukemia development and n=5 CTRL recipients. (A) peripheral 
blood counts demonstrating leukocytosis, anemia and thrombopenia in the NHD13+ recipient with leukemia in 
comparison to  the control recipients. (B) Percentage of CD45.2+ MNCs in the bone marrow (left panel) of control 
and NHD13+ recipients; and representative image of myeloblasts (right panel) in the bone marrow of the NHD13+ 
recipient with leukemia development. (C) Percentage of CD45.2+ MNCs in the spleen (left panel) of the control and 
NHD13+ recipients; and splenomegaly (middle panel) due to infiltration of leukemic blasts of CD45.2 origin in the 
NHD13+ recipient. 
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Supplemental Figure 3. The NHD13 BMME supports normal hematopoietic cell function in a transplantation 
setting. (A) Scheme of primary transplantation of CD45.1+ normal hematopoietic cells into 7 months old CTRL (n=7) 
or NHD13 (n=7) recipients for 7 weeks, followed by secondary competitive transplantation of the isolated CD45.1+ 
BM cells into WT secondary recipients (n=6 pairs) with 16 weeks follow-up. (B) Whole blood counts of primary 
CTRL and NHD13 recipients. (C) Peripheral blood (PB) and BM chimerism of CD45.1+ cells in the primary recipients 
at 7 weeks. (D) Differentiation capacity of CD45.1+ BM hematopoietic cells in CTRL and NHD13 recipients. (E) The 
composition of immunophenotypically defined BM CD45.1+ HSPCs in primary control and mutant recipients. (F) 
Chimerism of CD45.1+ cells isolated from CTRL or NHD13 primary recipients in the PB of secondary recipients for 
16 weeks of follow-up period. 
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1. SUMMARY 
The work presented in this thesis focused on the role of the bone marrow niche, mainly 
comprising different types of mesenchymal cells, in the development of MDS and Shwachman 
Diamond syndrome, conditions that are prone to progress towards leukemia. 
MDS is the principal pre-leukemic disorder where mesenchymal elements have been 
implicated in disease initiation1 and development2, at least in mouse models. Insights into 
the involvement of the mesenchyme in the development of MDS in humans have long been 
limited to data derived from ex vivo expanded stromal cells, with unknown relevance to the 
complex in vivo bone marrow architecture. Translation of findings from the mouse models 
to human disease has been hampered by the lack of insight into non-expanded, purified 
mesenchymal cells from MDS patients. To bridge this gap, in chapter 2, we prospectively 
purified CD271+ mesenchymal cells from low-risk MDS (LR-MDS) patients (n=12) and 
normal controls (n=10) and performed extensive transcriptome analysis. Strikingly, 
MDS mesenchymal cells are transcriptionally distinct from their normal counterparts, 
characterized by inflammatory signaling and cellular stress, reflected in reduced in vitro 
CFU-F capacity. In addition, in comparison to ex vivo expanded MDS stromal cells (published 
earlier)2, purified MDS mesenchyme is enriched in signatures like response to external 
stimuli, chemokine activity and immune regulation. This data likely reflects active cross-
talk of the mesenchymal cells with other cellular elements within the inflammatory bone 
marrow environment in LR-MDS3, eliciting or maintaining these transcriptional programs, 
which may not be fully appreciated in ex vivo cultures. 
Earlier work supporting the concept of “niche-induced” leukemogenesis has shown that 
primary dysfunction in the mesenchymal niche can induce myelodysplasia and AML with 
cytogenetic abnormalities in HSPCs.1,4 To understand the underlying mechanism behind 
the concept, and to assess its relevance to human disease, in Chapter 3, we modelled 
Shwachman-diamond syndrome (SDS) – a monogenic disease caused by compound 
heterozygous or homozygous loss of function mutation in the gene Sbds required for 
ribosome biogenesis as outlined in Chapter 1. A recent study from our group in a conditional 
knockout mouse model (Cebpɑ-Cre-driven Sbds deletion) showed that hematopoietic cell 
intrinsic loss of Sbds resulted in neutropenia, but the mice failed to develop MDS or AML5. 
These findings raised the possibility that Sbds-deficient niche cells may contribute to the 
malignant transformation of SDS. To address this hypothesis, we specifically deleted Sbds 
in the osterix-expressing mesenchymal progenitor cells (MPCs) by generating the mouse 
model OCSf/f (mutant: Sbdsf/fOsxcre/+) and OCSf/+ (control: Sbdsf/+Osxcre/+). As a result of 
mesenchymal Sbds deletion, the mutant mice developed an osteoporotic bone phenotype 
and a myelodysplastic hematopoietic phenotype, faithfully recapitulating the typical clinical 
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features in SDS patients. Investigating the HSPCs in the OCS model further, we observed 
accumulation of mitochondrial dysfunction, oxidative stress and DNA damage, along with 
G1-S cell cycle checkpoint activation. These data implicate disruptions in the mesenchymal 
niche can induce genotoxic stress in the HSPCs,  which may play a pivotal role in the disease 
pathogenesis of SDS, MDS and/or AML. 
Next, we defined the molecular mechanism associated with the bone and 
hematopoietic phenotype. Upon Sbds deletion, we observed activation of the p53 
pathway, a molecular mechanism commonly associated with ribosomopathies. To test 
if the phenotypes we observed were p53 driven, we performed genetic rescue study by 
creating a double transgenic mouse model where deletion of Sbds and p53 occurred in the 
same mesenchymal cells. We observed a rescue of the osteoporotic bone phenotype and 
genotoxic stress hematopoietic phenotype, suggesting the phenotypes we observed are p53 
dependent. Then we investigated the potential molecules downstream of p53 driving these 
genotoxic stress in HSPCs. By comparing gene expression data from the mouse model to 
human SDS patients, where we performed transcriptional profiling of the human equivalent 
(CD271+) of murine MPCs, we observed common overexpression of many inflammatory 
molecules including the alarmins (also known as DAMPs) S100a8 and S100a9 – bona fide 
p53 downstream targets.6 Niche-derived S100A8 and S100A9 induced genotoxic stress in 
HSPCs in an in vivo transplantation assay, which is in line with the in vitro data showing 
that  S100A8/9 induces DNA damage and apoptosis in HSPCs. Interestingly, the canonical 
S100A8/9 receptor TLR4 is partially involved here, as in vivo blocking of this receptor 
resulted in a partial reduction of DNA damage.
Because SDS is a rare congenital disease, we explored the broader relevance of our 
findings to human disease by analyzing the molecular profile of BM CD271+ MPCs purified 
from 45 LR-MDS patients. Intriguingly, gene expression analysis revealed a subset of LR-MDS 
patients with high mesenchymal S100A8/9 expression,  p53 and TLR activation. Patients in 
this subset are clinically undiscernible from the rest based on classical risk scores. However, 
patients in this subset with mesenchymal S100A8/9 overexpression have a higher frequency 
of leukemic evolution, significantly shorter time to leukemic progression and a shorter event-
free survival. Taken together, our findings reveal the novel concept of inflammatory niche-
induced genotoxic stress in HSPCs, suggesting a potential underlying mechanism supporting 
the model of niche-induced leukemogenesis and the human relevance of this concept. In 
addition to our study where inflammatory niche-derived P53-S100A8/9-TLR feedback loop 
is implicated in human pre-leukemic disorders, two other recent studies also showed the 
relevance of S100A8/9 overexpression in the pathogenesis of MDS.7,8 
Continuing the work discussed in chapter 2 and chapter 3, Chapter 4 aims to further dissect the 
molecular mechanism(s) potentially driving inflammation by comparing the transcriptional 
analysis of the mesenchymal cells isolated from 45 LR-MDS patients to the normal 
counterparts (n=10). Interestingly, activation of NF-κB mediated inflammatory signaling 
Chapter 6
165
appears to be a biological commonality in MDS mesenchymal cells. To test the functional 
relevance of this observation, we activated NF-κB pathway in mesenchymal cells ex vivo. We 
observed transcriptional upregulation of several inflammatory molecules, among which are 
the negative regulators of hematopoiesis observed in LR-MDS mesenchyme (Chapter 2) and 
S100A8/9, shown (in Chapter 3) to cause genotoxic stress in HSPCs. In a co-culture setting, 
mesenchymal NF-κB activation attenuated the number and function of normal HSPCs. These 
data implicate activation of NF-κB signaling may underlie the inflammatory phenotypes of 
LR-MDS mesenchyme, although unlikely to explain the overexpression of S100A8/9 in a 
subset of MDS patients described in Chapter 3. The cause of NF-κB activation in the LR-
MDS mesenchymal elements remains to be established. However, earlier demonstration 
of activated NF-κB signaling in CD34+ HSPCs in MDS patients9 suggests a possible NF-κB-
mediated inflammatory feedback loop as an important pathophysiological factor in MDS 
bone marrow. The data in this chapter suggest  primary disruptions (e.g. NF-κB activation) 
in MDS HSPCs can remodel their niche (e.g. induce mesenchymal NF-κB activation) into 
a disease-supporting niche that impairs normal hematopoiesis and contributes to disease 
pathogenesis. We then tested this hypothesis in an in vivo MDS model in the next chapter.
In Chapter 5, we used the hematopoietic cell-autonomous model of MDS – the Vav-
NUP98-HOXD13 (NHD13) model to address the question whether primary disruptions in 
hematopoietic cells in MDS can induce alterations in the bone marrow microenvironment 
(BMME) that impair normal hematopoiesis. The NHD13 model serves as an ideal model 
to test our hypothesis as expression of the disease-causing fusion gene NUP98-HOXD13 is 
driven by the hematopoietic-cell specific Vav1 promoter and these mice recapitulate key 
clinical features in MDS patients. NHD13 mice present progressive loss of HSPCs; however, 
transplantation of normal HSPCs in NHD13 recipients did not result in altered differentiation 
and secondary transplant experiments revealed normal numbers and function of wildtype 
HSPC after exposure to the NHD13+ BMME. The data in this particular mouse model of 
MDS do not support our hypothesis that hematopoietic cells in MDS induce long-term 
effects on niche cells attenuating normal hematopoiesis, indicating the loss of the NHD13+ 
HSPCs in NHD13 mice is probably a cell autonomous effect caused by the transgene. This 
is supported by previous work demonstrating NHD13+ MDS can be cell autonomously 
propagated.10,11 However, we cannot completely exclude the niche interactions specific to 
genetically aberrant NHD13+ hematopoietic cells and our main conclusion should be seen in 
the light of several experimental limitations. Here, we only investigated one particular MDS 
model, so the conclusion of NHD13+ BMME has no effect on normal hematopoiesis cannot 
be extrapolated to other MDS models. In addition, in this NHD13 MDS model, the effect of 
the altered niche cells may be short-term relying on the continuous contacts with MDS cells. 
This transient contacts-dependent niche effect likely suggests NHD13+ MDS cells do no elicit 
epigenetic or genetic alterations in their niche. 
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2. Mesenchymal inflammation in the development of myeloid malignancies – 
broader relevance to cancer-related inflammation 
It is now generally accepted that inflammation plays an important role in tumorigenesis 
and an inflammatory microenvironment is an essential component of many tumors, 
although a direct causal relationship is yet to be proven in some tumor types.12,13 In some 
cases, inflammatory conditions precede the occurrence of malignant changes; whereas in 
other types of cancer, oncogenic alterations in the malignant cells induce an inflammatory 
microenvironment contributing to tumor development.12,13 The pro-tumorigenic effect 
of inflammatory signaling is often coupled with other mechanisms including senescence, 
immunity, angiogenesis, metabolism and cytokine/chemokine interactions, together 
contributing to the hallmarks of cancer.13-15 Most of these hallmarks are enabled and 
sustained through reciprocal communications between the cancer (stem) cells and the 
tumorigenic microenvironment.16 The stromal constituents of the tumor microenvironment 
are complex containing a wide range of diverse subcellular types. Three general classes 
have been defined including infiltrating immune cells, angiogenic vascular cells and 
cancer-associated fibroblasts (CAFs).16 All three stromal classes have been indicated in an 
inflammatory tumor microenvironment, however, the importance and function of each of 
these classes vary with tumor types and disease states. Although the role of an inflammatory 
tumor microenvironment is increasingly appreciated, many important questions remain 
unanswered among which include a) whether inflammation is sufficient for cancer 
development; b) What are the cellular and molecular components that are common to all 
cancer-promoting inflammatory responses, and which are specific to particular tissues and 
tumor types.12 The work discussed in this thesis provides new insights into the contribution 
of an inflammatory bone marrow niche, emphasizing the importance of the stem cell niche 
to the pathogenesis of pre-leukemic disorders and highlights the mesenchymal niche as a 
direct active participant in creating a disease-relevant inflammatory BMME. Our findings 
add new insights into the link between mesenchymal niche inflammation and oncogenesis 
(in the hematopoietic system), revealing mechanistic commonalities between our findings 
to the role of the inflammatory microenvironment in solid tumors. 
Chapter 2 revealed inflammation and cellular stress in mesenchymal elements purified 
from LR-MDS patients comparing to the normal counterparts. Chapter 3 uncovered 
mesenchymal inflammation driving genotoxic stress in HSPCs in both pre-leukemic mouse 
models and human patients, contributing to leukemogenesis. In Chapter 4, we defined NF-
κB mediated mesenchymal inflammation as a biological commonality in the bone marrow 
of LR-MDS patients. Together, mesenchymal inflammation in pre-leukemic disorders seems 
to be a converging theme in this dissertation. In the meantime, our findings invigorate the 
ongoing conundrum in the field whether (a) mesenchymal inflammation corrupts HSPCs 
through direct or indirect mechanisms; (b) inflammation in the niche is a primary event 
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or secondary to the primary alterations in the HSPCs; (b) an inflammatory niche induces 
malignant transformation of HSPCs or selects specific already-present malignant clones 
allowing clonal evolution. While these conundrums remain to be further explored, this 
discussion aims to speculate that these mechanisms may not be mutually exclusive, but 
act synergistically together in driving bone marrow failure and leukemogenesis. To start 
with, our data suggests a direct genotoxic effect of the mesenchymal-derived inflammatory 
molecules S100A8/9 on HSPCs; however, they are unlikely to be the only drivers. In fact, 
upregulation of genes encoding other inflammatory factors in the mesenchymal cells are 
observed in human MDS and the SDS model as detailed below. Thus, in addition to the 
direct effect of the niche-produced inflammatory factors as we described, indirect effects of 
these molecules are anticipated. 
2.1 Deregulated immunity and inflammatory cytokines derived from mesenchymal 
cells are essential factors in myeloid malignancies through direct and/or indirect 
mechanisms
Congruent with our findings, several other studies have implicated inflammatory cytokines 
produced by the HSPC niche in initiating or facilitating myeloid malignancies. A recent 
study modeling Noonan syndrome showed that activating mutation of the RAS signaling 
mediator PTPN11 in mesenchymal cells and osteoprogenitors can drive MPN progression. 
This process involves excessive production of CCL3 by the activated mesenchymal 
cells, recruiting inflammatory monocytes, which hyperactivate HSPCs by secreting the 
inflammatory cytokine IL-1ß, responsible for disease progression.17 Interestingly, similar 
inflammatory cascades have been implicated in solid tumors. Stromal expression of CCL3 - 
an inflammatory chemoattractant - together with CCL2, CCL4 and CCL5 have been shown to 
affect the macrophage composition of tumors by recruiting monocytes and other immature 
myeloid cells into the tumor microenvironment.18 Together with T cells, tumor-associated 
macrophages (TAMs) are among the most frequently found immune cells within the 
tumor microenvironment and are generally pro-tumorigenic by promoting processes like 
angiogenesis, tumor invasion and metastasis.19 It is therefore conceivable that a comparable 
mechanism could take place in MPN, via mesenchymal-derived inflammation.  
In addition to the niche-induced MPN model mentioned above, the inflammatory 
cytokine IL-1ß has been implicated in several other models of myeloid malignancies. In 
an inducible BCR/ABL CML mouse model, CML cells alter the function of osteoblasts and 
remodel these cells into an inflammatory osteoblastic niche, secreting pro-inflammatory 
molecules including IL-1ß, which amplifies MPN progression to the leukemic stage.20 In 
this model, osteoblasts in CML mice fail to support normal HSCs due to reduced Cxcl12 
expression, but favor LSC expansion, partially via the secretion of inflammatory cytokines. In 
another study of the JAK2(V617F) MPN model, the mutated hematopoietic cells “created” an 
inflammatory environment by secreting molecules such as IL-1ß, causing neuropathy in the 
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BM and subsequent loss of nestin+ mesenchymal cells. Such an inflammatory environment 
adversely contributed to MPN development.21 IL-1ß is a pleiotropic inflammatory cytokine 
that is often upregulated in the microenvironment of solid tumors, including breast, colon, 
lung, head/neck cancers and melanomas. Its accumulation in the tumor microenvironment 
is often correlated with worse prognosis.22 Though the exact mechanisms of this cytokine 
are being explored, it is increasingly evident that IL-1ß activates the expression of pro-
tumorigenic factors including metastatic genes matrix metalloproteinases (MMPs), 
angiogenic factors and inflammatory cytokines by adjacent cells.22 
Interestingly, we also observed upregulation of CCL3 and IL-1ß in the Sbds deleted MPCs 
in our OCS mouse model and CD271+ mesenchymal cells from SDS patients (Figure 
1A). Along with CCL3, CCL4 and CCL5, which are also involved in monocyte recruitment 
during inflammation, are upregulated in patient mesenchymal cells as well (Figure 1B). 
Furthermore, in the OCS model where CCL3 and IL-1ß are overexpressed in the mutant 
MPCs, CCL3 receptor CCR1 and IL-1ß receptors IL-1RI and IL-1RII are overexpressed in the 
mutant HSPCs (Figure 1C), suggesting an inflammatory crosstalk between the mesenchymal 
elements and HSPCs. In addition to SDS patients, CCL3, is also enriched in mesenchymal 
cells purified from LR-MDS patients (Chapter 2, Supplementary Table 3). This may be 
regulated via the NF-κB pathway, as ex vivo activation of NF-κB signaling in mesenchymal 
cells resulted in CCL3 upregulation (Chapter 4, Figure 2B). Interestingly, NF-κB activation is 
also present in the MDS hematopoietic cells9. CCL3 has long been recognized as a canonical 
NF-κB downstream target23 suggesting a possible feedback/feedforward loop reinforcing an 
inflammatory milieu in the bone marrow relevant to MDS pathogenesis.
In addition to the CCL family of chemoattractants, many alarmins, including S100A8 and 
S100A9, have been reported to attract immune cells, such as monocytes and macrophages.24 
Specifically in lung cancer, the release of S100A8 and S100A9 can recruit CD11b+ myeloid 
cells, which subsequently promote tumor invasion and metastasis.25 In Chapter 3, our 
finding of S100A8/9 derived from the mesenchymal niche as a driver of myelodysplasia 
converge with another report showing S100A8/9 drive the expansion of CD11b+ myeloid-
derived suppressor cells (MDSCs), which directly contributed to the myelodysplasia 
phenotype.26 In line with our findings, immunological alterations accompanied by perturbed 
cytokine regulation are key factors contributing to the transition from normal to aberrant 
hematopoiesis.27 Altered cytokine networks within the bone marrow have been implicated 
in clonal stem cell disorders, as well as the expansion of LSCs.28 Notably, deregulation of 
TLRs – critical for innate immune signaling – is a common feature in MDS and leukemia.29
For example, in MDS, TLR1, 2, and 6 upregulation have been observed and activation of 
TLR2 signaling axis is associated with elevated IL-8 expression; likewise, elevated levels of 
TNF-ɑ, IFN-ɣ, TGF-ß and IL-6 have also been reported.30-32 Furthermore, these receptors are 
important for the cooperative regulation of pro-inflammatory cytokines and chemokines. 
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Figure 1: Upregulation of inflammatory cytokines/chemokines and the binding receptors in the MPCs and HSPCs 
from OCS mice and SDS patients. (A) Upregulation of CCL3 and IL-1ß in the MPCs isolated from mutant OCS mice 
(upper panel) and the CD271+ mesenchymal cells from SDS patients (lower panel). (B) Upregulation of CCL4 and 
CCL5 in the purified CD271+ mesenchymal cells from SDS patients comparing to healthy donors. (C) Upregulation 
of receptors CCR1 (for chemokine CCL3), IL-1RI and IL-1RII (for cytokine IL-1ß) in HSPCs from mutant OCS mice 
comparing to the control counterparts. 
Dysfunction of these receptors have been implicated in MDS pathogenesis where signal 
transduction of key proliferative and apoptotic pathways is not properly activated.33 Markedly, 
the S100A8/9-TLR4 axis is implicated in our mouse model of niche-induced genotoxic stress 
(Chapter 3) and upregulation of IL-6, IL8 and TGF-ß is observed in LR-MDS mesenchymal 
elements (Chapter 2), suggesting cytokine imbalances and dysregulated activation of TLRs 
contribute to the formation of an inflammatory genotoxic niche.  
Taken together, in the OCS model, it is reasonable to hypothesize that other inflammatory 
factors in addition to S100A8/9 cooperating with deregulated TLR signaling may contribute 
to the genotoxic milieu exerting a direct effect on HSPCs. In addition, these secreted factors 
may exert indirect effects by recruiting immune cells like monocytes or MDSCs to the site, 
secreting additional inflammatory molecules and suppressive cytokines that can further 
compromise the functional integrity of adjacent HSPCs, promoting disease progression. 
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Similar interplay may be extrapolated to SDS and MDS patients, specifically the subsets of 
patients with enriched S100A8/9 expression in mesenchymal cells. Therefore, in relation to 
the inflammatory microenvironment in solid tumors, we suggest an inflammatory cascade 
in the HSPC niche of SDS and MDS patients, where diverse inflammatory cytokines and 
diverse cellular subsets are involved, including recruited immune cells. This cascade could 
have direct and/or indirect effects in disrupting normal hematopoiesis and perhaps support 
the expansion of leukemic clones (Figure 2). 
2.2 Mesenchymal-inflammation associated tumorigenesis
Our findings indicating that inflammation in the bone marrow niche may contribute to 
oncogenesis in the hematopoietic system concur with a similar concept and mechanism 
identified in solid tumors. In fact, the notion of niche-induced tumorigenesis in solid 
tumors has been proposed already twenty years ago in the context of colon34 and prostate 
cancers.35 For instance, Bhowmick et al demonstrated that deletion of the gene encoding 
TGF-ß receptor type II (Tgfbr2) in fibroblasts resulted in epithelial tumors in prostate 
and forestomach in a conditional mouse model.36 A follow-up study using the same 
model uncovered the underlying mechanism.37 Tgfbr2 deletion in stromal cell resulted in 
inflammation-induced DNA damage and cell cycle alterations due to epigenetic silencing 
of p21 in the heterotypic epithelial cells, directly causing increased epithelial proliferation 
and ultimately the development of epithelial tumor formation in specific organ tissues.37 
These findings demonstrated that stromal alterations, specifically inflammation-mediated 
mechanisms, have significant genetic and epigenetic impact on the adjacent epithelial 
compartment critical for tumor initiation and development.  
In parallel, another study investigating skin cancer demonstrated that mesenchymal loss of 
Notch/CSL signaling (specifically CSL/RPB-Jƙ gene, a key Notch effector) in mice triggered 
spontaneous formation of multifocal epithelial tumors in the skin via the recruitment of 
macrophages, upregulation of inflammatory factors (including MMPs) and diffusible 
growth factors.38 Interestingly, in this model the suppression of inflammation delayed 
tumor formation, suggesting inhibition of inflammation may prevent secondary tumor 
development. 
These data indicated that the stroma can play a primary role in the progression and initiation 
of cancer, supporting the longstanding concept of “field cancerization” that was first 
introduced in 1953 in squamous cell carcinomas with important clinical implications.39 Field 
cancerization is defined as broader tissue and organ changes beyond localized neoplastic 
areas of tumor development resulting in multifocal and recurrent tumors.40,41 While the 
mechanisms underlying this concept remain to be fully revealed, recent studies (including 
our own work) where primary stromal alterations are shown to induce tumorigenesis 
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Figure 2: Inflammation in the mesenchymal HSPC niche drives genotoxicity in HSPCs through direct and/or 
indirect mechanisms contributing to disease pathogenesis. Ribosomal stress (e.g. Sbds deletion) in the HSPC 
mesenchymal niche results in elevated secretion of a wide range of inflammatory cytokines (e.g. S100A8/9, CCL3, 
4, 5 and IL-1ß) and activation of TLR signaling, resulting in (a) direct induction of genotoxic stress in the heterotypic 
HSPCs; or (b) recruitment of immune cells s
uch as inflammation-associated macrophages/monocytes, MDSCs, neutrophils or T-lymphocytes secreting 
inflammatory or suppressive cytokines that further contribute to the inflammatory-genotoxic milieu. Such an 
inflammatory cascade within the HSPC niche contributes to the initiation and/or progression of BMF and MDS/
AML development. In addition, inflammatory cytokines secreted from the recruited immune cells could corrupt the 
architecture of the HSPC niche (e.g. reduced nestin+ mesenchymal cells due to IL-1ß induced neuropathy), further 
compromising the niche support to normal HSPC function. 
may help explain the concept of “field cancerization”, i.e., the occurrence of multifocal 
and recurrent tumors that are preceded by and associated with spreading alterations in 
surrounding parenchymal and stromal tissues.40 It is worth noting that both in our OCS model 
and the abovementioned stromal-Notch/CSL skin cancer model, all mesenchymal cells were 
genetically altered/targeted. Although the translation of such models to human patients 
remains to be further investigated, based on these findings we may begin to appreciate 
that epigenetic or genetic alterations in one mesenchymal cell can perhaps spread into a 
field affecting the surrounding stroma and contribute to the process of “field cancerization”. 
In the meantime, stromal inflammation seems to significantly contribute to the 
phenomenon of field cancerization. In addition to the aforementioned mouse models 
where niche-derived inflammatory signaling resulted in tumorigenesis, a few other 
models have been described. In a mouse model with gastric-specific overexpression of the 
proinflammatory cytokine IL-1ß, these transgenic mice developed gastric cancer through 
a cascade of NF-κB-activating inflammatory cytokines and associated recruitment of 
MDSCs.42 Interestingly, increased expression of IL-1ß resulted in increased proliferation 
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and transformation of the gastric epithelium, as well as severe atrophy in the stroma. Later 
work revealed that stromal atrophy and associated fibroblast senescence are important 
contributing factors in field cancerization process.40 
Although alterations in mesenchymal stromal cells are usually assumed to play a 
more secondary reactive role, in some cases, especially for UV-induced skin cancer where 
the UV light can directly affect the dermal (stroma in the skin) compartment, stromal cell 
senescence acts as a putative tumor-promoting or –triggering mechanism.43 The gene 
expression programs of senescent fibroblasts overlap with that of cancer-associated 
fibroblasts (CAFs), including the production of senescence-associated-secretory-phenotype 
(SASP) factors, mediating immune cell recruitment, angiogenesis and tumorigenesis.44,45 For 
example, the overexpression of SASP factor IL-6 can promote inflammation and proliferation 
of neighboring parenchymal tumor cells by cooperating with transcription factor C/EBPß.46 
CAFs express a proinflammatory gene signature in a range of cancer types including skin, 
breast and pancreatic cancer. In a transgenic mouse model of squamous cell carcinoma, 
the tumor-promoting effect of CAFs is mediated via NF-κB signaling where inhibition of 
this pathway abolished the tumor-enhancing effect of CAFs.47 To our interest, LR-MDS 
mesenchymal cells displayed a number of signatures indicating response to UV irradiation 
(Chapter 2, supplemental table 2). In addition, the molecular profiles of these cells are 
reminiscent of senescent fibroblasts, including the upregulation of numerous SASP factors 
such as IL-6, discussed in detail later on.  
Additional analysis on the GSEA signatures from Chapter 2 revealed several programs 
indicating “field cancerization”, “tumor field effect” in CD271+ mesenchymal cells in LR-
MDS patients compared to the normal counterparts (Figure 3A-B). The observed “field 
cancerization” signatures in MDS mesenchymal cells suggest that in MDS patients, there 
could be a “field” of altered stroma (e.g. characterized by NF-kB activation as in Chapter 
4) contributing to MDS pathogenesis. Data derived from Chapter 3 supports the concept 
of niche-induced leukemogenesis, indicating a primary role the stroma can play in both 
leukemia progression and initiation, proposing a new aspect of the multi-hit hypothesis 
of cancer. A hit can occur outside of the cancer cells themselves, indicating a cell non-
autonomous contribution to the emergence of malignancy.48 However, such hypothesis is 
derived from data in mouse models, where the relevance to human patients remains to be 
formally demonstrated. 
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2.3 The mechanism behind inflammation-associated tumorigenesis 
What drives S100A8/9 expression? 
The alarmins S100A8/9 are overexpressed in the mesenchymal cells from the mutant 
OCS mice and SDS patients, driving genotoxic stress in HSPCs. Interestingly, we found that 
mesenchymal overexpression of these two DAMP proteins identified a subset of MDS 
patients with worse clinical outcome (Chapter 3). Our data indicate that the mesenchymal 
niche may actively contribute to the formation of a “mutagenic” environment that facilitates 
cancer initiation and progression. At this moment, the question what drives the upregulation 
of the inflammatory molecules S100A8/9 in these two related yet distinct pre-leukemic 
disorders remains to be answered.
In the OCS model, we specifically deleted Sbds in the MPCs; whereas in SDS patients, SBDS 
deletion is intrinsic to nearly every cell including the mesenchymal elements. Therefore, it 
seems that ribosomal stress due to loss of Sbds in the mesenchymal cells could cause the 
inflammatory response, including the activation of TLR signaling and upregulation of DAMP 
proteins S100A8/9. Our data further demonstrated that inflammation induced by ribosomal 
stress in the mesenchymal cells is dependent on the p53 pathway, a common molecular 
mechanism associated with ribosomal defects. This finding is in agreement with another 
study investigating the effect of ribosomal defect in the context of 5q- syndrome - a subset 
of MDS. In this study, a mouse model of Rps14 (component of small ribosomal subunit) 
deletion in the erythroid progenitors was generated, resulting in impaired erythropoiesis, 
which was mediated via p53 activation and downstream S100A8/9 overexpression. The data 
linked Rps14 haploinsufficiency to the activation of innate immunity and the induction of 
S100A8/9 overexpression, leading to defects in erythroid differentiation in a p53 dependent 
manner.8 Together, it is reasonable to postulate that S100A8/9 induction in ribosomopathies 
SDS and 5q- syndrome could be driven by stress signaling due to ribosomal dysfunction and 
subsequent p53 activation in specific cellular types. 
In LR-MDS, transcriptome comparison of mesenchymal cells from S100-niche+ patients 
(n=17) to patients in the S100-niche-  group (n=28) revealed potential molecular pathways 
leading to DAMP signaling (Chapter 3, Figure 7). Interestingly, activation of p53 pathway and 
TLR signaling are observed in the S100-niche+ mesenchyme, in line with findings in the OCS 
model, Rps14 mice and SDS patients, suggesting p53 activation may be a common pathway 
driving S100A8/9 overexpression in pre-leukemic disorders. It is worth noting that in other 
systems, S100A8 and S100A9 have been identified to be bona fide p53 downstream targets, the 
above-mentioned data confirmed this finding in the mesenchymal HSPC niche component.6 
In SDS and 5q- syndrome, p53 activation in the mesenchymal niche could be driven by stress 
associated with ribosomal dysfunction due to Sbds or Rps14 deficiency; whereas in MDS, it 
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could reflect activation of senescence programs in the LR-MDS mesenchymal cells (Figure 3 
C-E), as indicated by the upregulation of numerous SASP factors (Table 1) and activation of 
NF-kB pathway (Chapter 4). Data in Chapter 4 (Figure 2) suggests ex vivo activation of NF-kB 
pathway in mesenchymal cells could drive transcriptional upregulation of S100A8/9, in line 
with a mouse model of hepatocellular carcinoma where NF-kB activation induced S100A8/9 
overexpression. In this model, NF-kB-induced S100A8/9 overexpression resulted in higher 
level of reactive oxygen species (ROS)-dependent signaling that contributed to malignant 
progression of the hepatocellular tumor cells.49 
This senescence-associated inflammatory feature of MDS mesenchymal cells is probably 
the result of being in contact with aberrant hematopoietic or other surrounding cells, as 
signatures of inflammation and cytokine stimulation are enriched in purified MDS CD271+ 
mesenchyme compared to the in vitro expanded stroma, emphasizing the relevance 
of tissue context in this case (Chapter 2, Figure 2). It has been shown that in LR-MDS, 
senescence programs also characterize hematopoietic cells, including HSPCs.50,51 Therefore, 
it is possible that senescence is initially established in the hematopoietic compartment 
due to MDS, and then propagated to the BMME via the production of SASP factors52; this 
senescent environment could then contribute to disease progression. Like in solid tumors, 
senescent fibroblasts could sustain the growth of parenchymal tumor cells53-55, and promote 
the malignant transformation, invasion and metastasis of tumor cells.56,57
A recent study suggested that one of the hallmarks of MDS – activation of NLRP3 inflammasome 
in the HSPCs resulted in elevated secretion of IL-1ß, inducing the upregulation of DAMP 
molecules S100A8/9 and the accumulation of ROS. These processes are associated with 
the inflammasome-mediated HSPC pyroptosis, which significantly contributes to disease 
progression.7 This link between S100A8/9 expression and inflammation has been supported 
by a broad range of studies, specifically in association with acute and chronic inflammatory 
disease.58-60 Lately, alarmins S100A8 and S100A9 have been recognized as biomarkers for 
local inflammatory activity.61 Typically, alarmins S100A8/9 are secreted by immune cells (e.g. 
neutrophils) in response to external insults. However, increasing evidence including our own 
data has demonstrated that the secretion of S100A8/9 by non-hematopoietic niche-derived 
elements could be stimulated by inflammatory factors such as prostaglandin E2 (PGE2)62, 
IL-1ß, FGF-2 and TGFß63. In addition, in the skin tissue, expression of S100A8/9 could be 
induced by UV irradiation64,65. Interestingly, signatures of response to UV irradiation are 
enriched in the MDS CD271+ mesenchymal cells (Chapter 2, supplementary Table 4).      
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Figure 3: Signatures associated with field cancerization and senescence are enriched in MDS mesenchymal 
elements. (A-B) Representative GSEA signatures indicating “field cancerization” and “tumor-field-effect” in 
the CD271+ mesenchymal cells isolated from LR-MDS patients. (C-D) Representative GSEA plots implicating the 
activation of senescence programs in MDS CD271+ mesenchymal cells. (E) A list of GSEA signatures showing 
upregulation of P53-associated senescence programs in MDS CD271+ mesenchymal cells.
NES: Normalized Enrichment Scores; FDR: False Discovery Rate
Taken together, the data from our work and that of others suggest that stress signaling 
due to inflammation or ribosomal dysfunction could directly or indirectly induce S100A8/9 
expression in the HSPC niche of SDS and MDS patients. These DAMP molecules, together with 
other inflammatory cytokines are important components of a premalignant inflammatory 
environment that critically contributes to leukemogenesis while compromising normal 
hematopoiesis. Therefore, better understanding of the working mechanisms underlying 
these inflammatory components and the upstream driving force may offer new avenues for 
therapeutic strategies. 
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   FC FDR 
IL6 (Interleukin 6) 5.10 0.005
IL8 (Interleukin 8) 7.24 4,36E-005
CCL3 (Chemokine (C-C motif) ligand 3) (MIP-1a) 4.21 0.022
CCL7 (Chemokine (C-C motif) ligand 7) (MCP-3) 9.65 0.006
CXCL-4 (Chemokine (C-X-C motif) ligand 4) (PF4) 6.96 0.005
CXCL14 (Chemokine (C-X-C motif) ligand 14) 5.54 0.023
CXCL3 (Chemokine (C-X-C motif) ligand 3) 6.23 0.026
VEGFa (Vascular endothelial gorwth factor A) 6.36 <0.001
IGFBP-3 (Insulin-like growth factor binding protein 3) 2.53 0.010
IGFBP-4 (Insulin-like growth factor binding protein 4) 2.17 0.004
IGFBP-7 (Insulin-like growth factor binding protein 7) 2.00 0.016
TIMP-1 (Tissue Inhibitor Of Metalloproteinases 1) 2.22 0.012
ISG15 (ISG15 ubiquitin-like modifier) 2.45 0.014
SERPINB2 (Serpin peptidase inhibitor, member 2) 4.11 0.029
SMURF2 (SMAD specific E3 ubiquitin protein ligase 2) 2.46 0.029
ICAM1 (Intercellular adhesion molecule 1) 2.51 0.010
PLAUR (Plasminogen activator, urokinase receptor) (uPAR) 3.36 <0.001
FN1 (fibronectin) 2.00 0.037
Col1a1 (Collagen, type I, alpha 2) 3.27 0.005
CLTB (Clathrin, light chain (Lcb) 3.20 0.009
Cryab (Crystallin, alpha B) 3.18 0.012
Cyp1b1 (Cytochrome P450, family 1, subfamily B, polypeptide 1) 2.22 0.004
Map1lc3b (Micotubule-associated protein 1 light chain 3, beta) 2.75 0.016
Nme2 (NME/NM23 nucleoside diphosphate kinase 2) 1.83 0.020
RAC1 (Ras-related C3 botulinum toxin substrate 1, rho family, 
small GTP binding protein) 1.75 0.020
Vim (Vimentin) 
MDM2 (Mdm2 p53 binding protein homolog) 
2.00 0.003
      Soluble Factors & 
Chemokines (CXCL, CCL) 
Growth Factors & Regulators
Proteases & Regulators
Soluble or Shed Receptors 
& Ligands
Insoluble Factors (ECM)
Other
GenesSASP factors
2.13 0.029
Table 1:  List of SASP factors upregulated at the transcript level in MDS CD271+ Mesenchymal cells compared to the 
normal counter parts. 
The mechanism behind inflammation-associated tumorigenesis - induction of 
genotoxic stress? 
Tumorigenesis typically requires more than one single mutation to occur, providing specific 
clone(s) the survival and proliferative advantage to expand and escape from immune 
surveillance.14 An inflammatory microenvironment containing activated inflammatory cells 
(mainly neutrophils and macrophages) serves as a source of ROS and reactive nitrogen 
intermediates (RNI) that are capable of inducing genomic instability, enhancing the 
proliferation of mutated cells and increasing mutation rates.13,66,67 The infiltrating immune 
cells such as neutrophils and macrophages have been considered to be the main cellular 
sources of such genotoxic effects. Our work adds the mesenchymal niche components to 
this notion, as inflammation in the BM mesenchymal elements, specifically the DAMPs 
S100A8/9 actively induced genotoxic stress in HSPCs characterized by mitochondrial 
dysfunction, accumulation of ROS and DNA damage (Chapter 3). Not limited to hematological 
malignancies, in breast cancer, overexpression of MMP-3 (also known as stromelysin) in the 
tumor microenvironment causes genomic instabilities in the parenchymal cells, resulting in 
malignant transformation.68,69 In the mouse model of MMP-3 overexpression in the stromal 
compartment, malignant transformation of mammary epithelial cells was observed.68 A 
later study investigating the mechanistic insight reveals that the overexpression of stromal 
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MMP-3 exerted several genotoxic effects in the parenchymal epithelial cells characterized by 
accumulation of ROS mediated by the activation of GTPase Rac1b, stimulation of epithelial-
to-mesenchymal transition (EMT), mitochondrial dysfunction and DNA damage.69 Our data 
link mesenchymal inflammation to genotoxicity in HSPCs highlighting the stem cell niche as 
a cellular source of genotoxic effects.
In the OCS model, S100A8/9 act partially via their canonical receptor TLR4 – known pattern 
recognition receptor; in MDS patients, TLR signaling is activated in the mesenchymal cells 
with high levels of S100A8/9 expression (Chapter 3, Figure 5 & 7). Interestingly, in addition to 
our study, a recent work showed continuous stimulation of TLR4 with LPS treatment resulted 
in high level of ROS associated DNA damage in BM HSCs, linking chronic inflammation or 
severe infection to hematopoietic dysfunction and expansion of malignant HSC.70 These data 
together indicate that genotoxic signaling is intimately related to the activation of innate 
immunity. A well-recognized effect of S100A8/9 binding to TLR4 or RAGE is the activation of 
NF-κB pathway (Chapter 3, supplemental Figure 6), which often results in the consequent 
secretion of NF-κB-associated inflammatory factors such as TNF-ɑ, TGF-ß, IL-1ß and 
MMPs.26,71,72 These inflammatory factors can recruit immune cells (as discussed in section 
2.1), which augment S100A8/9 production73, but they may also be relevant for inducing 
genotoxic stress in HSPCs.  For instance, an inflammatory molecule Lcn2 – upregulated in 
the niche cells from mutant OCS mice and SDS patients (Chapter 3, Figure 4), can be induced 
upon S100A8 stimulation74 and has been recently shown to promote oxidative stress and 
DNA damage in hematopoietic cells in the context of MPN.75,76 Therefore, in concert with 
S100A8/9, other inflammatory factors and TLR ligands may also contribute to the creation of 
a genotoxic environment, essential for leukemogenesis to take place (Figure 2). Our finding 
of the stem cell niche as the source of genotoxic insults is particularly relevant as recent 
work has demonstrated that under stress conditions such as infection or inflammation, 
HSPCs can directly respond to environmental cytokines by adapting their functions (incl. 
HSPC mobilization, proliferation and differentiation) and producing diverse cytokines for 
the regulation of stress hematopoiesis.77-80 In addition, chronic inflammation in the BM can 
promote the exit of HSCs from dormancy, resulting in the accumulation of oxidative stress 
and DNA damage, eventually hematopoietic dysfunction and malignant transformation.81,82 
Our data indicate inflammatory molecules derived from the HSPC niche may equally 
contribute to HSPC DNA damage. 
On the other hand, mouse models of solid tumors have shown that DNA damage can 
also lead to inflammation and thereby promote tumorigenesis, indicating the connection 
between inflammation and tumor initiation is bi-directional. For example, in the model of 
hepatocellular carcinoma induced by the carcinogen diethylnitrosamine (DEN), DNA damage 
in tumor cells resulted in accumulation of ROS and subsequent necrotic cell death, which 
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promoted an inflammatory reaction further contributing to tumorigenesis.83,84 Deficiency 
of the gene flap endonuclease 1 (Fen1) resulted in elevated DNA damage due to impaired 
DNA-damage repair response, which led to a pro-tumorigenic inflammatory response, most 
likely through the activation of a pattern recognition receptor.85 Therefore, it is possible for 
the HSPCs suffering from niche-derived genotoxic stress to undergo apoptosis, which in turn 
further promote inflammation, like a two-way street, forming a feedforward inflammatory 
loop that accelerates leukemogenesis. 
The mechanism behind inflammation-associated tumorigenesis – deregulation of 
epigenetic programs? 
Besides inducing genotoxicity, some reports have linked inflammation to epigenetic 
reprogramming. For example, upon stimulation of inflammatory cytokines, inflammation-
associated macrophages express the Jmjc-domain protein  Jmjd3 – a H3K27me demethylase 
and a NF-kB target, associated with the silencing of polycomb group (PcG) target genes.86 In 
a mouse model of intestinal cancer, inflammation can also induce DNA methyltransferase 
(DNMT)-dependent DNA methylation and silencing of a group of PcG target genes, some of 
which overlap with genes silenced by methylation in human colon cancer.87 Interestingly, 
recent work demonstrated that overexpression of Jmjd3 in LR-MDS HSPC regulates the 
expression level of several NF-kB targets and is associated with impaired erythropoiesis, a 
key clinical feature in LR-MDS patients.9 Still, the exact contribution of inflammation-induced 
epigenetic reprogramming to tumor initiation remains to be established, either in a relevant 
mouse model or through prospective analysis of human samples.13 
Taken together, an inflammatory microenvironment is crucial for tumorigenesis and 
our findings suggest the stem cell niche in addition to the infiltrating immune cells are 
key components to this microenvironment. DAMPs S100A8/9 in concert with other 
inflammatory factors may play a critical role in attenuating normal hematopoiesis and driving 
leukemogenesis via mechanisms such as genotoxic stress and epigenetic reprogramming 
among others. It is therefore reasonable to hypothesize that an inflammatory “mutagenic” 
environment may serve as an active participant in driving mutagenesis. 
3. Can niche-induced inflammatory signaling drive or facilitate the selection and/
or expansion of dominant HSPC clones with specific mutations? 
Bone marrow failure (BMF) syndromes are characterized by ineffective hematopoiesis, 
clonal evolution and malignant transformation to leukemia. In this dissertation, we focused 
on MDS and SDS, two major BMF syndromes with striking propensity for developing AML. 
As discussed in Chapter 1, a number of most frequently mutated genes has been identified 
in MDS, among which are the epigenetic/chromatin remodeling regulator genes DNMT3A, 
TET2, and ASXL1. Mutations in the classical tumor suppressor gene TP53 are associated 
Chapter 6
with poor prognosis and treatment resistance (Chapter 1 section 3.2). Interestingly, recent 
large-scale studies of population-based whole-exome sequencing revealed that somatic 
mutations of these four genes that are mutated in patients with myeloid cancers are 
recurrently mutated in apparently healthy people (termed as Clonal Hematopoiesis of 
Indeterminate Potential or ‘CHIP’), suggesting these mutations may represent early events in 
driving the development of hematologic cancers. Mutations in these genes are increasingly 
prevalent as people age and this age-related clonal hematopoiesis is often associated with 
increased risks of hematologic cancer and death.88,89,90 These emerging insights could reflect 
Darwinian selection, where the “failed” bone marrow environment selects a highly biased 
set of mutations and enables malignant evolution of these “selected” clones. However, the 
factors driving the emergence, selection and evolution of these mutational clones remain 
a mystery. 
In Chapter 3, high level of mesenchymal S100A8/9 expression independently predicted 
poor clinical outcome in MDS patients, suggesting the possibility of an inflammatory niche 
favoring hematopoietic cells carrying certain mutations associated with worse clinical 
outcome. In addition, abundance of S100A8/9 is associated with aging in a wide range of 
mouse and human tissues, linking chronic inflammation as a novel mechanism to aging.91 
To investigate whether high level of mesenchymal S100A8/9 expression selects for certain 
MDS clone, we can compare MDS mutations in S100 niche+ patients to S100 niche- patients. 
Interestingly, from this comparison, the frequency of ASXL1 mutation is clearly higher in S100 
niche+ patients (43.8% vs. 11.1%) (Table 2). ASXL1 mutations are found in CHIP, suggesting 
mutations in this gene could be an early driver event for leukemogenesis, supported by 
data from a mouse model of global ASXL1 deletion. ASXL(-/-) mice developed MDS-like 
phenotype via reduced HSC self-renewal and elevated apoptosis in myeloid-committed 
progenitors.92,93 In MDS, ASXL1 mutations are frequent molecular aberrancies that predict 
an adverse prognostic outcome.94,95 Our data open the possibility that inflammation in the 
HSPC niche, specifically S100A8/9 overexpression, might favor the expansion of ASXL1 
mutated cells as they could be resistant to insults like genotoxic stress allowing them to 
expand while other cells are eliminated in this inflammatory niche. 
Mutations in gene DNMT3A is another CHIP mutation. Notably, recent work has shown 
DNMT3A mutations resulted in the inability to sense and repair DNA torsional stress in 
response to daunorubicin (causing double-stranded breaks at higher concentration), 
resulting in increased mutagenesis.96 Interestingly, the inability of DNMT3A mutant cells 
to respond to DNA damage signaling is mediated via attenuation of p53 response and 
ɣH2AX accumulation96, indicating DNMT3A mutant cells could bypass S100A8/9-induced 
genotoxic stress, as similar mechanisms were implicated in our data. However, whether 
DNMT3A mutation in the MDS cells is associated with an inflammatory niche remains to be 
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investigated. Taken together, while our data on one hand supports niche-induced BMF or 
leukemogenesis mediated via inflammatory signaling, it is conceivable to speculate that in 
the meantime, this inflammatory “mutagenic” stem-cell niche provides selective pressure 
on certain clones that are resistant to such an environment driving clonal expansion while 
eliminating the “less fit” clones. 
Patient ID WHO Cytogenetics IPSS Genetic Abnormalities
MDS020 RCMD-RS 46,XX[20] 0 SRSF2 mutation
MDS486 CMML-1 46,XX,t(3;3)(q21;q26)[10] 0.5 SF3B1 mutation
MDS610 RCMD-RS 46,XX[20] 0.5 TET2, DNMT3A, SF3B1 and RUNX1 mutation
MDS627 RCMD 46,XY[20] 0 TET2 and ASXL1 mutation 
MDS008 RCMD 46,XX[20] 0.5 ASXL1 and EZH2 mutation
MDS092       RAEB-1 46,XX,del(5)(q1?5q3?5)[15] 0.5 sequenced: no mutations found
MDS174     RCMD-RS 47,XY,+19[9]/46,XY[11] 1 SETBP1 and  U2AF1 mutation
MDS176 RCMD-RS 46,XY[22] 0 Not Sequenced
MDS019 RCMD-RS 46,XX[20] 0 SF3B1 mutation
MDS061 RAEB-1 46,XY[20] 0.5 DNMT3A, SF3B1 and TET2 mutation
MDS069 CMML-1 46,XY,der(13)t(1;13)(q11;p11)[10] 1.0 ASXL1, IDH2, SF3B1 and TET2 mutation
MDS079 RCMD 47,XY,t(2;14)(q3?7;q2?2),idic(21)(p1?2),+idic(21)(p1?2)[8] 1.0 ASXL1 mutation
MDS135 RCMD-RS 46,XX[20] 0 ASXL1, TET2 mutation
MDS183 MDS-U 47,XX,+8[12] 0.5 ASXL1, IDH2  and SRSF2 mutation
MDS203 RCMD-RS 46,XY,del(5)(q13q31)[7]/47,XY,del(5)(q13q31),+8[4]/46,XY[1] 0.5 ASXL1 and SF3B1 mutation
MDS206 Del(5q) 46,XX,del(5)(q13q33)[7}/46,XX[13] 0 SF3B1 and TET2 mutation
MDS010 RCMD 46,XY[20] 0 sequenced: no mutations found
MDS006 RAEB-1 46,XX[20] 1 DNMT3A and SRSF2 mutation
MDS118 RARS 46,XX[20] 0 TET2, DNMT3A and SF3B1 mutation
MDS159 Del(5q) 46,XX,del(5)(q15q33)[10] 0 sequenced, no mutations found
MDS209 RCMD-RS 46,XX[10] 0 SF3B1 mutation
MDS222 RARS 46,XX[21] 0 SF3B1 and 2 TET2 mutations
MDS025 RCMD-RS 46,XY[20] 0 SF3B1 mutation
MDS433 RCMD-RS 45,X,-Y[10]/46,XY[10] 0 sequenced: no mutations found
MDS646 RAEB-1 46,XX[20] 1 ASXL1 mutation
MDS893 RARS 46,XX[20] 0 SF3B1 mutation
MDS111 RCMD 46,XX[20] 0 sequenced: no mutations found
MDS623 RCMD 46,XY[20] 0.5 sequenced: no mutations found
MDS247 RCMD-RS 46,XY[20] 0 DNMT3A and SF3B1 mutation
MDS150     RCMD-RS 46,XX[20] 0.5 not sequenced
MDS158     RCMD-RS 46,XX[20] 0 DNMT3A, SF3B1 and TET2 mutation
MDS172      RARS 46,XY[20] 0 SF3B1 and 2 TET2 mutations
MDS022 RAEB-1 46,XY[20] 1.0 sequenced: no mutations found
MDS053 RARS 45,X,-Y][7]/46,XY[3] 0.0 SF3B1, TET2 mutation
MDS055 RCMD 46,XY,der(22)(t(1;22)(q12;p11)[16]/46,XY,SL,del(20)(q12)[3] 0.5 sequenced: no mutations found
MDS093 RCMD 46,XY[20] 0.5 TET2 mutation
MDS101 RCMD-RS 46,XY[21] 0.0 ASXL1, DNMT3A and SF3B1 mutation
MDS121 RCMD 46,XY[20] 0.5 sequenced: no mutations found
MDS144 RCMD 47,XY,+19[6]/48,idem,+21[3]/46,XY[4] 1.0 ASXL1, U2AF1 mutation
MDS167 RCMD 46,XY[21] 0.0 SF3B1 mutation
MDS182 RCMD 46,XY,del(5)(q13q33)[10]/46,XY[10] 0.0 DNMT3A, TET2 mutation
MDS201 RCMD-RS 46,XX[20] 0.0 SF3B1 mutation
MDS001 RCMD-RS 46,XY[20] 0.0 SF3B1 mutation
MDS007 RCMD-RS 46,XY[20] 0.0 SF3B1, TET2 mutation
MDS013 Del(5q) 46,XX,del(5)(q13q33)[15]/46,XX[1] 0.0 sequenced: no mutations found
S100 niche signature -
S100 niche signature +
Table 2:  Summary of genetic abnormalities in LR-MDS patients divided in S100 niche+/- group. (Associated with 
Chapter 3, Supplemental Table 6) 
Summarizing this discussion chapter, a metaphor from the botanical garden proposed by 
Dotto et al. could be of relevance: when a bad plant (weed) is difficult to eradicate, it could 
be because of its many roots deeply embedded in the terrain or by the spreading of multiple 
bad seeds. It is, however, also possible that a bad soil could corrupt properties of otherwise 
perfectly good plants or favor the growth of bad plants. In the latter case, unless the soil is 
corrected, different interventions are of little or no use (Figure 4).40 
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Local invasion
Procancer Stromal Alterations
Distant Spread
primary tumor
spreading “seeds”
De novo primary tumor Secondary tumors
 
Figure 4. Metaphorical hypothesis of bad plant and bad soil. (Created based on Dotto, 2014)40 (A) The bad 
seeds hypothesis suggests the ability of the primary tumors to root deeply in the soil and “spread bad seeds” to 
neighboring or distant cells (plants), transforming them into tumor. These primary tumors are likely to grow in 
many conditions. (B) On the other hand, the bad soil hypothesis suggests the initial insults and alterations occur in 
the stroma (soil) allowing the growth of various tumors of monoclonal (primary tumors) or polyclonal (secondary 
tumors) origin.
4. Perspective and future directions
This dissertation deals with  the role of the HSPC niche in leukemia predisposition syndromes, 
particularly SDS and MDS. Our data uncovered an important novel concept of niche-induced 
inflammation driving genotoxic stress in HSPCs as a potential mechanism with relevance to 
human pre-leukemic disorders. In the meantime, our findings intrigued further questions 
and hypothesis worth investigating. First of all, leukemia transformation was not observed 
in the OCS model, likely due to a) the limited lifespan (~28 days) of these mice precluding 
long-term exposure of HSPCs to the mutagenic niche or b) the DNA repair-proficient HSPCs 
can overcome the mutagenic stress preventing the accumulation of stable genetic damage. 
To prolong the lifespan of the OCS mice, the tetracycline-off (TetO)-cassette in the Osterix-
cre construct could be utilized. So Sbds deletion from the mesenchymal cells in the OCS 
model could be achieved postnatally, allowing the mice to age. As a result, the prolonged 
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exposure of the HSPCs to a genotoxic milieu may lead to complete HSPC dysfunction and 
eventually leukemia transformation from the myelodysplasia stage observed in the current 
OCS model. For a long time, we wanted to test in our model if leukemia evolution would be 
the result of a mutagenic environment cooperating with the aberrant HSPCs, unable to cope 
with the inflammatory genotoxic stress. Interestingly, a recent work supported our idea. 
This report demonstrated that mice with PTPN11 mutations in both hematopoietic cells and 
mesenchymal elements reached malignant transformation much more rapidly than mice 
with PTPN11 mutations in either one of the cellular compartments alone.17 To test our idea, 
an experimental model where Sbds deficient mesenchymal microenvironment is combined 
with Sbds deficient HSPCs could generate interesting insights. This could be achieved by 
introducing Sbds(-/-) HSPCs5 into the OCS recipients via intrahepatic transplantation into 
the newborn OCS mice, considering the short lifespan of the OCS mice. Alternatively, if 
the Tet-off system proves efficient, transplantation of Sbds(-/-) HSPCs into the adult Tet-off 
OsterixcreSbdsf/f recipients could be performed and interrogated following the typical scheme 
of transplantation and leukemia-watch analysis. In addition, in a transplantation assay using 
S100A9Tg mice, we demonstrated niche-derived S100A8/9 is sufficient in driving genotoxic 
stress in HSPCs. Thus, it would also be interesting to transplant the DNA repair deficient 
Sbds(-/-) HSPCs into S100A9Tg recipients and examine if such cooperation would result in 
leukemic transformation. 
As discussed earlier, other inflammatory cytokines such as CCL3, CCL4, CCL5 and IL-1ß are 
likely to contribute to the inflammatory-genotoxic milieu in addition to S100A8/9. Therefore, 
it is worth investigating if niche-derived S100A8/9 is required to induce genotoxicity (our 
data showed they are sufficient in inducing genotoxicity), particularly in the new models 
proposed above where leukemogenesis might be observed. Anti-TLR4 antibodies could 
be used, as suggested in Chapter 3. However, it is worth noting that in the OCS model, a 
partial rescue was observed suggesting S100A8/9 might engage other cognate receptors like 
CD33 in addition to TLR4, or other inflammatory factors may be invovled.26 Small molecule 
inhibitors of S100A8/9 could be considered as well, such as the quinolone-3-carboxamide 
derivatives (ABR-215050 and ABR-215757) which have recently been tested as potential 
treatments in prostate cancer and inflammatory diseases.97-99 Such studies will provide new 
insights into the possibility of targeting niche-derived S100A8/9 as therapeutic strategies in 
pre-leukemic patients. 
In addition to the described mesenchymal inflammation-induced genotoxic stress, it is 
worth investigating if impaired energy metabolism could be another underlying mechanism. 
In a mouse model of prostate cancer, reduced level of p62 (also known as sequestosome-1) 
in CAFs resulted in impaired stromal glucose and amino acid metabolism via the redox 
mTORC1/c-Myc pathway, which in turn led to higher stromal IL-6 production and consequent 
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tumor promotion.100 These data suggest metabolic reprogramming in the stroma is linked to 
inflammation and tumorigenesis. Another study also revealed that adipocytes could engage 
in the “metabolic coupling” process with cancer cells via mitochondria metabolism, thereby 
promote tumor progression.101,102 Furthermore, in solid tumors, the well-known “Warburg 
effect” of cancer cells can “educate” the CAFs to switch on aerobic glycolysis, secreting 
lactate and pyruvate, which in turn can serve as fuel for tumor cell proliferation.103,104 This 
symbiotic relationship in energy metabolism between the tumor microenvironment and 
cancer cells seem to be bi-directional. Notably, HSPCs in the OCS model present deregulated 
mechanism of mitochondrial ATP generation characterized by downregulation of oxidative 
phosphorylation pathways; whereas MDS CD271+ mesenchymal cells display strong hypoxic 
signatures, which can activate HIF response system stimulating aerobic glycolysis (data not 
shown).16 Therefore, further pinpointing the metabolic dysfunctions in the mesenchymal 
niche and HSPCs in the OCS model could reveal if such a symbiotic relationship between 
the HSPCs and their niche exists in this pre-leukemic model, demonstrating the relevance of 
stromal inflammation and metabolism in leukemogenesis.
Another important conclusion of this thesis is mesenchymal S100A8/9 expression at the 
transcript level independently predicted disease outcome in LR-MDS patients regardless 
of the mutational status of the MDS clones. Interestingly, S100A8 expression has been 
shown to correlate with poor outcome in AML where high S100A8 level in leukemic 
blasts predicted worse clinical outcome.105 In solid tumors, stromal parameters have been 
shown to predict clinical outcome and resistance to chemotherapy in a broad range of 
cancer types including breast cancer, lung cancer and liver tumors.106-109 In a recent report 
studying microenvironmental remodeling as a prognostic factor in AML, the distinct pattern 
of stromal composition in the leukemic bone marrow at diagnosis is associated with the 
heterogeneous post-treatment clinical course of AML. Specifically, higher number of 
immunophenotypically defined primitive mesenchymal stromal cells (CD146+ enriched) in 
the BM is strongly associated with early relapse, whereas higher number of osteoblasts 
is significantly associated with late relapse.110 Considering the precedents, our data shows 
inflammatory BM niche factors may be used as prognostic markers in LR-MDS. Nonetheless, 
future investigations are required to confirm our finding in larger patient cohorts of other 
independent studies, paving the way to incorporate molecular cues in the inflammatory 
BM niche as novel prognostic parameters and hopefully as new therapeutic avenues for 
leukemia predispositions. 6
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LIST OF ABBREVIATIONS 
AML Acute myeloid leukemia
ASXL1 Additional sex combs like 1
BCR-ABL1  Breakpoint cluster region - Abelson murine leukemia viral oncogene 
homolog 1
CD48  Cluster of Differentiation 48 / signaling lymphocytic activation molecule  
family member 2 
CD150 Cluster of Differentiation 150 / Signaling Lymphocytic Activation Molecule
 Family Member 1
CXCR4 C-X-C Motif Chemokine Receptor 4
CXCL4 Chemokine (C-X-C Motif) Ligand 4 / Platelet Factor 4
c-kit  Mast/stem cell growth factor receptor / CD117
CCL3 C-C Motif Chemokine Ligand 3
DHE Dihydroethidium 
EZH2 Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit
EIF6  Eukaryotic Translation Initiation Factor 6
FGF1 Fibroblast Growth Factor 1
HSC Hematopoietic stem cell
HSPC Hematopoietic stem progenitor cell
IDH1 Isocitrate Dehydrogenase 1
IDH2 Isocitrate Dehydrogenase 2
IL-1ß Interleukin 1 Beta
IGFBP2 Insulin Like Growth Factor Binding Protein 2
JAK Janus Kinase 
KITL  Proto-Oncogene receptor tyrosine kinase (KIT) ligand
LIF:  Leukemia Inhibitory Factor 
MPL  Thrombopoietin Receptor
MPP Multipotent progenitors 
MPN Myeloproliferative neoplasms
MDS Myelodysplastic syndromes
LR-MDS Low-risk myelodysplastic syndromes
MAPK Mitogen-Activated Protein Kinase 
RPS small subunit ribosomal protein
ROS Reactive oxygen species 
SF3B1 Splicing Factor 3b Subunit 1
Sca-1 stem cell antigen 1 
STAT Signal Transducer And Activator Of Transcription
TMRM Tetramethylrhodamine, methyl ester
List of Abbreviations
A
TET2 Tet Methylcytosine Dioxygenase 2
TGF-ß Transforming Growth Factor Beta 
VEGFR2  Vascular Endothelial Growth Factor Receptor 2
VEGFA Vascular Endothelial Growth Factor A
ASXL1  Additional Sex Combs Like 1
CML Chronic myeloid leukaemia 
DAMP Danger associated molecular pattern 
DNMT3A DNA Methyltransferase 3 Alpha
JMJD3 Lysine-Specific Demethylase 6B
LPS Lipopolysaccharide 
Lcn-2 Lipocalin 2
MMP-3 Matrix Metallopeptidase 3
PTPN11 Protein Tyrosine Phosphatase, Non-Receptor Type 11
PGE2 prostaglandin E2
RAGE receptor for advanced glycation endproducts
S100A8 S100 Calcium Binding Protein A8
S100A9 S100 Calcium Binding Protein A9
TLR Toll-like receptor 
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ENGLISH SUMMARY
In the adult hematopoietic system, the mature blood cells including red blood cells, white 
blood cells and platelets are short-lived and must be continuously replenished by the 
differentiation of rare hematopoietic stem cells (HSCs) residing in the adult bone marrow. 
Under homeostatic conditions, the HSCs must be able to renew themselves (termed as self-
renewal) via proliferation while differentiating into mature blood cells. Dysregulation of this 
process may lead to the malignant transformation of HSCs, giving rise to hematopoietic 
malignancies. The diverse functions of HSCs including self-renewal, differentiation, and 
proliferation must therefore be tightly regulated and delicately maintained, depending on 
both cell intrinsic programs and extrinsic molecular cues coming from non-hematopoietic 
cells in the bone marrow microenvironment. These non-hematopoietic cells are collectively 
known as the HSC niche, of which the cellular composition is rather complex comprising 
a wide range of cell types. One of the essential components of the HSC niche is the 
mesenchymal progenitor cell (MPC). 
It is increasingly evident that hematopoietic disorders are the result of an altered tissue 
homeostasis, rather than disrupted function of hematopoietic cells alone. Although 
researchers have primarily focused on hematopoietic cell-autonomous contributions, the 
role of the HSC niche in disease pathogenesis is increasingly appreciated. Data derived from 
genetic mouse modeling have revealed that primary disruption of specific components of 
the HSC niche can initiate hematopoietic alterations and even leukemogenesis. However, 
the underlying molecular mechanisms and the relevance of these findings from mouse 
models to human disease remain understudied. The work described in this thesis aims to 
provide new insights addressing these key issues, trying to  answer the following questions: 
1.  Can niche cells critically contribute to leukemogenesis?
2.  What is the molecular mechanisms underlying the concept of “niche-induced 
leukemogenesis” and what is the relevance of such mechanisms to human disease? 
3. What’s the effect of diseased hematopoietic cells on their niche?  
To answer these questions, the pre-leukemic disorders: Shwachman-Diamond Syndrome 
(SDS) and myelodysplastic syndromes (MDS) were investigated. We analyzed SDS and 
MDS mouse models as well as bone marrow samples from human SDS/MDS patients. SDS 
is particularly relevant in the context of this thesis because it is an inherited, monogenic, 
disease with a mutation in both hematopoietic and niche cells and characterized by skeletal 
defects ( osteoporosis), bone marrow failure (neutropenia) and a strong predisposition 
to develop acute myeloid leukemia (AML). Previous work, including our own, has shown 
that hematopoietic cell intrinsic loss of the disease-causing gene Sbds in mice did not 
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result in leukemia, suggesting that Sbds deficiency in the hematopoietic cells alone is not 
sufficient to drive leukemogenesis and ancillary (niche) cells may be implicated. While, SDS 
is a rare disease, it can be modelled because of its monogenic origin and findings in SDS 
may be of broader significance to more prevalent hematopoietic diseases characterized by 
bone marrow failure and leukemogenesis such as  MDS. Therefore, we also studied the 
contribution of the HSC niche in MDS pathogenesis in mouse models and human patients. 
Chapter 2 describes the first transcriptomic analysis of purified mesenchymal cells from 
low-risk MDS (LR-MDS) patients. The data address a key issue in the field where the 
current knowledge about mesenchymal elements in pre-leukemic patients is derived from 
observations in ex vivo expanded stromal cells, with uncertain relevance to their in vivo 
counterparts. Findings from this chapter revealed that purified LR-MDS mesenchymal cells 
are transcriptionally distinct from their normal counterparts, characterized by inflammatory 
signaling, cellular stress and the upregulation of negative regulators of hematopoiesis. In 
comparison to expanded stromal cells, purified MDS mesenchyme is enriched in signatures 
indicative of  response to external stimuli, chemokine activity and immune regulation, 
stressing the relevance of tissue context and active cross-talk of mesenchymal cells with 
other cellular elements in the MDS bone marrow that is lacking in the culture dish. 
Chapter 3 of this thesis aims to define the molecular mechanism(s) underlying the recently 
described concept of “niche-induced leukemogenesis” by modeling SDS in a model where 
Sbds is specifically deleted in MPCs in the bone marrow microenvironment. As a result 
of this mesenchymal Sbds deletion, mice developed osteoporosis and myelodysplasia 
recapitulating clinical symptoms in SDS patients. Molecularly, Sbds deficiency in the MPCs 
caused genotoxic stress in hematopoietic stem/progenitor cells (HSPCs), characterized by 
mitochondrial dysfunction, oxidative stress and DNA damage, along with cell cycle checkpoint 
activation. To define the molecular mechanisms driving this genotoxic stress in HSPCs, we 
performed transcriptomic analysis of Sbds-deficient MPCs in comparison to control MPCs. 
This analysis revealed activation of the p53 pathway, a molecular mechanism commonly 
associated with ribosomopathies. Interestingly, genetic rescue studies revealed that both 
the bone and hematopoietic phenotypes described above are p53 dependent, raising the 
important question what molecules downstream of p53 could drive genotoxic stress in the 
HSPCs. By comparing the gene expression data of purified mesenchymal cells from the SDS 
mouse model to human SDS patients, we demonstrated that Sbds deficient MPCs in both 
mice and human display overexpression of many inflammatory molecules, including the 
alarmins S100a8 and S100a9, which are bona fide p53 downstream targets. Next, via in 
vivo transplantation analysis and in vitro recombinant S100A8/9 studies, we observed that 
niche-derived S100A8 and S100A9 (S100A8/9) are sufficient to induce genotoxic stress in 
HSPCs, partially via their canonical receptor toll-like-receptor 4 (TLR4).
Seeking the broader relevance of the abovementioned findings to human pre-leukemic 
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disorders, we performed transcriptional analyses in MPCs purified from a homogeneous 
cohort of 45 LR-MDS patients. Mesenchymal S100A8/9 overexpression identified a subset 
of LR-MDS patients with activated niche p53 and TLR signaling. These patients are clinically 
undiscernible from the patients with low niche-S100A8/9 expression based on current 
risk scores, which are largely based on hematopoietic cell autonomous parameters. 
Interestingly, patients with a high level of mesenchymal S100A8/9 expression have worse 
clinical outcome, characterized by higher frequency of leukemic evolution and a shorter 
time to leukemia progression, reflected a shorter event-free survival. Together, the data 
in chapter 3 establish a novel concept of an inflammatory niche-induced genotoxic stress 
in HSPCs. It is conceivable that this pathophysiologic mechanism induces a higher rate of 
genetic aberrancies in HSPC and/or the selection of certain genetic aberrancies that confer 
a competitive advantage of aberrant cells to their normal counterparts, thus contributing 
to the bone marrow failure and leukemogenesis. Ongoing experiments in the lab are 
testing this notion and offer the perspective of niche-instructed prognostic and therapeutic 
strategies in human leukemia predisposition syndromes. 
Chapter 4 aims to further investigate the potential molecular mechanism(s) driving the 
inflammatory signatures in the MPCs from LR-MDS patients. By comparing the transcriptional 
data obtained from LR-MDS patients to their counterparts, we observed activation of the NF-
κB mediated inflammatory signaling as a biological commonality in LR-MDS mesenchymal 
cells. Testing the functional relevance of this molecular program, we took an ex vivo genetic 
approach in combination with co-culture studies demonstrating that mesenchymal NF-κB 
activation attenuated the number and function of normal HSPCs. These data complement a 
recent finding of NF-κB activation in the HSPCs in MDS patients suggesting NF-κB-mediated 
inflammatory feedback loop can be an important pathophysiological factor in MDS.
The previous chapters indicate that inflammatory alterations in the mesenchymal niche can 
play an important role in the pathophysiology of bone marrow failure and leukemogenesis. 
An important remaining question is what drives these inflammatory alterations in niche 
cells.  In the SDS model it is clear that loss of Sbds is the cause of a series of (p53-driven) 
events leading to inflammation, but in the case of MDS this is much less apparent. Chapter 
5 studies whether primary alterations in hematopoietic cells can affect their niche using 
a transgenic mouse model of MDS: vav1-NUP98-HOXD13 (NHD13). In this mouse model, 
the expression of the disease-causing transgene NHD13 (which infrequently occurs in 
human MDS) is restricted to the hematopoietic cells, making it a suitable model to study 
the effect of MDS cells on their niche. NHD13 mice dysplay reduced numbers of HSPCs, but 
transplantation of normal HSPCs in NHD13 recipients did not result in altered differentiation 
suggesting the loss of HSPCs in NHD13 mice is likely due to hematopoietic-cell intrinsic 
factors. A series of primary and secondary transplantation experiments revealed normal 
A
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numbers and function of wildtype donor HSPCs after exposure to the NHD13+ bone marrow 
microenvironment (BMME). Together, the findings in this particular mouse model of MDS 
do not support the notion that hematopoietic cells in MDS induce long-term effects on 
niche cells attenuating normal hematopoiesis. Future investigations, including those using 
different genetic abnormalities in HSPC (more common in human MDS), are warranted to 
shed further light on this important topic. 
To conclude, the work described in this thesis provides novel mechanistic insights into the 
contribution of the HSC niche to leukemogenesis, establishing the relevance of concepts 
and mechanisms revealed in mouse models to human disease states. These insights 
further stress the importance of incorporating niche contributions in our thinking about 
the pathophysiology of bone marrow failure and leukemogenesis.  They  set the stage for 
future investigations aiming to better understand niche contributions to leukemogenesis 
and integrate niche-derived molecular clues into the current prognostic and treatment 
regimens for human leukemia predisposition syndromes. 
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NEDERLANDSE SAMENVATTING (DUTCH SUMMARY) 
Rode bloedcellen, witte bloedcellen en bloedplaatjes hebben bij volwassenen een korte 
levensduur en worden voortdurend aangemaakt door differentiatie vanuit zeldzame hema-
topoëtische stamcellen (HSCs) in het beenmerg. HSCs moeten tijdens fysiologische omstan-
digheden in staat zijn om zichzelf te delen in zowel een andere HSC als een meer uitgerijpte 
cel met de capaciteit om zich te ontwikkelen naar verschillende soorten volwassen bloed-
cellen. Een verstoring in dit proces kan leiden tot kwaadaardige transformatie van gezonde 
HSCs naar bloedkanker stamcellen, wat leidt tot de ontwikkeling van hematopoëtische 
maligniteiten. Daarom worden de diverse functies van HSCs streng bewaakt en in balans 
gehouden door zowel cel-intrinsieke factoren als cel-extrinsieke moleculaire signalen van 
cellen in de beenmerg micro-omgeving. Deze niet-hematopoëtische cellen staan bekend 
als de zogenaamde HSC niche. De HSC niche bestaat uit verschillende celtypes, waaronder 
mesenchymale voorloper/progenitor cellen (MPCs).
Het wordt steeds duidelijker dat, net als solide maligniteiten, hematopoëtische maligniteiten 
waarschijnlijk ontstaan door een verstoorde orgaan/weefsel homeostase in plaats van een 
ontregeling in één enkele cel. Hoewel een groot deel van het wetenschappelijke onderzoek 
zich richt op cel-intrinsieke bijdragen aan bloedkanker, zoals veel voorkomende mutaties 
in leukemiecellen, is de rol van de HSC niche in de pathogenese van bloedkanker in zekere 
mate ondergewaardeerd gebleven. Data verkregen uit genetische muizenmodellen 
hebben aangetoond dat primaire veranderingen in de HSC niche voldoende kunnen zijn 
om veranderingen in bloedcellen te induceren waaronder een aanleg voor het ontstaan 
van acute myeloide leukemie (AML). Echter, de onderliggende moleculaire mechanismen 
voor deze ‘niche-geinduceerde leukemogenese’ en hun relevantie voor humane ziekte is 
nog onbekend. Het werk beschreven in dit proefschrift heeft als doel om nieuwe inzichten 
over deze cruciale onderwerpen te verschaffen, en probeert de volgende vragen te 
beantwoorden:
1. Wat is de bijdrage van niche cellen aan het ontstaan van leukemie?
2.  Welke moleculaire mechanismen zijn verantwoordelijk voor deze  bijdrage en wat is de 
relevantie van deze bevindingen voor humane ziekten? 
3. Wat is het effect van de genetisch veranderde hematopoëtische cellen op hun niche?
Hiertoe werden in dit proefschrift twee beenmergzieken met een verhoogd risico op 
het ontwikkelen van leukemie bestudeerd: Shwachman-Diamond Syndroom (SDS) en 
myelodysplastische syndromen (MDS). Door het combineren van muizenmodellen van 
deze ziekten en weefselmonsters van SDS/MDS patiënten hebben we getracht onze 
vraagstellingen te adresseren. SDS is bijzonder geschikt voor dit onderzoek, omdat een 
zeldzaam optredende, aangeboren mutatie in één enkel gen (Sbds) in alle cellen van het A
Nederlandse samenvatting (Dutch summary) 
200
lichaam (waaronder zowel niche als bloedcellen) neutropenie (lage aantal neutrofielen), 
leukemie predispositie, skeletafwijkingen en osteoporose veroorzaakt. Onderzoek in 
muizen heeft eerder aangetoond dat verlies van Sbds in bloedcellen alleen niet leidt naar 
het ontwikkelen van leukemie, wat impliceert dat een bijdrage van verstoorde niche cellen 
mogelijk nodig is. In tegenstelling tot SDS is MDS een relatief veel voorkomende pre-
leukemische aandoening, wat het belang van het ontrafelen van de bijdrage van de HSC niche 
aan de pathogenese van deze ziekte onderstreept. Het is voorstelbaar dat mechanistische 
inzichten in een zeldzame, goed te modelleren ziekte als SDS, van belang zijn voor andere, 
vakere voorkomende ziekten met gedeelde klinische aspecten zoals beenmergfalen en een 
verhoogde kans op het ontstaan van AML. 
Hoofdstuk 2 beschrijft voor het eerst het transcriptoom (genexpressie profiel) van, niet-
gemanipuleerde, mesenchymale cellen gezuiverd uit laag-risico MDS-patiënten en 
pakt hiermee een belangrijke vraag in het onderzoeksveld aan. De huidige kennis over 
mesenchymale cellen in patienten met een verhoogde kans op het onstaan van AML is 
beperkt tot bevindingen in ex vivo geëxpandeerde stromale cellen. Een belangrijke vraag 
is of deze, buiten het lichaam in een kweekschaal ge-expandeerde en gemanipuleerde, 
cellen vergelijkbaar zijn met hun tegenhangers in het zieke beenmerg. De bevindingen 
in dit hoofdstuk laten zien dat MDS mesenchymale cellen transcriptioneel fundamenteel 
verschillen met hun normale tegenhangers. Deze verschillen worden gekenmerkt door 
inflammatoire signalering, cellulaire stress, en opregulatie van hematopoëtische factoren 
die een negatieve invloed hebben op de ontwikkeling van bloedvormende stamcellen. 
Bovendien bleken de mesenchymale cellen die direct uit het beenmerg gewonnen werden 
meer verschillen dan overeenkomsten te vertonen met deze cellen na ex vivo expansie. 
Deze transcriptionele verschillen betroffen onder andere reactie op externe stimuli, 
chemokine-activiteit en immuunsysteem-regulatie. De data suggereren dat de activiteit 
van mesenchymale cellen in het beenmerg van MDS patienten beinvloedt wordt door hun 
omgeving (waaronder afwijkende bloedvormende cellen) en benadrukken het belang van 
actieve cross-talk van de mesenchymale cellen met andere cellulaire elementen in het MDS 
beenmerg dat in een kweekschaal ontbreekt.
Hoofdstuk 3 van dit proefschrift heeft als doelstelling om de onderliggende moleculaire 
mechanisme(n) van het recent beschreven concept “niche-geïnduceerde leukemie” 
te ontrafelen. Hiervoor werd gebruikt gemaakt van een SDS muizenmodel waarbij 
het gemuteerde gen (Sbds) specifiek in MPCs van de beenmerg micro-omgeving 
werd verwijderd. Als gevolg van deze gen-deletie ontwikkelden muizen botontkalking 
(osteoporose) en myelodysplasie, wat ook voorkomt bij SDS patiënten. Moleculair gezien, 
veroorzaakte het tekort aan Sbds in MPCs  genotoxische stress in hematopoëtische stam / 
progenitorcellen (HSPC), gekenmerkt door mitochondriale dysfunctie, ophoping van vrije 
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zuurstofradicalen, en DNA schade, evenals activatie van celcyclus barrières. Transcriptoom 
(genexpressieprofiel) analyse van Sbds-deficiënte mesenchymale cellen wees op activatie 
van het p53 signaalpad, een moleculaire signalerings-cascade geassocieerd met ribosomale 
aandoeningen. Uitschakeling van p53 in het SDS muizenmodel liet zien dat zowel de bot - als 
bloed veranderingenhierboven beschreven afhankelijk van p53 activatiezijn. Deze bevinding 
riep de belangrijke vraag op welke moleculen, geinduceerd door p53, de genotoxische stress 
in HSPC veroorzaken. Hiervoor werd de genexpressie van mesenchymale cellen uit het 
muizenmodel met de genexpressie van mesenchymale cellen gezuiverd uit SDS patiënten 
met elkaar vergeleken. Uit deze vergelijking bleken de ontstekings-gerelateerde moleculen 
S100A8 en S100A9, welke geactiveerd kunnen worden door p53, verhoogd te zijn in de 
Sbds-deficiënte mesenchymale cellen van zowel muizen als SDS patiënten. Vervolgens 
werd het duidelijk uit in vivo transplantatie analyses en in vitro recombinante S100A8/
A9 behandelingen, dat S100A8/S100A9, uitgescheiden door de niche,  voldoende is om 
genotoxische stress in HSPC te induceren. Dit effect werd deels veroorzaakt door binding 
aan de toll-like-receptor 4 (TLR4). Om uit te zoeken in hoeverre deze bevinding relevant is 
voor andere pre-leukemische aandoeningen, werden MPCs gezuiverd uit een homogene 
cohort van 45 laag-risico MDS-patiënten en werd hun genexpressieprofiel geanalyseerd. 
Hieruit bleek dat mesenchymale S100A8/A9 expressie een subgroep van laag-risico MDS 
patiënten kon identificeren waarin p53 en TLR signalering geactiveerd is. De patiënten met 
een hoge mesenchymale expressie van   S100A8/9 waren op klinische gronden (gebruik 
makend van risico-classificaties die gebruik maken van kenmerken van bloedvormende 
cellen) niet te onderscheiden van de rest van de patienten. De MDS patiënten met een 
hoge S100A8/9 expressie hadden echter een slechtere klinische uitkomst een hogere 
incidentie van AML met een significant kortere tijd tot het ontstaan daarvan, wat tot  een 
kortere “event-vrije” overleving leidde. Samengevat postuleert het onderzoek in hoofdstuk 
3 een nieuw concept waarin inflammatoire veranderingen in een stamcelniche kunnen 
leiden tot genotoxische stress in stam en progenitorcellen. Het is voorstelbaar dat dit 
pathofysiologische mechanisme kan leiden tot een verhoogde kans op het ontstaan van 
genetische afwijkingen in HSPC en/of een competatief voordeel van cellen met genetische 
afwijkingen ten opzichte van normale bloedcellen, en daarmee een belangrijke rol speelt in 
het onstaan van beenmergfalen en AML. Dit opent het perspectief dat niche-verstoringen 
in patiënten met pre-leukemische aandoeningen in de toekomst wellicht gericht aangepakt 
kunnen worden om de ontwikkeling van leukemie te vertragen of zelfs te voorkomen. 
Hoofdstuk 4 richt zich verder op onderzoek naar de mogelijke moleculaire mechanismen die 
de inflammatoire niche veranderingen in laag-risico MDS veroorzaken. We hebben dit gedaan 
door transcriptionele data verkregen uit laag-risico MDS-patiënten te vergelijken met cellen 
verkregen uit mensen zonder hematologische aandoeningen. Opvallend is dat de activatie 
van NF-κB gemedieerde-inflammatoire signalering een biologische overeenkomst lijkt te 
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zijn in laag-risico MDS mesenchymale cellen. De functionele relevantie van dit moleculaire 
programma werd getoetst door ex vivo genetische activatie van NF-κB in mesenchymale 
cellen. Het kweken van normale HSPC op deze genetisch veranderde mesenchymale cellen 
leiide tot vermindering van het aantal en de functie van normale HSPCs. Deze resultaten 
sluiten aan bij de recente bevinding dat NF-κB signalering ook actief is in HSPC van MDS 
patienten wat mogelijk duidt op het feit dat NF-κB gemedieerde-inflammatoire samenspraak 
tussen mesenchymale cellen en HSPC een belangrijke pathofysiologische factor in MDS is.
De voorafgaande hoofdstukken toonden aan dat inflammatoire veranderingen in 
mesenchymale niche cellen een belangrijke rol kunnen spelen in de pathofysiologie van 
beenmergfalen en leukemische evolutie. Een belangrijke vraag blijft hoe deze inflammatoire 
veranderingen in niche cellen ontstaan. In het SDS model is dit het gevolg van het verlies 
van Sbds in deze cellen maar wat deze veranderingen veroorzaakt in MDS is veel minder 
duidelijk.  Hoofdstuk 5 onderzoekt of primaire veranderingen in hematopoëtische cellen 
(zoals gevonden in MDS) hun niche kunnen beinvloeden in een transgeen muizenmodel 
van MDS: het vav1-NUP98-HOXD13 (NHD13) model. In dit muismodel, is  de expressie van 
de ziekte-veroorzakende transgen NHD13 beperkt tot hematopoëtische cellen, waardoor 
het een geschikt model is om het effect van MDS cellen op hun niche te bestuderen. 
NHD13 muizen hebben tekenen van beenmergfalen (lage celaantallen in het bloed) en een 
verhoogde kans op leukemie maar transplantatie van normale HSPC in NHD13 ontvangers 
(na het verwijderen van de afwijkende bloedcellen middels bestraling) resulteerde niet in 
een duidelijk en consistent veranderde bloedvorming.  Ook verder onderzoek naar de functie 
van normale HSPC blootgesteld aan de MDS niche (middels secundaire transplantatie-
experimenten) bracht geen overtuigend bewijs dat afwijkende bloedcellen in MDS een 
permanente verandering van de niche veroorzaken die bijdraagt aan het onderdrukken van 
de normale bloedvorming. Verder onderzoek, onder andere gebruik makend van andere 
MDS modellen, zal meer inzicht moeten verschaffen in de onderliggende vraag omdat het 
goed mogelijk is dat niche-effecten afhankelijk zijn van de aard van de genetische afwijking 
in HSPC in MDS. 
Concluderend, verschaft het werk beschreven in dit proefschrift nieuwe conceptionele en 
mechanistische inzichten in de bijdrage van de niche aan het ontstaan en ontwikkelen van 
leukemie en verheldert in hoeverre deze inzichten, ontrafelt in muismodellen, relevant 
zijn voor humane ziekten. Deze inzichten benadrukken het belang veranderingen in de 
beenmergniche te incorporeren in het denken over de pathofysiologie van beenmergfalen 
en het onstaan van leukemie.  Een abnormale niche en verstoorde hematopoëtische 
cellen vormen waarschijnlijk samen de drijfkracht achter het ontwikkelen van leukemie in 
humane pre-leukemische aandoeningen. De bevindingen in dit proefschrift zullen hopelijk 
de weg effenen naar toekomstig onderzoek naar bijdragen van de niche aan het ontstaan 
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van hematopoietische ziekten en uiteindelijk leiden tot nieuwe therapeutische strategieen 
waarin de niche wordt ‘getarged’ ten einde beenmergfalen te verminderen en ontstaan van 
leukemie te vertragen of voorkomen.
A
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I would also like to thank Leenke, I really appreciate your responsiveness and willingness to 
help in any way you can. 
In these 5 years, I am very lucky to have worked with many amazing colleagues who have 
become my dearest friends. In addition to the some of you who I have mentioned earlier, 
I want to acknowledge my awesome paranymph Paulette. Dear Paulette, we have worked 
side by side on every transplantation experiment. I will never forget my first transplant 
experience, you stayed with me until late in the evenings and remained supportive. When 
Niken left, you have been a great help to my sequencing project. We always say you have 
a magic touch, whenever we have problems, you always managed to solve it and make the 
experiments work. Not only are you a countable colleague, but also you are a loving friend. 
Outside the lab, we have shared many great memories together, which I will miss very dearly. 
Your delicious bakeries, our gym-times, dinners, brunches and girl-talks, we must continue 
all these when you come to visit me in the US. Thank you for being a helpful colleague and 
a supportive and loving friend. Sometimes you guys would call me the adopted Asian kid 
of the Touw group as a joke, there is certainly some truth in it, as the next person I want 
to thank is Onno. Dear Onno, you are one of the kindest people I know! You are patient, 
caring and genuine. Thank you for helping me with all the confocal experiments. You had to 
stay behind the confocal for hours for some of the experiments, yet you were always there 
to help. You are a great listener and counselor, thank you for all the coffee chats during my 
difficult moments! I am counting on you coming to visit me and Noemi in SF, so I can repay 
you all the coffee. Take care and see you soon! I want to extend my acknowledgement to 
the other members (present and past) of the Touw group. Dear Patricia, I admire how you 
organized the tremendous amount of culturing work of the IPS cells together with Paulette. 
Thank you for all the little hallway conversations and your support during my DSSCR talk and 
preparation for ASH. Good luck with finishing up your PhD, I am sure you will do a great job! 
Dear Emanuele, you are a very warm-hearted person! Thank you for all the tips about Rome 
and helping me with the arrangements. You are a great addition to the Asian office! Actually, 
it was more that we crashed your office, haha! I had a lot of fun being your officemate; there 
are always snacks, fresh coffee and Italian liquor. Thank you for that! All the best with your 
PhD as well! Dear Michiyo, thank you for bringing us amazing local snacks wherever you 
travel. Hearing the stories from you about your family, I admire your passion for research. 
Wish you all the best in the rest of the time you are here. Dear Szaby and Hans, thank you 
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for your input on my work during our Thursday morning meetings. Good luck with your 
own projects. Dear Julia, or Germie, thank you for being a wonderful roommate! I will bring 
the minion socks wherever I go. I will never forget that you taught me to make my first pie. 
I hope to see you soon. Dear Piotr, thank you for all the little chats we have had, I hope you 
are doing well and enjoying your new position. 
Certainly, there are other members of the “crazy Hema13 crew” I shall not forget to thank 
for their support and fun times together. The first person on the list is Jana. Dear Jana, my 
long-lost sister, ex-roommate and partner-in-crime, I appreciate our honest and genuine 
friendship. We feel completely comfortable with telling each other the utmost truth. To me, 
this is the definition of a true friendship. No matter under what circumstances, we know we 
can count on one another. Thank you for being in my life and being an amazing friend. Finish 
your PhD soon and join me on the west coast! Dear Kasia, thank you for giving me the honor 
to be your paranymph. I am so happy to have met you and become good friends with you. 
I have learned a lot from you. Thank you for sharing your life experiences with me, and 
giving me so much good advice. You are strong, caring and determined, and I am sure you 
will succeed in your life adventures. I look forward to welcoming you in SF when you visit 
Noemi and me. Dear Roberto, you have given me so much mental support I don’t even 
know where to begin. I truly appreciate all the talks we have had and the experiences you 
have shared with me, they were very helpful. Thank you for cheering me up during my 
paper-rejection period, encouraging me for my ASH talk, and supporting me in the difficult 
times. I admire your brilliance and dedication to science and wish you all the best in your 
scientific journey. Dear Ferry, or I should call you “Jan”, I really enjoyed our little hall-way 
conversations on life outside/after a PhD. From the many talks we have had, I started to 
see post-PhD career opportunities from a different angle, thank you for that. Dear Monica 
and Julien, thank you both for the fun times we have had together, the bbqs, wipeouts, 
halloween parties, etc! Monica, good luck with finishing up your PhD! And Julien, all the best 
in Sanquin! Dear Tim and Sophie, I wish I have spent more time with you two, you brought 
a fun and fresh energy to the department. I wish you both all the best in your PhD and am 
sure you both will do a great job! Dear Adil, thank you for helping me with the Qubit system! 
I am definitely coming to visit you one day in beautiful Oman. Good luck with your PhD! 
I also want to thank Roger, Leonie, Davine, Amiet, Inge, Marije, Eric, Aniko, Ruth, Johan, 
Avinash, Kazem, Jasper, Joyce and the rest of the people in the department for all the little 
conversations we have had, for your support and help.   
There are several past Hema13 members that I would like to acknowledge. Dear Marshall, 
I miss the super fun costume parties and game nights you organized. You are our barbeque 
captain. I am looking forward to joining you and Noemi in SF to continue the fun moments 
we have had in Rotterdam. Dear Jurre, your travel stories make me very excited, it is still on 
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my bucket list to do what you have done. Thank you for all the fun times together! I cannot 
wait to hear your adventures after you PhD, whether it will be about a non-profit in Africa 
or back to the wonderland of Australia. I want to thank the group of Chinese friends at EMC, 
dear Diya, Arwen, Wu Bin, Ruoyu, Zhanmin, Yingying, Huang Ling, Tong Wei, Qiushi, Bei 
Bei, Liu Fan, Lu Tao, Kui Kui, Danli, Xiaolei, Zhouqiao, Changbin, Haibo, and the others in 
the group, thank you for the delicious dinners and very fun Werewolf nights we have had. 
I wish you all the best of luck in your PhD or post-PhD careers. I hope to stay in touch. 
From here, I would like to shift my acknowledgements to my dear friends outside the 
ErasmusMC. The first one on the list is Greg. Dear Greg, starting from Boston, we have 
become friends for life. To me, you are a good friend, but also a great life mentor. I appreciate 
every suggestion you have given me on how to handle difficult situations during my PhD. Your 
wisdom and advice have greatly fostered my personal growth during these years. You have 
taught me so much including the best way to handle conflicts, public speaking, dealing with 
failures, etc. there is not enough space here to list them all. Thank you for being a wonderful 
true friend, who is always there to listen, willing to help, and cares about my well-being. 
Thank you for all the prayers! I look forward to joining you in the US! I extend this sincere 
gratitude to your parents Rosemary and Miron, and your beautiful family! I appreciate their 
love and care! My wholehearted thanks to the girls from UC, Neda, MJ and Souki, you girls 
are not only friends, but also family to me. I am so lucky to have you girls in my life, we are 
lifetime friends no matter where we are. Thank you girls for all the moral support during 
my PhD! I will spare the cheesy words here, you girls know how much each of you means 
to me. From UC, to China, to Amsterdam, we have been each other’s best friends for 10 
years. We experienced life and grew up together. No matter where life will bring us, we are 
there with one another. This gratitude obviously goes to the other members of our UC crew, 
- Dear Neha, we had so much fun together as the crazy Asians in the group, we became 
very close friends as we were in the same pre-medicine classes back in college. We went 
through midterms and finals with sleepless nights and partied the next day. From Utrecht, to 
Boston, to London, distance was never an issue. I cannot wait to visit you in Singapore this 
summer and look forward to having you over in SF. Thank you for all the support and career 
counseling! You helped me build a lot of confidence for my next career move. Dear Timor, 
thank you for agreeing on being my other awesome paranymph! I appreciate all your help 
and support with organizing everything! You have been an amazing and true friend. You 
always tell me the truth! Even though it might be something unpleasant, you tell me what I 
need to hear at that moment. I really appreciate your honesty and our genuine friendship. 
I was so happy to hear you will start your PhD at Erasmus. Good luck with finishing up! No 
matter what you decide to do afterwards, I know you will have an amazing time because you 
bring happiness to wherever you go. Dear Bob, I love how we can always joke around, but 
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never take it personal because we both know we care a lot about each other deep down. We 
can laugh about everything. Spending time with you is a good way to distress. Thank you for 
being there for me! I look forward to continuing our crazy friendship wherever life takes us. 
Dear Layla, Marleen, Jocelyn, Nafi, and Mischa, thank you guys for being amazing friends 
from UC to now. Although most of us are all in different cities and/or countries now, our fun 
times together will always remain a precious part of my memory. I am looking forward to 
our visits. I also want to thank Saskia - Souki’s mum, Han and Lisbeth - MJ’s parents. Dear 
Saskia, thank you for having us over in Koudum, and encourage us young girls to go out and 
enjoy life. Dear Han and Lisbeth, thank you for having me over in Barcelona, and helping me 
with my life and financial planning. Dear Vicky and Jay, you are such a beautiful couple! I am 
so lucky to have met you two and become good friends with both of you. Thank you both 
for always being there for me, from back to Boston until now. I cannot wait to finally join 
you in SF, I am so excited!. 
I would like to thank my Salsa families from Boston and here in Rotterdam. Salsa is more 
than a hobby to me. It has brought me many lifetime true friends. Let’s start with my salsa 
buddies in Boston first. Dear Nikki and Mat, the wonderful Mattikki! You two are a match 
made in heaven. I will never forget the crazy fun times we have had together! Thank you 
for supporting my PhD thesis, I really appreciate it! I am so excited to join you two in the 
US. Dear Matilda, my Swedish princess! Thank you for supporting my thesis! I am so happy 
to have known you and become close friends with you - a talented dancer with a beautiful 
heart. Cheers to many more crazy stories we will continue to write together. Dear Bryn, 
Cordula, Talia and Meghan, thank you girls for your friendship, love and fun times together! 
See you girls very soon in the US. My salsa family in Rotterdam is one big reason this city 
feels like home to me. Poetic motion is one of the places I cannot say goodbye to. Dear 
Johnny and Gina, thank you both for creating this family! I am so happy to have joined 
this big family run by you two - beautiful, talented and genuine artist couple. I have no 
doubt that your vision will succeed and your dream will grow big. Dear Willem and Ruth, 
 I appreciate all your support throughout these two years! I am very lucky to have known 
your beautiful family and become your xiao mei mei, I hope to welcome you two together 
with the kids in SF one day! Dear Razia, we became close friends since fragilidad. I will 
always remember your super delicious dinners and bakeries. Thank you for being a genuine 
and supportive friend. I appreciate all the conversations and fun moments we have had. 
Enjoy your world travel! I will for sure come back to Rotterdam to visit you. I hope to see 
you soon in SF! Dear Rene, thank you for supporting my thesis! I appreciate all the LV salsa 
nights you organized and every conversation we have had. I look forward to seeing you in SF 
one day. I want to thank Raymond, Lily, Clara, Krisia and the rest of the PM family for the 
wonderful dances and times together.
A
Acknowledgments
My heartfelt thanks go to my dearest parents, Mama and Eric! Words cannot describe how 
grateful I am for all your unconditional love and support that you have generously given me! 
I wouldn’t have been where I am today without you. I am sorry that I haven’t spent much 
time by your side, thank you for always being so understanding and supportive of what I do. 
Because of you, I dare to fly high as I know you have got my back. Thank you for being the 
amazing parents and my best friends! 
 
Dear Bowen, I don’t think I would have made it through my PhD without you being by my 
side. Starting from Boston, you supported me to finish my Master's; then you supported 
me for five years to finish my PhD. Because of you, all the very difficult moments seemed 
lighter and easier. Who would have thought we could succeed a 5-year cross-continent 
long-distance relationship, but we made it. We share the same attitude and value in our 
relationship, but also in our career and life: once we set our goal, we don’t give up, we keep 
trying; we don’t settle, we keep looking. Thank you for being my safe haven, for having faith 
in me, for encouraging me to follow my heart and chase my dream. Life is unpredictable, 
but I am excited to take the adventure together with you. Just as we always have been, 
supporting each other, learning from each other and loving each other.
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